0001998781 2025-10-01 2026-03-31 0001998781 dei:BusinessContactMember 2025-10-01 2026-03-31 0001998781 2025-09-30 0001998781 2024-09-30 0001998781 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember 2025-01-01 2025-03-31 0001998781 2024-10-01 2025-09-30 0001998781 2023-10-01 2024-09-30 0001998781 IBAC:RedeemableCommonStockMember 2024-10-01 2025-09-30 0001998781 IBAC:RedeemableCommonStockMember 2023-10-01 2024-09-30 0001998781 IBAC:NonredeemableCommonStockMember 2024-10-01 2025-09-30 0001998781 IBAC:NonredeemableCommonStockMember 2023-10-01 2024-09-30 0001998781 2026-01-01 2026-03-31 0001998781 2025-01-01 2025-03-31 0001998781 2024-10-01 2025-03-31 0001998781 IBAC:RedeemableCommonStockMember 2026-01-01 2026-03-31 0001998781 IBAC:RedeemableCommonStockMember 2025-01-01 2025-03-31 0001998781 IBAC:RedeemableCommonStockMember 2025-10-01 2026-03-31 0001998781 IBAC:RedeemableCommonStockMember 2024-10-01 2025-03-31 0001998781 IBAC:NonredeemableCommonStockMember 2026-01-01 2026-03-31 0001998781 IBAC:NonredeemableCommonStockMember 2025-01-01 2025-03-31 0001998781 IBAC:NonredeemableCommonStockMember 2025-10-01 2026-03-31 0001998781 IBAC:NonredeemableCommonStockMember 2024-10-01 2025-03-31 0001998781 us-gaap:CommonStockMember 2023-09-30 0001998781 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001998781 IBAC:SharesToBeIssuedMember 2023-09-30 0001998781 IBAC:ShareSubscriptionReceivableMember 2023-09-30 0001998781 us-gaap:WarrantMember 2023-09-30 0001998781 IBAC:EquityIncentivePlanMember 2023-09-30 0001998781 us-gaap:RetainedEarningsMember 2023-09-30 0001998781 2023-09-30 0001998781 us-gaap:CommonStockMember 2024-09-30 0001998781 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001998781 IBAC:SharesToBeIssuedMember 2024-09-30 0001998781 IBAC:ShareSubscriptionReceivableMember 2024-09-30 0001998781 us-gaap:WarrantMember 2024-09-30 0001998781 IBAC:EquityIncentivePlanMember 2024-09-30 0001998781 us-gaap:RetainedEarningsMember 2024-09-30 0001998781 us-gaap:CommonStockMember 2025-09-30 0001998781 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001998781 us-gaap:RetainedEarningsMember 2025-09-30 0001998781 us-gaap:CommonStockMember 2025-12-31 0001998781 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001998781 us-gaap:RetainedEarningsMember 2025-12-31 0001998781 2025-12-31 0001998781 us-gaap:CommonStockMember 2024-12-31 0001998781 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001998781 us-gaap:RetainedEarningsMember 2024-12-31 0001998781 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:RetainedEarningsMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:RetainedEarningsMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:SharesToBeIssuedMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:RetainedEarningsMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2025-12-31 0001998781 us-gaap:CommonStockMember 2023-10-01 2024-09-30 0001998781 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2024-09-30 0001998781 IBAC:SharesToBeIssuedMember 2023-10-01 2024-09-30 0001998781 IBAC:ShareSubscriptionReceivableMember 2023-10-01 2024-09-30 0001998781 us-gaap:WarrantMember 2023-10-01 2024-09-30 0001998781 IBAC:EquityIncentivePlanMember 2023-10-01 2024-09-30 0001998781 us-gaap:RetainedEarningsMember 2023-10-01 2024-09-30 0001998781 us-gaap:CommonStockMember 2024-10-01 2025-09-30 0001998781 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2025-09-30 0001998781 IBAC:SharesToBeIssuedMember 2024-10-01 2025-09-30 0001998781 IBAC:ShareSubscriptionReceivableMember 2024-10-01 2025-09-30 0001998781 us-gaap:WarrantMember 2024-10-01 2025-09-30 0001998781 IBAC:EquityIncentivePlanMember 2024-10-01 2025-09-30 0001998781 us-gaap:RetainedEarningsMember 2024-10-01 2025-09-30 0001998781 us-gaap:CommonStockMember 2025-10-01 2025-12-31 0001998781 us-gaap:AdditionalPaidInCapitalMember 2025-10-01 2025-12-31 0001998781 us-gaap:RetainedEarningsMember 2025-10-01 2025-12-31 0001998781 2025-10-01 2025-12-31 0001998781 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001998781 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001998781 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001998781 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001998781 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001998781 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001998781 2024-10-01 2024-12-31 0001998781 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001998781 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001998781 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:RetainedEarningsMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:SharesToBeIssuedMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001998781 IBAC:SharesToBeIssuedMember 2025-09-30 0001998781 IBAC:ShareSubscriptionReceivableMember 2025-09-30 0001998781 us-gaap:WarrantMember 2025-09-30 0001998781 IBAC:EquityIncentivePlanMember 2025-09-30 0001998781 us-gaap:CommonStockMember 2026-03-31 0001998781 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001998781 us-gaap:RetainedEarningsMember 2026-03-31 0001998781 us-gaap:CommonStockMember 2025-03-31 0001998781 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001998781 us-gaap:RetainedEarningsMember 2025-03-31 0001998781 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:SharesToBeIssuedMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:RetainedEarningsMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:RetainedEarningsMember 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember 2026-02-05 2026-02-05 0001998781 us-gaap:IPOMember 2024-03-28 2024-03-28 0001998781 us-gaap:OverAllotmentOptionMember 2024-03-28 2024-03-28 0001998781 us-gaap:OverAllotmentOptionMember 2024-03-28 0001998781 us-gaap:PrivatePlacementMember 2024-03-28 2024-03-28 0001998781 us-gaap:PrivatePlacementMember 2024-03-28 0001998781 us-gaap:IPOMember 2024-10-01 2025-09-30 0001998781 us-gaap:CommonStockMember 2025-09-22 2025-09-22 0001998781 us-gaap:CommonStockMember 2025-09-22 0001998781 2024-06-30 0001998781 us-gaap:IPOMember 2025-10-01 2026-03-31 0001998781 2025-09-22 2025-09-22 0001998781 2026-03-25 2026-03-25 0001998781 us-gaap:CommonStockMember 2026-03-25 2026-03-25 0001998781 us-gaap:CommonStockMember 2026-03-25 0001998781 2026-03-25 0001998781 2026-03-16 2026-03-16 0001998781 IBAC:SideLetterAgreementMember 2026-03-16 0001998781 IBAC:SideLetterAgreementMember 2026-03-16 2026-03-16 0001998781 IBAC:IBAcquisitionMember IBAC:LockUpAgreementMember 2026-03-16 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:SubsequentEventMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:SubsequentEventMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:SubsequentEventMember 2026-04-22 0001998781 IBAC:FounderSharesMember 2020-09-02 2020-09-02 0001998781 IBAC:FounderSharesMember 2023-10-26 2023-10-26 0001998781 IBAC:FounderSharesMember 2023-10-26 0001998781 IBAC:FounderSharesMember 2023-10-01 2024-09-30 0001998781 IBAC:FounderSharesMember 2024-09-30 0001998781 IBAC:SuDeTangGlobalCorporationMember 2024-10-01 2025-09-30 0001998781 IBAC:SuDeTangGlobalCorporationMember 2023-10-01 2024-09-30 0001998781 IBAC:FounderSharesMember IBAC:SubscriptionAgreementMember 2023-10-01 2024-01-31 0001998781 IBAC:FounderSharesMember IBAC:SubscriptionAgreementMember 2024-01-31 0001998781 IBAC:FounderSharesMember IBAC:SubscriptionAgreementMember 2024-01-22 2024-01-22 0001998781 IBAC:FounderSharesMember us-gaap:OverAllotmentOptionMember IBAC:SubscriptionAgreementMember 2024-01-22 2024-01-22 0001998781 IBAC:FounderSharesMember us-gaap:OverAllotmentOptionMember 2024-01-22 0001998781 IBAC:FounderSharesMember IBAC:SubscriptionAgreementMember 2024-09-11 2024-09-11 0001998781 IBAC:FounderSharesMember us-gaap:OverAllotmentOptionMember IBAC:SubscriptionAgreementMember 2024-09-11 2024-09-11 0001998781 IBAC:FounderSharesMember us-gaap:OverAllotmentOptionMember 2024-09-11 0001998781 IBAC:FounderSharesMember IBAC:SponsorMember IBAC:SubscriptionAgreementMember 2024-09-11 2024-09-11 0001998781 IBAC:FounderSharesMember us-gaap:OverAllotmentOptionMember 2024-09-11 2024-09-11 0001998781 IBAC:DirectorsAndDirectorNomineesMember IBAC:SubscriptionAgreementMember 2024-03-28 2024-03-28 0001998781 IBAC:DirectorsAndDirectorNomineesMember IBAC:SubscriptionAgreementMember 2024-03-28 0001998781 IBAC:DirectorsAndDirectorNomineesMember IBAC:SubscriptionAgreementMember 2024-09-12 2024-09-12 0001998781 IBAC:DirectorsAndDirectorNomineesMember IBAC:SubscriptionAgreementMember 2024-09-12 0001998781 srt:ChiefFinancialOfficerMember 2023-10-01 2023-10-01 0001998781 srt:ChiefFinancialOfficerMember 2024-01-22 2024-01-22 0001998781 srt:ChiefFinancialOfficerMember 2024-10-01 2025-09-30 0001998781 srt:ChiefFinancialOfficerMember 2025-09-30 0001998781 srt:ChiefFinancialOfficerMember 2023-10-01 2024-09-30 0001998781 srt:ChiefFinancialOfficerMember 2024-09-30 0001998781 IBAC:FounderSharesMember 2025-10-01 2026-03-31 0001998781 IBAC:FounderSharesMember 2026-03-31 0001998781 IBAC:FounderSharesMember 2024-10-01 2025-03-31 0001998781 IBAC:SuDeTangGlobalCorporationMember 2025-10-01 2026-03-31 0001998781 IBAC:DirectorsAndDirectorNomineesMember IBAC:SubscriptionAgreementMember 2024-09-11 2024-09-11 0001998781 IBAC:DirectorsAndDirectorNomineesMember IBAC:SubscriptionAgreementMember 2024-09-11 0001998781 srt:ChiefFinancialOfficerMember 2026-01-01 2026-03-31 0001998781 srt:ChiefFinancialOfficerMember 2025-10-01 2026-03-31 0001998781 srt:ChiefFinancialOfficerMember 2026-03-31 0001998781 srt:ChiefFinancialOfficerMember 2025-01-01 2025-03-31 0001998781 srt:ChiefFinancialOfficerMember 2024-10-01 2025-03-31 0001998781 srt:ChiefFinancialOfficerMember 2025-03-31 0001998781 us-gaap:MeasurementInputPriceVolatilityMember IBAC:FounderSharesMember 2023-11-15 0001998781 us-gaap:MeasurementInputPriceVolatilityMember IBAC:FounderSharesMember 2024-01-15 0001998781 us-gaap:MeasurementInputRiskFreeInterestRateMember IBAC:FounderSharesMember 2023-11-15 0001998781 us-gaap:MeasurementInputRiskFreeInterestRateMember IBAC:FounderSharesMember 2024-01-15 0001998781 us-gaap:MeasurementInputSharePriceMember IBAC:FounderSharesMember 2023-11-15 0001998781 us-gaap:MeasurementInputSharePriceMember IBAC:FounderSharesMember 2024-01-15 0001998781 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember IBAC:FounderSharesMember 2023-11-15 0001998781 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember IBAC:FounderSharesMember 2024-01-15 0001998781 us-gaap:IPOMember IBAC:UnderwritersAgreementMember 2024-10-01 2025-09-30 0001998781 us-gaap:IPOMember IBAC:UnderwritersAgreementMember 2025-09-30 0001998781 IBAC:UnsecuredPromissoryNoteMember IBAC:SuDeTangGlobalCorporationMember 2024-09-16 0001998781 IBAC:UnsecuredPromissoryNoteMember IBAC:SuDeTangGlobalCorporationMember 2025-09-30 0001998781 IBAC:UnsecuredPromissoryNoteMember IBAC:SuDeTangGlobalCorporationMember 2024-10-01 2025-09-30 0001998781 us-gaap:IPOMember IBAC:UnderwritersAgreementMember 2025-10-01 2026-03-31 0001998781 us-gaap:IPOMember IBAC:UnderwritersAgreementMember 2026-03-31 0001998781 IBAC:UnsecuredPromissoryNoteMember IBAC:SuDeTangGlobalCorporationMember 2026-03-31 0001998781 us-gaap:FairValueInputsLevel1Member 2025-09-30 0001998781 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001998781 IBAC:GnqInsilicoIncMember IBAC:BridgeFinancingMember us-gaap:SubsequentEventMember IBAC:LetterAgreementMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember IBAC:BridgeFinancingMember us-gaap:SubsequentEventMember IBAC:LetterAgreementMember 2026-03-16 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember IBAC:BridgeFinancingMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember IBAC:LetterAgreementMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:SubsequentEventMember IBAC:BusinessCombinationAgreementMember 2026-03-16 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:SubsequentEventMember IBAC:BusinessCombinationAgreementMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember IBAC:SecuredPromissoryNoteMember us-gaap:SubsequentEventMember IBAC:LetterAgreementMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember IBAC:SecuredPromissoryNoteMember us-gaap:SubsequentEventMember IBAC:LetterAgreementMember 2026-05-04 0001998781 IBAC:GnqInsilicoIncMember us-gaap:SubsequentEventMember IBAC:SubleaseAgreementMember 2026-05-05 0001998781 IBAC:GnqInsilicoIncMember us-gaap:SubsequentEventMember IBAC:SubleaseAgreementMember 2026-06-01 0001998781 IBAC:GnqInsilicoIncMember us-gaap:SubsequentEventMember IBAC:SubleaseAgreementMember 2026-05-05 2026-05-05 0001998781 srt:MinimumMember IBAC:GnqInsilicoIncMember us-gaap:SubsequentEventMember IBAC:SubleaseAgreementMember 2026-05-05 2026-05-05 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember 2026-02-05 2026-02-05 0001998781 IBAC:TomEnglishMember IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember 2026-02-05 2026-02-05 0001998781 IBAC:DrMalihaHashmiMember IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember 2026-02-05 2026-02-05 0001998781 IBAC:DaveJohnsonMember IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember 2026-02-05 2026-02-05 0001998781 IBAC:EmployeesMember IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-01 0001998781 IBAC:EmployeesMember IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember 2026-04-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2026-01-01 2026-01-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2026-01-01 2026-01-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2026-01-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember IBAC:GreenSkyLabsIncMember 2026-01-01 2026-01-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember IBAC:GreenSkyLabsIncMember 2026-01-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember IBAC:GreenSkyLabsIncMember 2026-01-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-01-01 2026-01-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember 2026-01-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember IBAC:TwoThousandTwentyFourPrivatePlacementMember 2026-01-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember us-gaap:PrivatePlacementMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2026-04-01 2026-04-01 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember IBAC:RelatedPartyLoanAgreementMember 2026-03-09 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember IBAC:RevenueAgreementMember 2025-09-25 2025-09-25 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember IBAC:RevenueAgreementMember 2025-09-25 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember IBAC:RevenueAgreementMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember IBAC:SoftwareServicesAgreementMember 2025-11-20 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember IBAC:SoftwareServicesAgreementMember 2025-11-20 2025-11-20 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember IBAC:SoftwareServicesAgreementMember 2026-03-11 2026-03-11 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember IBAC:ConsultingAgreementMember 2026-04-22 2026-04-22 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember us-gaap:SubsequentEventMember IBAC:ConsultingAgreementMember 2026-04-22 0001998781 IBAC:GnqInsilicoIncMember IBAC:SecuredPromissoryNoteMember IBAC:LetterAgreementMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:SecuredPromissoryNoteMember us-gaap:SubsequentEventMember IBAC:LetterAgreementMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityInstrumentsIssuancesMember us-gaap:PrivatePlacementMember 2026-04-01 2026-07-20 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityInstrumentsIssuancesMember 2026-04-01 2026-07-20 0001998781 IBAC:GnqInsilicoIncMember IBAC:GSLorMNHMember IBAC:ShareSubscriptionReceivableMember us-gaap:PrivatePlacementMember 2026-04-01 2026-07-20 0001998781 IBAC:GnqInsilicoIncMember 2026-04-01 2026-07-20 0001998781 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:ComputerEquipmentMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:FurnitureAndFixturesMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:OfficeEquipmentMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:LeaseholdImprovementsMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:VendorReceivableMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:VendorReceivableMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EmployeeReceivableMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EmployeeReceivableMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:VendorReceivableMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EmployeeReceivableMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugAssessmentPlatformMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DigitalTwinsPlatformMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugSimulationPlatformMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FiniteLivedIntangibleAssetsNetMember 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugAssessmentPlatformMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DigitalTwinsPlatformMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugSimulationPlatformMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FiniteLivedIntangibleAssetsNetMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugAssessmentPlatformMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DigitalTwinsPlatformMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugSimulationPlatformMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FiniteLivedIntangibleAssetsNetMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugAssessmentPlatformMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DigitalTwinsPlatformMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugSimulationPlatformMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FiniteLivedIntangibleAssetsNetMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugAssessmentPlatformMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DigitalTwinsPlatformMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugSimulationPlatformMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FiniteLivedIntangibleAssetsNetMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugAssessmentPlatformMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DigitalTwinsPlatformMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugSimulationPlatformMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FiniteLivedIntangibleAssetsNetMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugAssessmentPlatformMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DigitalTwinsPlatformMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:DrugSimulationPlatformMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FiniteLivedIntangibleAssetsNetMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember 2025-09-13 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncMember 2023-01-01 2023-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantTechnologiesCapitalCorpMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:PrivatePlacementMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FounderSharesMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:PrivatePlacementMember 2025-01-01 2025-12-31 0001998781 IBAC:ConsultantMember IBAC:GnqInsilicoIncMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareSubscriptionReceivableMember us-gaap:PrivatePlacementMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:PrivatePlacementMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember 2026-04-01 2026-04-01 0001998781 IBAC:GnqInsilicoIncMember us-gaap:PrivatePlacementMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:GreenSkyLabsIncMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:GreenSkyLabsIncMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:GreenSkyLabsIncMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:GreenSkyLabsIncMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncMember IBAC:RevolvingLoanAgreementMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncMember IBAC:RevolvingLoanAgreementMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncMember 2024-12-31 0001998781 srt:DirectorMember IBAC:GnqInsilicoIncMember IBAC:BearcoInvestmentsLtdMember 2025-12-31 0001998781 srt:DirectorMember IBAC:GnqInsilicoIncMember IBAC:TrenchantTechnologiesCapitalCorpMember 2025-12-31 0001998781 srt:DirectorMember IBAC:GnqInsilicoIncMember IBAC:OntarioInc2809539Member 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:OntarioInc2809539Member 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:OntarioInc2809539Member 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FivePalisadesPlazaLLCMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:FivePalisadesPlazaLLCMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TsamutalisAndCompanyLLCMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TsamutalisAndCompanyLLCMember 2024-01-01 2024-12-31 0001998781 IBAC:NimishSaxenaMember IBAC:GnqInsilicoIncMember 2025-01-01 2025-12-31 0001998781 IBAC:NimishSaxenaMember IBAC:GnqInsilicoIncMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember 2025-01-15 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantWarrantsMember us-gaap:CommonStockMember 2024-04-29 2024-04-29 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantWarrantsMember 2024-04-29 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantsCommonSharesMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantsCommonSharesMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantWarrantsMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputExercisePriceMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001998781 srt:BoardOfDirectorsChairmanMember IBAC:GnqInsilicoIncMember 2026-01-01 2026-03-31 0001998781 srt:DirectorMember IBAC:GnqInsilicoIncMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:GreenSkyLabsIncMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:GreenSkyLabsIncMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:GreenSkyLabsIncMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncMember IBAC:RevolvingLoanAgreementMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncMember 2026-03-31 0001998781 srt:DirectorMember IBAC:GnqInsilicoIncMember IBAC:BearcoInvestmentsLtdMember 2026-03-31 0001998781 IBAC:NimishSaxenaMember IBAC:GnqInsilicoIncMember 2026-01-01 2026-03-31 0001998781 IBAC:NimishSaxenaMember IBAC:GnqInsilicoIncMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:GSLorMNHMember IBAC:RevolvingLoanAgreementMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:GreenSkyLabsIncMember IBAC:RevolvingLoanAgreementMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantWarrantsMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncCanadaMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncCanadaMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncUSMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncUSMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncCanadaMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MyNextHealthIncUSMember 2026-03-31 0001998781 srt:ScenarioPreviouslyReportedMember IBAC:GnqInsilicoIncMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantCommonSharesMember 2024-04-28 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantWarrantsMember 2024-04-28 0001998781 IBAC:GnqInsilicoIncMember 2024-04-28 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantCommonSharesMember 2024-04-29 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantWarrantsMember 2024-04-29 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember 2024-04-29 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantCommonSharesMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantWarrantsMember 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantCommonSharesMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantWarrantsMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantCommonSharesMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantCommonSharesMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantWarrantsMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:TrenchantCommonSharesMember 2026-03-31 0001998781 srt:ChiefExecutiveOfficerMember IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001998781 srt:MinimumMember IBAC:GnqInsilicoIncMember 2025-12-31 0001998781 srt:MaximumMember IBAC:GnqInsilicoIncMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EquityIncentivePlanMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EmployeeBenefitPlansMember 2025-01-01 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EmployeeBenefitPlansMember 2024-01-01 2024-12-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EmployeeBenefitPlansMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:EmployeeBenefitPlansMember 2025-01-01 2025-03-31 0001998781 IBAC:GnqInsilicoIncMember 2025-01-01 2025-01-01 0001998781 srt:MaximumMember IBAC:GnqInsilicoIncMember 2025-01-01 2025-01-01 0001998781 IBAC:GnqInsilicoIncMember us-gaap:StockOptionMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember 2026-06-26 2026-06-26 0001998781 IBAC:GnqInsilicoIncMember IBAC:BridgeFinancingMember IBAC:LetterAgreementMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:SecuredPromissoryNoteMember IBAC:LetterAgreementMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember IBAC:NoteAndWarrantsMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember 2026-03-16 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:SecuredPromissoryNoteMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:ConvertibleDebtMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2025-12-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:ConvertibleDebtMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2026-01-01 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:ConvertibleDebtMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:WarrantMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputExercisePriceMember us-gaap:ConvertibleDebtMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputExercisePriceMember us-gaap:ConvertibleDebtMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ConvertibleDebtMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ConvertibleDebtMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:MeasurementInputDiscountRateCalibratedMember us-gaap:ConvertibleDebtMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember IBAC:MeasurementInputDiscountRateCalibratedMember us-gaap:ConvertibleDebtMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputExercisePriceMember us-gaap:WarrantMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputExercisePriceMember us-gaap:WarrantMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputDiscountRateMember us-gaap:WarrantMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputDiscountRateMember us-gaap:WarrantMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2026-03-16 0001998781 IBAC:GnqInsilicoIncMember us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2026-03-31 0001998781 IBAC:PhaseOneMember IBAC:GnqInsilicoIncMember 2025-09-25 0001998781 IBAC:PhaseTwoMember IBAC:GnqInsilicoIncMember 2025-09-25 0001998781 IBAC:PhaseOneMember IBAC:GnqInsilicoIncMember 2026-03-31 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember IBAC:ConsultingAgreementMember 2025-11-20 2025-11-20 0001998781 IBAC:GnqInsilicoIncMember IBAC:ShareCapitalAndWarrantsMember IBAC:SoftwareServicesAgreementMember 2026-03-11 2026-03-11 iso4217:USD shares iso4217:USD shares pure iso4217:CAD shares iso4217:CAD utr:sqft false 0001998781

Unlimited

http://fasb.org/us-gaap/2026#UsefulLifeTermOfLeaseMember

Unlimited

S-4 IB Acquisition Corp. NV 6770 85-2946784 1200 N Federal Highway Suite 215 Boca Raton FL 33432 (214) 687-0020 I-B Good Works 4, LLC 1200 N Federal Highway Suite 215, Boca Raton FL 33432 (214) 687-0020 Non-accelerated Filer true true false

428700

822799

787365

27833

36216

339500

1243898

1198515

15890194

118601873

17134092

119800388

73757

86718

694245

635512

1061310

2788

1832100

722230

1832100

722230

1490880

11500000

10.72

10.26

15983315

117966361

0.0001

10000000

0.0001

100000000

4249090

425

-681748

1111372

-681323

1111797

17134092

119800388

748908

523974

-748908

-523974

5130712 3026873

5130712

3026873

4381804

2502899

965635

635512

3416169

1867387

11253200

5860274

0.22

0.20

11253200

5860274

0.22

0.19

4249090

3548500

0.22

0.20

4249090

3755982

0.22

0.19

3243590

324

2676

-8434

-5434

610500

6104939

6105000

2415000

-184528

395000

3867010

3867050

-12205097 -747581 -12952678

1867387

4249090

425

1111372

1111797

4249090

425

1111372

1111797

-4147979 -4147979 -1061310 -1061310

3416169

4249090

425

-681748

-681323

4249090

425

-681748

-681323

3416169

1867387

5130712 3026873

-8383

36216

-339500 339500

2788

-12961

78731

58733

635512

-1318100

-820959

-1711366 -106131025

115575000

107842391

-115575000

111550000

6105000

147629

2249805

2299805

-438795

106131025

-106131025

117166205

393266

770246

822799

52553

1216065

822799

428700

822799

787365

1216065

822799

3867050

81208 4147979 12952678 1061310

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS IB Acquisition Corp. f/k/a I-B Good Works 4 Corporation (the “Company”) is a blank check company originally incorporated under the laws of the State of Delaware on July 7, 2020 and which converted to a Nevada corporation on September 21, 2023 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company has not selected any potential business combination target, and the Company has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with the Company. The Company’s investment strategy is not specific to any sector, however, the management team and board members believe there are compelling investment opportunities in a number of areas including consumer goods, sports and entertainment, and healthcare technology. The Company anticipates targeting companies domiciled in North America, Europe and Asia, with an enterprise value of at least $500 million. As of September 30, 2025, the Company had not yet commenced any operations. All activity through September 30, 2025, relates to the Company’s formation, initial public offering (the “Initial Public Offering” as further defined below) and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income on cash and cash equivalents in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected September 30 as its fiscal year end. The registration statement for the Company’s Initial Public Offering was declared effective on March 25, 2024. On March 28, 2024, the Company consummated the Initial Public Offering of 11,500,000 units (the “Units”), which includes the full exercise by the underwriters of their over-allotment option in the amount of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zRlb1y4KZRD8" title="Number of units sold">1,500,000 Units, at a purchase price of $10.00 per Unit, generating gross proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zX5cdnP7DAmb" title="Gross proceeds from issuance">115,000,000, which is discussed in Note 3. Each Unit consists of one share of the Company’s common stock, and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of one share of common stock upon the consummation of the Business Combination. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 610,500 Units (the “Private Placement Units”) at a price of $10.00 per Unit in a private placement to the Company’s sponsor, I-B Good Works 4, LLC (the “Sponsor”), which is an affiliate of I-Bankers Securities, Inc. (“I-Bankers”). The Private Placement Units are identical to the units sold in the Initial Public Offering. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward completing a Business Combination. Transaction costs amounted to $7,755,845 consisting of the fair value amount of $3,867,050 related with the issued representative shares, $3,450,000 of cash underwriting discount, and $438,795 of other offering costs. The Company must complete its initial Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding any M&A fees (see note 6) held in the Trust Account and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to successfully effect a Business Combination. Upon the closing of the Initial Public Offering, management has agreed that $10.05 per Unit sold in the Initial Public Offering, including proceeds of the sale of the Private Placement Units, will be held in a trust account (“Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s stockholders, as described below. The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account (initially $10.05 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The shares of common stock were recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 upon such completion of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders, which are holders of the Founder Shares, have agreed to (i) waive their redemption rights with respect to their Private Placement Shares (as defined below) in connection with the completion of the Business Combination, (ii) waive their redemption rights with respect to their Founder Shares (defined below), Private Placement Shares (defined below) and any Public Shares they hold in connection with a stockholder vote to approve an amendment to the Company’s amended and restated articles of incorporation (a) to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete the Business Combination within the combination period or (b) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity and (iii) waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares and Private Placement Shares if the Company fails to complete the Business Combination within the combination period. In addition, the Sponsor has agreed to vote any Private Placement Shares held by it in favor of the Business Combination. Additionally, each public stockholder may elect to redeem its Public Shares, irrespective of whether they vote for or against a proposed Business Combination. Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s amended and restated articles of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares. The Company initially had until 18 months from the closing of the Initial Public Offering to complete a Business Combination, and further extended, as described below, to 24 months from the closing of the Initial Public Offering to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $100,000 of interest to pay dissolution expenses, which shall be net of taxes payable), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to its obligations under Nevada law to provide for claims of creditors and the requirements of other applicable law. The initial stockholders have agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The Underwriters will not receive their M&A fee (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.05). The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a third party for services rendered or products sold to the Company, or by a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.05 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the Underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”), in connection with both our initial public offering and the business combination. Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. On September 22, 2025, the Company held the Special Meeting and the stockholders approved the Company’s First Amendment to its Amended and Restated Articles of Incorporation (the “Extension Amendment”). The Extension Amendment, among other things, (i) extends the date by which the Company must consummate its initial business combination to March 28, 2026 or such later date as may be approved by the Company’s stockholders in accordance with its amended and restated articles of incorporation; (ii) provides that, prior to the earliest of the completion of a business combination, the redemption of 100% of the Offering Shares if the Company is unable to complete its initial Business Combination by March 28, 2026, and the redemption of shares in connection with a vote seeking to amend any provisions of the Company’s Amended and Restated Articles relating to stockholders’ rights or any pre-initial Business Combination activity, funds in the Company’s trust account will not be released, other than interest to pay franchise and income taxes; (iii) sets forth the redemption and liquidation procedures if the Company does not consummate a business combination by the March 28, 2026; and (iv) provides public stockholders with the right to redeem their shares in connection with any amendment that modifies the substance or timing of the Company’s obligation to redeem 100% of the public shares if it has not consummated a business combination by March 28, 2026, or with respect to other material pre-business combination provisions, subject to the applicable redemption limitation. In connection with the Special Meeting, stockholders holding 10,009,120 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.60 per share of the funds in the Trust Account. As a result, approximately $106.1 million was removed from the Trust Account to pay such holders, leaving approximately $15.8 million remaining in the Trust Account. This amount is subject to change to account for the payment of tax withdrawals. Risks and Uncertainties The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (“NATO”) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. On July 4, 2025, the One Big Beautiful Bill Act (the “OBBBA”) was enacted into law in the United States. The significant provisions of OBBBA include the permanent extension and modification of certain provisions of the Tax Cuts and Jobs Act, including international tax provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented in later years. The Company is evaluating the provisions of OBBBA but it is not expected to have a material impact on the Company’s financial statements. Excise Tax On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The IR Act applies only to repurchases that occur after December 31, 2022. Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete a Business Combination. During the second quarter of 2024, the Internal Revenue Service issued final regulations with respect to the timing and payment of the excise tax. These regulations provided that the filing and payment deadline for any liability incurred during the period from January 1, 2023 to December 31, 2023 would be October 31, 2024. The Company is currently evaluating its options with respect to this obligation. Any amount of such excise tax not paid in full, will be subject to additional interest and penalties which are currently estimated at 10% interest per annum and a 5% underpayment penalty per month or portion of a month up to 25% of the total liability for any amount that is unpaid from November 1, 2024 until paid in full. In connection with the Special Meeting held on September 22, 2025, stockholders holding 10,009,120 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.60 per share of the funds in the Trust Account. As a result, approximately $106.1 million was removed from the Trust Account to pay such holders, leaving approximately $15.8 million remaining in the Trust Account. This amount is subject to change to account for the payment of tax withdrawals. The Company has recorded 1% excise tax based on the amount redeemed or an aggregate amount of $1,061,310 excise tax payable. As of September 30, 2025 and September 30, 2024, the Company’s aggregate excise tax payable amounted to $1,061,310 and $0, respectively. Going Concern Consideration As of September 30, 2025, the Company had $428,700 in cash, $787,365 in restricted cash and a working capital deficit of $588,202. In connection with the Company’s assessment of going concern considerations in accordance with the authoritative guidance in Financial Accounting Standard Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Company currently lacks the liquidity it needs to sustain operations for a reasonable period of time, which is considered to be at least one year from the date that the financial statements are issued as it expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management plans to address this uncertainty through a Business Combination. There is no assurance that the Company’s plans to raise capital or to consummate a Business Combination will be successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

500000000

11500000

1500000

10.00

115000000

610500

10.00

7755845

3867050

3450000

438795

10.05

5000001 1 (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $100,000 of interest to pay dissolution expenses, which shall be net of taxes payable), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to its obligations under Nevada law to provide for claims of creditors and the requirements of other applicable law.

10.05

10009120

10.60

106100000

15800000

0.10 0.05 0.25

10009120

10.60

106100000

15800000

1061310

428700

787365

588202

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”). Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company had $428,700 and $822,799 in cash as of September 30, 2025, and September 30, 2024, respectively, and no cash equivalents. Cash – Restricted Cash that is encumbered or otherwise restricted as to its use is included in cash – restricted. As of September 30, 2025 and 2024, the balance was $787,365 and $0, respectively. Cash – restricted at September 30, 2025 represents cash that was withdrawn from the Trust Account to pay income taxes but is yet to be utilized at the end of the period. Cash and investments held in Trust account As of September 30, 2025 and 2024, all of the assets held in the Trust Account were held in money market funds which are invested only in U.S. government securities. Investments in money market funds are presented on the balance sheet at fair value at the end of each reporting period. Interest and dividends earned from investments in these securities are included in the statements of operations. Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering”. Offering costs consist principally of professional and registration fees, cash underwriting discount, and deferred underwriting fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on relative fair value basis, compared to total proceeds received. Offering costs allocated to the Public Shares were charged against the carrying value of ordinary shares subject to possible redemption upon the completion of the Initial Public Offering and offering costs allocated to Public Rights (as defined in Note 3) were charged to additional paid in capital at the completion of the Initial Public Offering. Common Stock Subject to Possible Redemption The Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, or if there is a shareholder vote or tender offer in connection with the Company’s initial business combination. In accordance with ASC 480-10-S99, the Company classifies Public Shares subject to redemption outside of permanent equity as the redemption provisions are not solely within the control of the Company. The Public Shares sold as part of the Units in the Initial Public Offering were issued with other freestanding instruments (i.e., Public Rights) and as such, the initial carrying value of Public Shares classified as temporary equity are the allocated proceeds determined in accordance with ASC 470-20. The Company recognizes changes in redemption value immediately as it occurs and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable shares will result in charges against retained earnings or additional paid-in capital in the absence of retained earnings. Accordingly, as of September 30, 2025 and 2024, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable shares are affected by charges against retained earnings or additional paid-in capital in the absence of retained earnings. In connection with the Special Meeting held on September 22, 2025, stockholders holding 10,009,120 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.60 per share of the funds in the Trust Account. As a result, approximately $106.1 million was removed from the Trust Account to pay such holders, leaving approximately $15.8 million remaining in the Trust Account. This amount is subject to change to account for the payment of tax withdrawals. As of September 30, 2025 and 2024, the common stock subject to redemption reflected in the balance sheet are reconciled in the following table: SCHEDULE OF COMMON STOCK SUBJECT TO REDEMPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross proceeds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--GrossProceedsSubjectToRedemption_c20231001__20240930_zLpNT9Uy0Wd9" style="width: 16%; text-align: right" title="Gross proceeds">115,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Proceeds allocated to Public Rights</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ProceedsAllocatedToPublicRights_c20231001__20240930_z55IgWhcFq6g" style="text-align: right" title="Proceeds allocated to Public Rights">(2,415,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common stock issuance costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--CommonStockIssuanceCost_c20231001__20240930_zxH6MwAuToS1" style="text-align: right" title="Common stock issuance costs">(7,571,317</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20231001__20240930_zL9V3Lr8Qlr4" style="border-bottom: Black 1pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">12,952,678</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption, September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20241001__20250930_zJOI2fkhui8c" style="text-align: right" title="Common stock subject to possible redemption, September 30, 2024">117,966,361</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Redemptions of common stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--RedemptionsOfCommonStock_c20241001__20250930_zJtaT1H2C0j3" style="text-align: right" title="Redemptions of common stock">(106,131,025</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20241001__20250930_zZhvmO95rpFf" style="border-bottom: Black 1pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">4,147,979</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption, September 30, 2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20241001__20250930_zTIeTfvQcgJ5" style="text-align: right" title="Common stock subject to possible redemption, September 30, 2025">15,983,315</td><td style="text-align: left"> </td></tr> </table> Income Taxes The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, Income Taxes, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of September 30, 2025 and 2024, the Company’s deferred tax asset had a full valuation allowance recorded against it. Our effective tax rate was 22.04% and 25.39% for the year ended September 30, 2025 and 2024, respectively. The effective tax rate differs from the statutory tax rate of 21% for the period ended September 30, 2025 and 2024, due to the valuation allowance on the deferred tax assets, interest and penalties and true up of startup costs per 2024 filed return. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Net Income Per Common Stock The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding for the period. Remeasurement associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted net income per share does not consider the effect of the rights issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the rights are contingent upon the occurrence of future events. As of September 30, 2025 and 2024, the rights are exercisable to purchase 605,525 shares of common stock in the aggregate. The weighted average of these shares was excluded from the calculation of diluted net income common stock since the inclusion of such rights would be anti-dilutive. The rights cannot be converted to shares of common stock prior to an initial Business Combination; therefore, they have been classified as anti-dilutive. The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET LOSS PER COMMON STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241001__20250930__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zShcEJE9Ef69" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241001__20250930__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zpCmnkDlo6Xd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231001__20240930__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zCI5WdhpLr0d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20231001__20240930__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zgYZUKKpg764" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareBasicAbstract_iB_zfA9gyZRvoF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Basic net income per common share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zgPq6HDp0KS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 44%; text-align: left">Allocation of net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,479,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">936,353</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,163,106</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">704,281</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zF7YWV7agDlc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Basic weighted-average shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,253,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,249,090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,860,274</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,548,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_zfTo421FLrI4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic net income per common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareDilutedAbstract_iB_znkNGq5n6o6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Diluted net income per common share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_zWENfsjxW8L2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 44%; text-align: left">Allocation of net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,479,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">936,353</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,138,010</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">729,377</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zk0aYZHO1fAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Diluted weighted average shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,253,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,249,090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,860,274</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,755,982</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_pid_ztNIGrzidoZj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Diluted net income per common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.19</td><td style="text-align: left"> </td></tr> </table> Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on the cash account and management believes that the Company is not exposed to significant risks on such account. Uninsured cash amount as of September 30, 2025 and 2024, are $966,065 and $572,799, respectively. Fair value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. Recent Accounting Standards In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating officer decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. The ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in this ASU and existing segment disclosures in Topic 280. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. ASU 2023-07 became effective as of December 31, 2024 and the Company’s management adopted ASU 2023-07 in its financial statements and related disclosures (see Note 10). Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Basis of Presentation The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”).

Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company had $428,700 and $822,799 in cash as of September 30, 2025, and September 30, 2024, respectively, and no cash equivalents.

428700

822799

Cash – Restricted Cash that is encumbered or otherwise restricted as to its use is included in cash – restricted. As of September 30, 2025 and 2024, the balance was $787,365 and $0, respectively. Cash – restricted at September 30, 2025 represents cash that was withdrawn from the Trust Account to pay income taxes but is yet to be utilized at the end of the period.

787365

Cash and investments held in Trust account As of September 30, 2025 and 2024, all of the assets held in the Trust Account were held in money market funds which are invested only in U.S. government securities. Investments in money market funds are presented on the balance sheet at fair value at the end of each reporting period. Interest and dividends earned from investments in these securities are included in the statements of operations.

Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering”. Offering costs consist principally of professional and registration fees, cash underwriting discount, and deferred underwriting fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on relative fair value basis, compared to total proceeds received. Offering costs allocated to the Public Shares were charged against the carrying value of ordinary shares subject to possible redemption upon the completion of the Initial Public Offering and offering costs allocated to Public Rights (as defined in Note 3) were charged to additional paid in capital at the completion of the Initial Public Offering.

Common Stock Subject to Possible Redemption The Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, or if there is a shareholder vote or tender offer in connection with the Company’s initial business combination. In accordance with ASC 480-10-S99, the Company classifies Public Shares subject to redemption outside of permanent equity as the redemption provisions are not solely within the control of the Company. The Public Shares sold as part of the Units in the Initial Public Offering were issued with other freestanding instruments (i.e., Public Rights) and as such, the initial carrying value of Public Shares classified as temporary equity are the allocated proceeds determined in accordance with ASC 470-20. The Company recognizes changes in redemption value immediately as it occurs and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable shares will result in charges against retained earnings or additional paid-in capital in the absence of retained earnings. Accordingly, as of September 30, 2025 and 2024, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable shares are affected by charges against retained earnings or additional paid-in capital in the absence of retained earnings. In connection with the Special Meeting held on September 22, 2025, stockholders holding 10,009,120 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.60 per share of the funds in the Trust Account. As a result, approximately $106.1 million was removed from the Trust Account to pay such holders, leaving approximately $15.8 million remaining in the Trust Account. This amount is subject to change to account for the payment of tax withdrawals. As of September 30, 2025 and 2024, the common stock subject to redemption reflected in the balance sheet are reconciled in the following table: SCHEDULE OF COMMON STOCK SUBJECT TO REDEMPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross proceeds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--GrossProceedsSubjectToRedemption_c20231001__20240930_zLpNT9Uy0Wd9" style="width: 16%; text-align: right" title="Gross proceeds">115,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Proceeds allocated to Public Rights</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ProceedsAllocatedToPublicRights_c20231001__20240930_z55IgWhcFq6g" style="text-align: right" title="Proceeds allocated to Public Rights">(2,415,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common stock issuance costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--CommonStockIssuanceCost_c20231001__20240930_zxH6MwAuToS1" style="text-align: right" title="Common stock issuance costs">(7,571,317</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20231001__20240930_zL9V3Lr8Qlr4" style="border-bottom: Black 1pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">12,952,678</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption, September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20241001__20250930_zJOI2fkhui8c" style="text-align: right" title="Common stock subject to possible redemption, September 30, 2024">117,966,361</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Redemptions of common stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--RedemptionsOfCommonStock_c20241001__20250930_zJtaT1H2C0j3" style="text-align: right" title="Redemptions of common stock">(106,131,025</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20241001__20250930_zZhvmO95rpFf" style="border-bottom: Black 1pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">4,147,979</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption, September 30, 2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20241001__20250930_zTIeTfvQcgJ5" style="text-align: right" title="Common stock subject to possible redemption, September 30, 2025">15,983,315</td><td style="text-align: left"> </td></tr> </table>

10009120

10.60

106100000

15800000

As of September 30, 2025 and 2024, the common stock subject to redemption reflected in the balance sheet are reconciled in the following table: SCHEDULE OF COMMON STOCK SUBJECT TO REDEMPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross proceeds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--GrossProceedsSubjectToRedemption_c20231001__20240930_zLpNT9Uy0Wd9" style="width: 16%; text-align: right" title="Gross proceeds">115,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Proceeds allocated to Public Rights</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ProceedsAllocatedToPublicRights_c20231001__20240930_z55IgWhcFq6g" style="text-align: right" title="Proceeds allocated to Public Rights">(2,415,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common stock issuance costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--CommonStockIssuanceCost_c20231001__20240930_zxH6MwAuToS1" style="text-align: right" title="Common stock issuance costs">(7,571,317</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20231001__20240930_zL9V3Lr8Qlr4" style="border-bottom: Black 1pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">12,952,678</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption, September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20241001__20250930_zJOI2fkhui8c" style="text-align: right" title="Common stock subject to possible redemption, September 30, 2024">117,966,361</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Redemptions of common stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--RedemptionsOfCommonStock_c20241001__20250930_zJtaT1H2C0j3" style="text-align: right" title="Redemptions of common stock">(106,131,025</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20241001__20250930_zZhvmO95rpFf" style="border-bottom: Black 1pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">4,147,979</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption, September 30, 2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20241001__20250930_zTIeTfvQcgJ5" style="text-align: right" title="Common stock subject to possible redemption, September 30, 2025">15,983,315</td><td style="text-align: left"> </td></tr> </table> 115000000 -2415000 -7571317 12952678

117966361

-106131025 4147979

15983315

Income Taxes The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, Income Taxes, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of September 30, 2025 and 2024, the Company’s deferred tax asset had a full valuation allowance recorded against it. Our effective tax rate was 22.04% and 25.39% for the year ended September 30, 2025 and 2024, respectively. The effective tax rate differs from the statutory tax rate of 21% for the period ended September 30, 2025 and 2024, due to the valuation allowance on the deferred tax assets, interest and penalties and true up of startup costs per 2024 filed return. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

0.2204

0.2539

0.21

Net Income Per Common Stock The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding for the period. Remeasurement associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted net income per share does not consider the effect of the rights issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the rights are contingent upon the occurrence of future events. As of September 30, 2025 and 2024, the rights are exercisable to purchase 605,525 shares of common stock in the aggregate. The weighted average of these shares was excluded from the calculation of diluted net income common stock since the inclusion of such rights would be anti-dilutive. The rights cannot be converted to shares of common stock prior to an initial Business Combination; therefore, they have been classified as anti-dilutive. The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET LOSS PER COMMON STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241001__20250930__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zShcEJE9Ef69" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241001__20250930__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zpCmnkDlo6Xd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231001__20240930__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zCI5WdhpLr0d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20231001__20240930__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zgYZUKKpg764" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareBasicAbstract_iB_zfA9gyZRvoF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Basic net income per common share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zgPq6HDp0KS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 44%; text-align: left">Allocation of net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,479,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">936,353</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,163,106</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">704,281</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zF7YWV7agDlc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Basic weighted-average shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,253,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,249,090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,860,274</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,548,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_zfTo421FLrI4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic net income per common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareDilutedAbstract_iB_znkNGq5n6o6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Diluted net income per common share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_zWENfsjxW8L2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 44%; text-align: left">Allocation of net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,479,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">936,353</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,138,010</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">729,377</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zk0aYZHO1fAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Diluted weighted average shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,253,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,249,090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,860,274</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,755,982</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_pid_ztNIGrzidoZj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Diluted net income per common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.19</td><td style="text-align: left"> </td></tr> </table>

605525

The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET LOSS PER COMMON STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241001__20250930__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zShcEJE9Ef69" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241001__20250930__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zpCmnkDlo6Xd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231001__20240930__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zCI5WdhpLr0d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20231001__20240930__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zgYZUKKpg764" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareBasicAbstract_iB_zfA9gyZRvoF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Basic net income per common share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zgPq6HDp0KS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 44%; text-align: left">Allocation of net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,479,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">936,353</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,163,106</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">704,281</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zF7YWV7agDlc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Basic weighted-average shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,253,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,249,090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,860,274</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,548,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_zfTo421FLrI4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic net income per common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-redeemable</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareDilutedAbstract_iB_znkNGq5n6o6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Diluted net income per common share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_zWENfsjxW8L2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 44%; text-align: left">Allocation of net income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,479,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">936,353</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,138,010</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">729,377</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zk0aYZHO1fAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Diluted weighted average shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,253,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,249,090</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,860,274</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,755,982</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_pid_ztNIGrzidoZj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Diluted net income per common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.19</td><td style="text-align: left"> </td></tr> </table>

2479816

936353

1163106

704281

11253200

4249090

5860274

3548500

0.22

0.20

2479816

936353

1138010

729377

11253200

4249090

5860274

3755982

0.22

0.19

Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on the cash account and management believes that the Company is not exposed to significant risks on such account. Uninsured cash amount as of September 30, 2025 and 2024, are $966,065 and $572,799, respectively.

250000

966065

572799

Fair value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.

Recent Accounting Standards In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating officer decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. The ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in this ASU and existing segment disclosures in Topic 280. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. ASU 2023-07 became effective as of December 31, 2024 and the Company’s management adopted ASU 2023-07 in its financial statements and related disclosures (see Note 10). Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

NOTE 3. INITIAL PUBLIC OFFERINGs Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units, which includes a full exercise by the underwriter of their over-allotment option in the amount of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zguYGVacBPfi" title="Number of units sold">1,500,000 Units, at a purchase price of $10.00 per Unit. <span id="xdx_901_eus-gaap--SaleOfStockDescriptionOfTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z5Zt7i0tRkI7" title="Sale of units, description">Each Unit consists of one share of the Company’s common stock, and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of one share of common stock upon the consummation of the Business Combination.

11500000

1500000

10.00

Each Unit consists of one share of the Company’s common stock, and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of one share of common stock upon the consummation of the Business Combination.

NOTE 4. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor has purchased an aggregate of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zPBTiQ1LjIvi" title="Number of units sold">610,500 Private Placement Units at a price of $10.00 per Private Placement Unit from the Company in a private placement. Each Private Unit will consist of one share of common stock (“Private Placement Share”) and one right (“Private Placement Right”). Each Private Placement Right will entitle the holder to receive one-twentieth of one share of common stock at the closing of a Business Combination. Certain proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placements Units and all underlying securities will expire worthless.

610500

10.00

NOTE 5. RELATED PARTY TRANSACTIONS Founder Shares On September 2, 2020, the Sponsor subscribed to purchase an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200902__20200902__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_zILkKWXb8Onk" title="Issuance of shares">4,312,500 shares (the “Founder Shares”) for a subscription price of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20200902__20200902__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_zWDdkzikqDa" title="Subscription price">3,000. On October 26, 2023, the Sponsor agreed to surrender an aggregate of <span id="xdx_905_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20231026__20231026__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_zdsReNKZyCvh" title="Number of shares surrender">1,068,910 shares of the Company’s common stock for no consideration, which were cancelled, resulting in the Sponsor holding an aggregate of 3,243,590 Founder Shares. The subsequent cancellation is retrospectively reflected in the financial statements from day one. The Company maintains the ownership of Founder Shares by the initial stockholders at <span id="xdx_908_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20231001__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_z818Lxywa7Me" title="Ownership percentage">22.0% of the Company’s issued and outstanding shares of common stock upon the consummation of the Initial Public Offering, not including the Private Placement Shares or the Representative Shares. Up to <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_zQ2hVqQdjyr3" title="Common stock shares outstanding">423,077 Founder Shares held by the initial stockholders are no longer subject to forfeiture due to the underwriters’ over-allotment option exercised in full at the Initial Public Offering. The initial stockholders and the officers and directors have agreed not to transfer, assign or sell any of the Founder Shares until the earlier of (i) six months after the date of the consummation of the Business Combination or (ii) the date on which the Company completes a liquidation, merger, stock exchange or other similar transaction after its initial business combination that results in all of its public stockholders having the right to exchange their shares of common stock for cash, securities or other property. <span id="xdx_902_eus-gaap--SaleOfStockDescriptionOfTransaction_pid_c20231001__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_zqqtvrwZCTU5" title="Sale of stock description">Notwithstanding the foregoing, if the last sale price of the Company’s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after its initial business combination, the Founder Shares will be released from the lock-up. Due to Sponsor During the year ended September 30, 2025, the Sponsor incurred travel expenses amounting to $2,788 which are reimbursable by Su De Tang Global Corporation, the reimbursement was paid to the Company through the proceeds of the working capital loans. As of September 30, 2025 and 2024, the Company had due to Sponsor, non-interest bearing and due on demand in the amount of $2,788 and $0, respectively. Subscription Agreements From October 2023 through January 2024, the Company’s Sponsor entered into six subscription agreements to sell membership interests in the Sponsor to members of management, directors and director nominees. The membership interests represent the indirect equivalent of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231001__20240131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_ztx2QIQBowm9" title="Number of shares issued">525,000 Founders Shares which equates to <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zi4iAJYhyKfc" title="Ownership percentage">16.19% of the 3,243,590 Founders Shares issued and outstanding. The total purchase price paid for the membership interests was $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20231001__20240131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zVzAyj9Y04Ra" title="Value of shares issued">2,500. The Company modified the agreements in February 2024, with the intent to clarify that the Founder Shares are “earned upon the completion of a successful Business Combination” and the modified agreement is to be effective contemporaneously with the date and time of the initial subscription agreements. The sale of the membership interests to the Company’s management, directors and director’s nominees is in the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. On January 22, 2024, one of the subscription agreements representing an indirect equivalent of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240122__20240122__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z2Aa1Cc6AZnb" title="Number of shares terminted">100,000 Founders Shares or <span id="xdx_907_ecustom--PercentageOfSharesTerminated_pid_dp_uPure_c20240122__20240122__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zFwbmD3DYzle" title="Percentage of shares terminated">3.08% of the <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zcrGaqKeaOhd" title="Common stock shares outstanding"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_ziSc0nV64ij7" title="Common stock shares outstanding">3,243,590 Founders Shares (with over-allotment) issued and outstanding was terminated and $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_c20240122__20240122__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember_ziK2DKPTwGti" title="Paid to subscriber">500 was paid to the subscriber as a result of the termination of the agreement. On September 11, 2024, one of the subscription agreements representing an indirect equivalent of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zyWSxlUatCZb" title="Number of shares issued">100,000 Founders Shares or <span id="xdx_90C_ecustom--PercentageOfSharesTerminated_pid_dp_uPure_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zVVsTo9sWus9" title="Percentage of shares terminated">3.08% of the <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240911__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_ztjaNDs84KMh" title="Common stock shares outstanding">3,243,590 Founders Shares (with over-allotment) issued and outstanding was amended in which the Sponsor granted an additional <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zRIT7tOD5HFe" title="Number of shares issued">50,000 Founder Shares bringing the total to <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zPJ5Ui6qLBFf" title="Number of shares terminted">150,000 Founder Shares or <span id="xdx_905_ecustom--PercentageOfShareTerminated_pid_dp_uPure_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zC1xh1UCpbP9" title="Percentage of share terminated">4.06% of the <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240911__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zocqg1YZaXPh" title="Number of shares held">3,243,590 Founders Shares (with over-allotment) issued and outstanding. The total purchase price paid for the membership interest was $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240911__20240911__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember_zgvmGzBzfKel" title="Paid to subscriber">750. The fair value of the <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240328__20240328__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zWYheQBsy8d3" title="Number of shares issued">425,000 shares granted through March 28, 2024, to the Company’s directors and director nominees was approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240328__20240328__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z3UNvIM0gdHh" title="Number of shares issued, value">1,734,000 or approximately $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20240328__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zKfXSG9jwg8i" title="Share price">4.08 per share. The fair value of the additional <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240912__20240912__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zPvVRhsVWjok" title="Number of shares issued">50,000 shares granted on September 11, 2024, to the Company’s directors and director nominees was approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240912__20240912__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zwD9rpZhZdNf" title="Number of shares issued, value">499,000 or approximately $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240912__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zoEayD8tqJKe" title="Share price">9.98 per share. The Founders Shares were granted subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of September 30, 2025, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of Founders Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founders Shares. <p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zHkCWu7RRvti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Founder Shares issued to the directors and director nominees were valued using a Black-Scholes model. The following criteria presents the quantitative information regarding market assumptions used in the Founder Share valuations: SCHEDULE OF FAIR VALUE OF MARKET ASSUMPTIONS USED IN THE FOUNDER SHARE VALUATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231115__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember_zRTo60e8TuD7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">November 15, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240115__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember_zODhYqnlc414" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 15, 2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zEpzC6rkxt7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">5.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">5.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zmYGRUNhL8Lj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zLMooIO7s5na" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Spot price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.32</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountForLackOfMarketabilityMember_zKoyLgdDUnv" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Discount of lack of marketability (DLOM)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.4</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountForLackOfMarketabilityMember_zCDBkauloSDc" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Equity measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.4</td><td style="text-align: left">%</td></tr> </table> Administrative Support Agreement The Company entered into an Administrative Services Agreement pursuant to which the Company agreed to pay the Chief Financial Officer a sum of $5,000 per month commencing on October 1, 2023. Upon completion of the initial business combination or the liquidation, the Company will cease paying these monthly fees. On January 22, 2024, the Company’s Chief Financial Officer resigned, and the Administrative Services Agreement was terminated. On January 22, 2024, the Company appointed a new Chief Financial Officer and entered into an Administrative Services Agreement dated January 24, 2024, pursuant to which the Company agreed to pay the Chief Financial Officer a sum of $5,000 per month commencing at the time of the Initial Public Offering closing. The agreement further specified that upon completion of the initial business combination or the liquidation, the Company will cease paying these monthly fees. For the year ended September 30, 2025, the Company incurred $60,000 in fees for these services, of which $15,000 is recorded as accrued expenses in the balance sheet as of September 30, 2025. For the year ended September 30, 2024, the Company incurred $45,000 in fees for these services, of which $15,000 is included in accrued expenses in the accompanying balance sheet as of September 30, 2024

4312500

3000

1068910

3243590

0.220

423077

Notwithstanding the foregoing, if the last sale price of the Company’s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after its initial business combination, the Founder Shares will be released from the lock-up.

2788

525000

0.1619

3243590

2500

100000

0.0308

3243590

500

100000

0.0308

3243590

50000

150000

0.0406

3243590

750

425000

1734000

4.08

50000

499000

9.98

<p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zHkCWu7RRvti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Founder Shares issued to the directors and director nominees were valued using a Black-Scholes model. The following criteria presents the quantitative information regarding market assumptions used in the Founder Share valuations: SCHEDULE OF FAIR VALUE OF MARKET ASSUMPTIONS USED IN THE FOUNDER SHARE VALUATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231115__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember_zRTo60e8TuD7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">November 15, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240115__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember_zODhYqnlc414" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 15, 2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zEpzC6rkxt7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">5.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">5.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zmYGRUNhL8Lj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zLMooIO7s5na" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Spot price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.32</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountForLackOfMarketabilityMember_zKoyLgdDUnv" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Discount of lack of marketability (DLOM)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.4</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountForLackOfMarketabilityMember_zCDBkauloSDc" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Equity measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.4</td><td style="text-align: left">%</td></tr> </table>

5.0

4.8

4.1

8.95

9.32

0.2

0.4

0.2

0.4

5000

60000

15000

45000

15000

NOTE 6. COMMITMENTS AND CONTINGENCY Registration Rights The holders of the Founder Shares, Private Placement Units (and their underlying securities) any Units that may be issued upon conversion of the Working Capital Loans (and underlying securities), and Representative Shares are entitled to registration rights pursuant to a registration rights agreement signed on the effective date of the Initial Public Offering requiring the Company to register such securities for resale. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement and Business Combination Marketing Agreement The Company engaged I-Bankers to act as Underwriters on the Initial Public Offering of the Company’s Units, for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQu0shZhZESa" title="Stock issued during period value">115,000,000 and the simultaneous listing on the Nasdaq Global Market. The Underwriters had a 30-day option to purchase up to an additional <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDvwX31pHtC4" title="Stock issued during period shares">1,500,000 Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. On March 28, 2024, simultaneously with the closing of the Initial Public Offering, the Underwriters elected to fully exercise the over-allotment option to purchase an additional <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zm9ZDdhudyEj" title="Number of units sold">1,500,000 Units at a price of $10.00 per Unit. The Underwriters were entitled to a cash underwriting discount of $<span id="xdx_900_ecustom--CashUnderwritingDiscountPerUnit_iI_pid_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zci7mreSxkw6" title="Cash underwriting discount per unit">0.30 per Unit, or $<span id="xdx_900_eus-gaap--PaymentsForUnderwritingExpense_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zl5wVsyFDqq8" title="Cash underwriting fees">3,450,000 in the aggregate, paid upon the closing of the Initial Public Offering. In addition, under a business combination marketing agreement, the Company engaged I-Bankers to provide marketing services in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, <span id="xdx_90E_eus-gaap--ManagementAndServiceFeesRate_pid_dp_uPure_c20241001__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zKgTvfYYnbv3" title="Percentage of cash fee for service">3.5% of the gross proceeds of the Initial Public Offering (the “M&A fee”) or $<span id="xdx_90D_ecustom--MergersAndAcquisitionsCashFee_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zw1x5J7GrM4d" title="M&A cash fee">4,025,000 in the aggregate. If the Company doesn’t complete a business combination, no fee will be due. In addition, the Company will pay the I-Bankers a finder fee equal to <span id="xdx_90E_ecustom--PercentageOfFinderFee_pid_dp_uPure_c20241001__20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zMGbS0Xipce4" title="Percentage of finder fee">1.0% of the consideration issued to a target if the business combination is consummated with a target introduced by the I-Bankers. On the closing of the Initial Public Offering, pursuant to the underwriting agreement, the Company issued as compensation <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_c20241001__20250930__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFgcUwqSG6R2" title="Shares issued for compensation">395,000 shares of common stock for no cash consideration (the “Representative Shares”). Working Capital Loan On September 16, 2024, the Company issued an unsecured promissory note in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20240916__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--SuDeTangGlobalCorporationMember_zfGVyTc7FeZ5">150,000 to Su De Tang Global Corporation (the “Working Capital Loan”). The principal balance of this Promissory Note represents the first of potentially three instalments of the Working Capital Loan. The Working Capital Loan bears no interest and will be extinguished without any payment required at the consummation of a Business Combination with Su De Tang Global Corporation. The Company has borrowed a total of $<span id="xdx_902_eus-gaap--OtherBorrowings_iI_c20250930__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--SuDeTangGlobalCorporationMember_zPEXfUw9H6gj" title="Borrowings">147,629 under the Working Capital. As of September 30, 2025, the Company repaid an amount of $<span id="xdx_900_eus-gaap--RepaymentsOfDebt_c20241001__20250930__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--SuDeTangGlobalCorporationMember_zkF4FxnuLWT2" title="Borrowings">147,629. Borrowings under the note are no longer available.

115000000

1500000

10.00

0.30

3450000

0.035

4025000 0.010

395000

150000

147629

NOTE 7. STOCKHOLDERS’ EQUITY STOCKHOLDERS’ (DEFICIT) EQUITY Preferred Stock — The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2025 and 2024, there were no shares of preferred stock issued or outstanding. Common Stock — The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.0001 per share. Holders of common stock are entitled to one vote for each share. As of September 30, 2025 and 2024, there were 4,249,090 shares of common stock issued and outstanding, excluding 1,490,880 and 11,500,000 shares of common stock subject to possible redemption.

10000000

0.0001

100000000

0.0001

Holders of common stock are entitled to one vote for each share

4249090

1490880

11500000

NOTE 8. INCOME TAX INCOME TAXES The Company did not have any significant deferred tax assets or liabilities at September 30, 2025 and 2024. The Company’s net deferred tax asset (liabilities) are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250930_zcxhjHVzs3S" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240930_zapNdpj2JMK5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzGhQ_zqvN736jqdc1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net operating loss carryforward</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DeferredTaxAssetsStartupCosts_iI_maDTAGzGhQ_zKvxzX4yliI" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Startup Costs</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">153,540</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">111,674</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_mtDTAGzGhQ_maDTANzcNp_zQwB0n9fe96j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,674</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzcNp_zvzM7Owu9At9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(153,540</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(111,674</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzcNp_zWWBPoTWifB9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax assets, net of allowance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> </table> The income tax provision for the year ended September 30, 2025 and 2024 consists of the following: SCHEDULE OF INCOME TAX PROVISION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241001__20250930_zycc4k3jGaTh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231001__20240930_zHzqUaPBruGb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Federal</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentFederalTaxExpenseBenefit_zRDo9I8MzEd7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; width: 64%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">965,635</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">635,512</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zWS0QXaKUIOg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(41,866</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109,903</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zYix2y6Bqokl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_z44YdE5lZ945" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zGYtEaEUHDrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,866</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">109,903</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_zRrZTnwLaVM2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax provision</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">965,635</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">635,512</td><td style="text-align: left"> </td></tr> </table> As of September 30, 2025 and 2024, the Company had a total of $0 and $0, respectively, of U.S. federal net operating loss carryovers available to offset future taxable income. The federal net operating loss can be carried forward indefinitely. As of September 30, 2025 and 2024, the Company did not have any state net operating loss carryovers available to offset future taxable income. In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended September 30, 2024, the change in the valuation allowance was $109,903. For the year ended September 30, 2025, the change in the valuation allowance was $41,866. A reconciliation of the federal income tax rate to the Company’s effective tax rate is as follows: SCHEDULE OF RECONCILIATION OF FEDERAL INCOME TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241001__20250930_zkMmakvN1G2c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231001__20240930_z4KYJgESSij3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maA031_zy40FEbUMUN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maA031_zQzJGYTZxZhd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest and penalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.08</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_uPure_maA031_zusXR7Mc01Ce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">True up - Startup Costs and Net Operating Loss per 2024 filed tax return</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2.55</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsChangeInValuationAllowance_pid_dp_uPure_maA031_zQSvV3wXTQp8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3.51</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4.39</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtA031_zIGwuwOHzKm6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax provision</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22.04</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.39</td><td style="text-align: left">%</td></tr> </table> The Company’s effective tax rates for the periods presented differ from the expected (statutory) rates due to changes in fair value in warrants, transaction costs associated with warrants and the recording of full valuation allowances on deferred tax assets. The Company files income tax returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various taxing authorities.

The Company’s net deferred tax asset (liabilities) are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250930_zcxhjHVzs3S" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240930_zapNdpj2JMK5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzGhQ_zqvN736jqdc1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net operating loss carryforward</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DeferredTaxAssetsStartupCosts_iI_maDTAGzGhQ_zKvxzX4yliI" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Startup Costs</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">153,540</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">111,674</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_mtDTAGzGhQ_maDTANzcNp_zQwB0n9fe96j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,674</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzcNp_zvzM7Owu9At9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(153,540</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(111,674</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzcNp_zWWBPoTWifB9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax assets, net of allowance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> </table>

153540 111674

153540

111674

153540

111674

The income tax provision for the year ended September 30, 2025 and 2024 consists of the following: SCHEDULE OF INCOME TAX PROVISION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241001__20250930_zycc4k3jGaTh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231001__20240930_zHzqUaPBruGb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Federal</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--CurrentFederalTaxExpenseBenefit_zRDo9I8MzEd7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; width: 64%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">965,635</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">635,512</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zWS0QXaKUIOg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(41,866</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109,903</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zYix2y6Bqokl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_z44YdE5lZ945" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zGYtEaEUHDrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,866</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">109,903</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_zRrZTnwLaVM2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax provision</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">965,635</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">635,512</td><td style="text-align: left"> </td></tr> </table>

965635

635512

-41866

-109903

41866

109903

965635

635512

109903

41866

A reconciliation of the federal income tax rate to the Company’s effective tax rate is as follows: SCHEDULE OF RECONCILIATION OF FEDERAL INCOME TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241001__20250930_zkMmakvN1G2c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231001__20240930_z4KYJgESSij3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maA031_zy40FEbUMUN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maA031_zQzJGYTZxZhd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest and penalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.08</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_uPure_maA031_zusXR7Mc01Ce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">True up - Startup Costs and Net Operating Loss per 2024 filed tax return</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2.55</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsChangeInValuationAllowance_pid_dp_uPure_maA031_zQSvV3wXTQp8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3.51</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4.39</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtA031_zIGwuwOHzKm6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax provision</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22.04</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25.39</td><td style="text-align: left">%</td></tr> </table>

0.2100

0.0008

0.0000

-0.0255

0.0000

0.0351 0.0439

0.2204

0.2539

NOTE 9. FAIR VALUE MEASUREMENTS The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</td></tr> </table> As of September 30, 2025, assets held in the Trust Account were comprised of $15,890,194 in a money market fund that is invested primarily in U.S. Treasury Securities. For the period ended September 30, 2025, the Company had withdrawn $1,711,366 of interest earned on the Trust Account to pay for income taxes and $106,131,025 from Trust Account in connection with redemptions. As of September 30, 2024, assets held in the Trust Account were comprised of $118,601,873 in a money market fund that is invested primarily in U.S. Treasury Securities. Through September 30, 2024, the Company has not withdrawn any of the interest earned on the Trust Account. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.: SCHEDULE OF MEASURED FAIR VALUE ON RECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Cash and investments held in Trust Account</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsHeldInTrust_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRRLmskRMgl8" style="width: 14%; text-align: right" title="Marketable securities held in trust account">15,890,194</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsHeldInTrust_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqC6XFUTG8v8" style="width: 14%; text-align: right" title="Marketable securities held in trust account">118,601,873</td><td style="width: 1%; text-align: left"> </td></tr> </table>

15890194

1711366

-106131025

118601873

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.: SCHEDULE OF MEASURED FAIR VALUE ON RECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Cash and investments held in Trust Account</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsHeldInTrust_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRRLmskRMgl8" style="width: 14%; text-align: right" title="Marketable securities held in trust account">15,890,194</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsHeldInTrust_iI_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqC6XFUTG8v8" style="width: 14%; text-align: right" title="Marketable securities held in trust account">118,601,873</td><td style="width: 1%; text-align: left"> </td></tr> </table>

15890194

118601873

NOTE 10. SEGMENT INFORMATION ASC Topic 280, “Segment Reporting,” establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker, or group, in deciding how to allocate resources and assess performance. The Company’s chief operating decision maker has been identified as the Chief Financial Officer (“CODM”), who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment. When evaluating the Company’s performance and making key decisions regarding resource allocation, the CODM reviews key metrics, which includes general and administrative expenses and interest and dividends earned on cash and investments held in Trust Account which are included in the statements of operations. The key measures of segment profit or loss reviewed by our CODM are interest and dividends earned on cash and investments held in Trust Account and general and administrative expenses. The CODM reviews interest and dividends earned on cash and investments held in Trust Account to measure and monitor stockholder value and determine the most effective strategy of investment with the Trust Account funds while maintaining compliance with the trust agreement. General and administrative expenses are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination period. The CODM also reviews general and administrative costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget.

NOTE 11. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. Concurrently with the execution of the BCA, the Company entered into a side letter agreement with IBAC pursuant to which the Company is authorized to complete a bridge financing of up to $<span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember__us-gaap--BusinessAcquisitionAxis__custom--GnqInsilicoIncMember_zC0uTf7gSKEl" title="Secured convertible promissory note amount">2,000,000 through the issuance of secured convertible promissory notes and accompanying common share purchase warrants. <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateTerms_c20260316__20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember__us-gaap--BusinessAcquisitionAxis__custom--GnqInsilicoIncMember_z3hbIF7PKHw1" title="Convertible notes bear interest rate description">The convertible notes bear interest at 10% per annum, mature six months from issuance, and are convertible at the option of the holder into the Company’s common shares at a price equal to 80% of the deemed per-share value of the Company’s common shares, as adjusted pursuant to the exchange ratio set forth in the BCA. Each convertible note is accompanied by a <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--GnqInsilicoIncMember_zzGZ63Ruthn7" title="Warrant exercisable term">5-year warrant exercisable at the same conversion price, with the number of the Company’s underlying common shares determined on a discount to the $<span id="xdx_908_eus-gaap--SharePrice_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--BusinessAcquisitionAxis__custom--GnqInsilicoIncMember_z83sJxZBL4p9" title="Common shares price per share">10 reference value of IBAC’s Class A common shares.

2000000

The convertible notes bear interest at 10% per annum, mature six months from issuance, and are convertible at the option of the holder into the Company’s common shares at a price equal to 80% of the deemed per-share value of the Company’s common shares, as adjusted pursuant to the exchange ratio set forth in the BCA.

P5Y

4634

428700

787365

89157

27833

57501 137139

288431

1243898

8188994

15890194

8477425

17134092

686694

73757

694245

1140176 1061310

12788

2788

1839658

1832100

1839658

1832100

759139

1490880

10.97

10.72

8326133

15983315

0.0001

10000000

0.0001

100000000

4249090

425

-1688791

-681748

-1688366

-681323

8477425

17134092

748177

163485

928177

339926

-748177

-163485

-928177

-339926

137102 1250141 290391 2621671

137102

1250141

290391

2621671

-611075

1086656

-637786

2281745

28791

262530

60982

550551

-639866

824126

-698768

1731194

1442097

11500000

1466757

11500000

-0.11

0.05

-0.12

0.11

4249090

-0.11

0.05

-0.12

0.11

4249090

425

-681748

-681323

-121098 -121098

-58902

4249090

425

-861748

-861323

-108311 -108311 -78866 -78866

-639866

4249090

425

-1688791

-1688366

4249090

425

1111372

1111797

-1083509 -1083509

907068

4249090

425

934931

935356

-987611 -987611

824126

4249090

425

771446

771871

-698768

1731194

290391 2621671

61324

31614

57501 -169750

137139

10000

2788

612937

3578

-694245

-373449

-1316431

-1119424

-105000 -924000 -7886591

7991591

924000

292344

7886591

-7886591

-1211431

-195424

1216065

822799

4634

627375

4634

627375

4634

627375

229409 2071120 78866

<p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zYIlOyY2dafc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS IB Acquisition Corp. f/k/a I-B Good Works 4 Corporation (the “Company”) is a blank check company originally incorporated under the laws of the State of Delaware on July 7, 2020 and which converted to a Nevada corporation on September 21, 2023 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company has not selected any potential business combination target, and the Company has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with the Company. The Company’s investment strategy is not specific to any sector, however, the management team and board members believe there are compelling investment opportunities in a number of areas including consumer goods, sports and entertainment, and healthcare technology. The Company anticipates targeting companies domiciled in North America, Europe and Asia, with an enterprise value of at least $500 million. As of March 31, 2026, the Company had not yet commenced any operations. All activity through March 31, 2026, relates to the Company’s formation, initial public offering (the “Initial Public Offering” as further defined below) and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income on cash and cash equivalents in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected September 30 as its fiscal year end. The registration statement for the Company’s Initial Public Offering was declared effective on March 25, 2024. On March 28, 2024, the Company consummated the Initial Public Offering of 11,500,000 units (the “Units”), which includes the full exercise by the underwriters of their over-allotment option in the amount of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z3LyHxAYMOF4" title="Number of units sold">1,500,000 Units, at a purchase price of $10.00 per Unit, generating gross proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zl9gGdLZSCh9" title="Gross proceeds from issuance">115,000,000, which is discussed in Note 3. Each Unit consists of one share of the Company’s common stock, and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of one share of common stock upon the consummation of the Business Combination. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 610,500 Units (the “Private Placement Units”) at a price of $10.00 per Unit in a private placement to the Company’s sponsor, I-B Good Works 4, LLC (the “Sponsor”), which is an affiliate of I-Bankers Securities, Inc. (“I-Bankers”). The Private Placement Units are identical to the units sold in the Initial Public Offering. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward completing a Business Combination. Transaction costs amounted to $7,755,845 consisting of the fair value amount of $3,867,050 related with the issued representative shares, $3,450,000 of cash underwriting discount, and $438,795 of other offering costs. The Company must complete its initial Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding any M&A fees (see Note 6) held in the Trust Account and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to successfully effect a Business Combination. Upon the closing of the Initial Public Offering, management has agreed that $10.05 per Unit sold in the Initial Public Offering, including proceeds of the sale of the Private Placement Units, will be held in a trust account (“Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s stockholders, as described below. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account (initially $10.05 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The shares of common stock were recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 upon such completion of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders, which are holders of the Founder Shares, have agreed to (i) waive their redemption rights with respect to their Private Placement Shares (as defined below) in connection with the completion of the Business Combination, (ii) waive their redemption rights with respect to their Founder Shares (defined below), Private Placement Shares (defined below) and any Public Shares they hold in connection with a stockholder vote to approve an amendment to the Company’s amended and restated articles of incorporation (a) to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete the Business Combination within the combination period or (b) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity and (iii) waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares and Private Placement Shares if the Company fails to complete the Business Combination within the combination period. In addition, the Sponsor has agreed to vote any Private Placement Shares held by it in favor of the Business Combination. Additionally, each public stockholder may elect to redeem its Public Shares, irrespective of whether they vote for or against a proposed Business Combination. Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s amended and restated articles of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares. The Company initially had until 18 months from the closing of the Initial Public Offering to complete a Business Combination, and further extended, as described below, to 30 months from the closing of the Initial Public Offering to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $100,000 of interest to pay dissolution expenses, which shall be net of taxes payable), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to its obligations under Nevada law to provide for claims of creditors and the requirements of other applicable law. The initial stockholders have agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The Underwriters will not receive their M&A fee (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.05). IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a third party for services rendered or products sold to the Company, or by a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.05 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the Underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”), in connection with both our initial public offering and the business combination. Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. On September 22, 2025, the Company held a Special Meeting, and the stockholders approved the Company’s First Amendment to its Amended and Restated Articles of Incorporation (the “First Extension Amendment”). The First Extension Amendment, among other things, (i) extends the date by which the Company must consummate its initial business combination to March 28, 2026 or such later date as may be approved by the Company’s stockholders in accordance with its amended and restated articles of incorporation; (ii) provides that, prior to the earliest of the completion of a business combination, the redemption of 100% of the Offering Shares if the Company is unable to complete its initial Business Combination by March 28, 2026, and the redemption of shares in connection with a vote seeking to amend any provisions of the Company’s Amended and Restated Articles relating to stockholders’ rights or any pre-initial Business Combination activity, funds in the Company’s trust account will not be released, other than interest to pay franchise and income taxes; (iii) sets forth the redemption and liquidation procedures if the Company does not consummate a business combination by March 28, 2026; and (iv) provides public stockholders with the right to redeem their shares in connection with any amendment that modifies the substance or timing of the Company’s obligation to redeem 100% of the public shares if it has not consummated a business combination by March 28, 2026, or with respect to other material pre-business combination provisions, subject to the applicable redemption limitation. In connection with the Special Meeting, stockholders holding 10,009,120 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.60 per share of the funds in the Trust Account. As a result, approximately $106.1 million was removed from the Trust Account to pay such holders, leaving approximately $15.8 million remaining in the Trust Account on the date of redemption. On March 25, 2026, the Company held a Special Meeting, and the stockholders approved the Company’s Second Amendment to its Amended and Restated Articles of Incorporation (the “Second Extension Amendment”). The Second Extension Amendment, among other things, (i) extends the date by which the Company must consummate its initial business combination to September 28, 2026 or such later date as may be approved by the Company’s stockholders in accordance with its amended and restated articles of incorporation; (ii) provides that, prior to the earliest of the completion of a business combination, the redemption of 100% of the Offering Shares if the Company is unable to complete its initial Business Combination by September 28, 2026, and the redemption of shares in connection with a vote seeking to amend any provisions of the Company’s Amended and Restated Articles relating to stockholders’ rights or any pre-initial Business Combination activity, funds in the Company’s trust account will not be released, other than interest to pay franchise and income taxes; (iii) sets forth the redemption and liquidation procedures if the Company does not consummate a business combination by September 28, 2026; and (iv) provides public stockholders with the right to redeem their shares in connection with any amendment that modifies the substance or timing of the Company’s obligation to redeem 100% of the public shares if it has not consummated a business combination by September 28, 2026, or with respect to other material pre-business combination provisions, subject to the applicable redemption limitation. In connection with the Special Meeting, stockholders holding 731,741 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.78 per share of the funds in the Trust Account. As a result, approximately $7.9 million was removed from the Trust Account to pay such holders, leaving approximately $8.2 million remaining in the Trust Account on the date of redemption. Business Combination Agreement On March 16, 2026, the Company entered into a Business Combination Agreement (the “BCA”) with GNQ Insilico Inc., a corporation formed under the federal laws of Canada (“GNQ”). Under the agreement, and subject to court approval and other closing conditions, GNQ Shareholders will receive the following consideration in exchange for their respective shares of capital stock of GNQ upon completion of the transaction:. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For each share of GNQ common stock (the “GNQ Common Shares”) held by eligible electing Canadian shareholders of GNQ (“Electing Shareholders”), the Electing Shareholder will receive a number of exchangeable shares in an indirect, wholly owned Canadian subsidiary of IB Acquisition (the “ExchangeCo Shares”) equal to the quotient obtained by dividing 50,000,000 by the Fully-Diluted GNQ Common Shares (as defined below) (the “GNQ Exchange Ratio”); and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For each share of GNQ Common Shares held by all other shareholders of GNQ (“Non-Electing Shareholders”, and collectively with the Electing Shareholders, the “GNQ Shareholders”), such Non-Electing Shareholder will exchange their respective GNQ Common Shares for shares of SPAC Class A Common Stock equal to the GNQ Exchange Ratio (the “GNQ U.S. Shareholder Exchange” and, together with the other exchanges and subscriptions described above, the “Share Exchanges”).</td></tr> </table> IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) In addition, under the BCA and the Arrangement: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All outstanding options to purchase shares of GNQ Common Shares (the “GNQ Options”) will be exchanged for options to purchase shares of SPAC Class A Common Stock under the GNQ 2026 Stock Incentive Plan (“Replacement Options”) and such resulting GNQ Common Shares shall be exchanged in the Share Exchanges;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The GNQ Convertible Notes will be automatically converted into GNQ Common Shares immediately prior to the Arrangement Effective Time and such underlying GNQ Common Shares shall be exchanged in the Share Exchanges; and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(iii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The GNQ Warrants will be exchanged for shares of SPAC Class A Common Stock (the “GNQ Warrants Exchange”).</td></tr> </table> Side Letter Agreement Concurrently with the execution of the BCA, GNQ has also entered into a letter agreement (the “Side Letter Agreement”) with the Company pursuant to which the GNQ will complete a debt financing of <span id="xdx_905_ecustom--DebtInstrumentConvertibleConversionPercentage_iI_pid_dp_uPure_c20260316__us-gaap--TypeOfArrangementAxis__custom--SideLetterAgreementMember_zaXrKGWiA8Fk" title="Convertible, conversion price percentage">10% secured convertible promissory notes (“Convertible Notes”) and common share purchase warrants (“Warrants”) for aggregate gross proceeds of up to US$2,000,000 (the “Bridge Financing”). In connection with the execution of the BCA, an investor introduced by the Company purchased a Convertible Note for US$250,000 in aggregate principal amount of Convertible Notes. The Convertible Notes accrue on the outstanding principal balance at a rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20260316__20260316__us-gaap--TypeOfArrangementAxis__custom--SideLetterAgreementMember_zTbsUbjM3i11" title="Outstanding principal balance rate">10% per annum, calculated on the basis of a 360-day year and expire in six months from the date of issuance. At any time while the Convertible Notes remain outstanding, the holders may, at their option, elect to convert all or any portion of the aggregate principal amount outstanding under the Convertible Notes, together with any accrued and unpaid interest owing thereon, into that number of common shares in the capital of GNQ (“GNQ Common Shares”) as is equal to the quotient of (a) the aggregate principal amount outstanding under the Convertible Notes, together with any accrued and unpaid interest owing thereon as of the date immediately prior to conversion, divided by (b) a price per GNQ Common Share equal to <span id="xdx_90F_ecustom--CommonShareDeemedPricePercentage_pid_dp_uPure_c20260316__20260316__us-gaap--TypeOfArrangementAxis__custom--SideLetterAgreementMember_ziV08xhBwDW" title="Common share deemed price percentage">80% of the deemed price per GNQ Common Share as adjusted pursuant to the exchange ratio set forth in the BCA (the “Conversion Price”). Each Convertible Note shall be accompanied by a five-year Warrant to purchase GNQ Common Shares, with the number of GNQ Common Shares determined by dividing (a) 100% of the principal amount of the Convertible Notes by (b) an assumed value for a GNQ Common Share to be agreed upon by the parties based on a discount to the US$10.00 reference value of a share of SPAC Class A Common Stock as set forth in the BCA. The Warrants are exercisable for a period of five years from the date of issuance, provided that, in the event that the Transaction is effected in advance of such expiry date, immediately prior to the effective time of the Transaction, the holders may elect to exercise the Warrants into GNQ Common Shares on a cashless basis. The exercise price under the Warrants will be equal to the Conversion Price. Shareholder Support Agreement Contemporaneously with the execution of the BCA, the Company, GNQ and certain GNQ shareholders entered into a Shareholder Support Agreement, pursuant to which, among other things, the GNQ shareholders party to such agreement agreed (i) to vote their GNQ shares in favor of the Arrangement and other resolutions needed to consummate the Arrangement and the other Transactions, and, subject to limited exceptions, to not transfer such shares, and (ii) to waive, and not to exercise, any dissent rights for GNQ shares in connection with the Arrangement. The GNQ shareholders party to the Shareholder Support Agreement collectively have a sufficient number of votes to approve the Arrangement. The Shareholder Support Agreement and all of its provisions will terminate and be of no further force or effect upon the earlier of (i) the Closing, (ii) termination of the BCA pursuant to its terms, and (iii) a GNQ Modification in Recommendation made in connection with a Superior Proposal. Upon such termination of the Shareholder Support Agreement, all obligations of the parties under the Shareholder Support Agreement will terminate; provided, however, that such termination will not relieve any party thereto from liability arising in respect of any breach of the Shareholder Support Agreement prior to such termination. Sponsor Support Agreement Contemporaneously with the execution of the BCA, the Company entered into a Sponsor Support Agreement with the Sponsor and GNQ, pursuant to which, among other things, the Sponsor agreed (i) to vote its shares of SPAC Capital Stock in favor of the BCA and each of the Transaction Proposals, and to not transfer such shares, (ii) not to redeem any of its shares of IB Acquisition capital stock in connection with the Transactions, (iii) to waive its anti-dilution rights with respect to its shares of IB Acquisition common stock, under the IB Acquisition amended and restated articles of incorporation, and (iv) to subject certain of its shares of IB acquisition common stock to additional transfer restrictions and other conditions set forth in the Sponsor Support Agreement. The Sponsor Support Agreement and certain of its provisions will terminate and be of no further force or effect upon the earlier to occur of Closing and termination of the BCA pursuant to its terms and, if the BCA is terminated pursuant to its terms, all provisions of the Sponsor Support Agreement will terminate and be of no further force or effect. Lock-Up Agreement Prior to the Closing, IB Acquisition will enter into separate Lock-Up Agreements (each a “Lock-Up Agreement”) with a number of GNQ shareholders and Sponsor pursuant to which the securities of IB Acquisition and ExchangeCo held by such holders will be locked-up and subject to transfer restrictions for a period of time following the Closing, as described below, subject to certain exceptions. The securities held by such GNQ shareholders will be locked-up until the earlier of: <span id="xdx_907_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20260316__20260316__us-gaap--TypeOfArrangementAxis__custom--LockUpAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--IBAcquisitionMember_zBbUTDYoGWx5" title="Business combination, description of acquiree">(i) six (6) months after the date of the Closing, and (ii) subsequent to the Closing, the date on which SPAC consummates a liquidation, merger, capital stock exchange, reorganization, or other similar transaction that results in all of SPAC’s stockholders having the right to exchange their SPAC Common Stock for cash, securities or other property; provided, that if the closing trading price of the SPAC Common Stock on the stock exchange on which the SPAC Common Stock is listed exceeds US$12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 Trading Days within any 30-day Trading Day period, then Holder shall have the right to sell 50% of its SPAC Common Stock subject to applicable regulatory restrictions, and if the closing trading price of the SPAC Common Stock on the stock exchange on which the SPAC Common Stock is listed exceeds US$15.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 Trading Days within any 30-day Trading Day period, then Holder shall have the right to sell an the remaining 50% of its SPAC Common Stock subject to applicable regulatory restrictions. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) Risks and Uncertainties The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (“NATO”) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. On July 4, 2025, the One Big Beautiful Bill Act (the “OBBBA”) was enacted into law in the United States. The significant provisions of OBBBA include the permanent extension and modification of certain provisions of the Tax Cuts and Jobs Act, including international tax provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented in later years. The Company is evaluating the provisions of OBBBA but it is not expected to have a material impact on the Company’s financial statements. Excise Tax On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The IR Act applies only to repurchases that occur after December 31, 2022. Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete a Business Combination. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) During the second quarter of 2024, the Internal Revenue Service issued final regulations with respect to the timing and payment of the excise tax. These regulations provided that the filing and payment deadline for any liability incurred during the period from January 1, 2023 to December 31, 2023 would be October 31, 2024. The Company is currently evaluating its options with respect to this obligation. Any amount of such excise tax not paid in full will be subject to additional interest and penalties which are currently estimated at 10% interest per annum and a 5% underpayment penalty per month or portion of a month up to 25% of the total liability for any amount that is unpaid from November 1, 2024 until paid in full. In connection with the Special Meeting held on September 22, 2025, stockholders holding 10,009,120 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.60 per share of the funds in the Trust Account. As a result, approximately $106.1 million was removed from the Trust Account to pay such holders, leaving approximately $15.8 million remaining in the Trust Account. This amount is subject to change to account for the payment of tax withdrawals. The Company has recorded 1% excise tax based on the amount redeemed or an aggregate amount of $1,061,310 excise tax payable. In connection with the Special Meeting held on March 25, 2026, stockholders holding 731,741 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.78 per share of the funds in the Trust Account. As a result, approximately $7.9 million was removed from the Trust Account to pay such holders, leaving approximately $8.2 million remaining in the Trust Account. This amount is subject to change to account for the payment of tax withdrawals. The Company has recorded 1% excise tax based on the amount redeemed or an aggregate amount of $78,866 excise tax payable. As of March 31, 2026 and September 30, 2025, the Company had $1,140,176 and $1,061,310, respectively, in the excise taxes payable, as presented in the accompanying balance sheets. The excise taxes payable are due on April 30, 2026. Going Concern Consideration As of March 31, 2026, the Company had $4,634 in cash, $0 in restricted cash and a working capital deficit of $1,551,227. In connection with the Company’s assessment of going concern considerations in accordance with the authoritative guidance in Financial Accounting Standard Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Company currently lacks the liquidity it needs to sustain operations for a reasonable period of time, which is considered to be at least one year from the date that the financial statements are issued as it expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management plans to address this uncertainty through a Business Combination. There is no assurance that the Company’s plans to raise capital or to consummate a Business Combination will be successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited)

500000000

11500000

1500000

10.00

115000000

610500

10.00

7755845

3867050

3450000

438795

10.05

The First Extension Amendment, among other things, (i) extends the date by which the Company must consummate its initial business combination to March 28, 2026 or such later date as may be approved by the Company’s stockholders in accordance with its amended and restated articles of incorporation; (ii) provides that, prior to the earliest of the completion of a business combination, the redemption of 100% of the Offering Shares if the Company is unable to complete its initial Business Combination by March 28, 2026, and the redemption of shares in connection with a vote seeking to amend any provisions of the Company’s Amended and Restated Articles relating to stockholders’ rights or any pre-initial Business Combination activity, funds in the Company’s trust account will not be released, other than interest to pay franchise and income taxes; (iii) sets forth the redemption and liquidation procedures if the Company does not consummate a business combination by March 28, 2026; and (iv) provides public stockholders with the right to redeem their shares in connection with any amendment that modifies the substance or timing of the Company’s obligation to redeem 100% of the public shares if it has not consummated a business combination by March 28, 2026, or with respect to other material pre-business combination provisions, subject to the applicable redemption limitation.

10009120

10.60

106100000

15800000

The Second Extension Amendment, among other things, (i) extends the date by which the Company must consummate its initial business combination to September 28, 2026 or such later date as may be approved by the Company’s stockholders in accordance with its amended and restated articles of incorporation; (ii) provides that, prior to the earliest of the completion of a business combination, the redemption of 100% of the Offering Shares if the Company is unable to complete its initial Business Combination by September 28, 2026, and the redemption of shares in connection with a vote seeking to amend any provisions of the Company’s Amended and Restated Articles relating to stockholders’ rights or any pre-initial Business Combination activity, funds in the Company’s trust account will not be released, other than interest to pay franchise and income taxes; (iii) sets forth the redemption and liquidation procedures if the Company does not consummate a business combination by September 28, 2026; and (iv) provides public stockholders with the right to redeem their shares in connection with any amendment that modifies the substance or timing of the Company’s obligation to redeem 100% of the public shares if it has not consummated a business combination by September 28, 2026, or with respect to other material pre-business combination provisions, subject to the applicable redemption limitation.

731741

10.78

7900000

8200000

50000000

0.10

2000000

250000

0.10

0.80

Each Convertible Note shall be accompanied by a five-year Warrant to purchase GNQ Common Shares, with the number of GNQ Common Shares determined by dividing (a) 100% of the principal amount of the Convertible Notes by (b) an assumed value for a GNQ Common Share to be agreed upon by the parties based on a discount to the US$10.00 reference value of a share of SPAC Class A Common Stock as set forth in the BCA. The Warrants are exercisable for a period of five years from the date of issuance, provided that, in the event that the Transaction is effected in advance of such expiry date, immediately prior to the effective time of the Transaction, the holders may elect to exercise the Warrants into GNQ Common Shares on a cashless basis. The exercise price under the Warrants will be equal to the Conversion Price.

(i) six (6) months after the date of the Closing, and (ii) subsequent to the Closing, the date on which SPAC consummates a liquidation, merger, capital stock exchange, reorganization, or other similar transaction that results in all of SPAC’s stockholders having the right to exchange their SPAC Common Stock for cash, securities or other property; provided, that if the closing trading price of the SPAC Common Stock on the stock exchange on which the SPAC Common Stock is listed exceeds US$12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 Trading Days within any 30-day Trading Day period, then Holder shall have the right to sell 50% of its SPAC Common Stock subject to applicable regulatory restrictions, and if the closing trading price of the SPAC Common Stock on the stock exchange on which the SPAC Common Stock is listed exceeds US$15.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 Trading Days within any 30-day Trading Day period, then Holder shall have the right to sell an the remaining 50% of its SPAC Common Stock subject to applicable regulatory restrictions.

0.10 0.05 0.25

10009120

10.60

106100000

15800000

1061310

731741

10.78

7900000

8200000

78866

1140176

1061310

4634

1551227

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in unaudited financial statements prepared in accordance with GAAP have been omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended September 30, 2025, as filed with the SEC on December 29, 2025. The interim results for the three and six months ended March 31, 2026, are not necessarily indicative of the results to be expected for the year ending September 30, 2026 or for any future periods. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company had $4,634 and $428,700 in cash as of March 31, 2026, and September 30, 2025, respectively, and no cash equivalents. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) Cash – Restricted Cash that is encumbered or otherwise restricted as to its use is included in cash – restricted. As of March 31, 2026 and September 30, 2025, the balance was $0 and $787,365, respectively. Cash – restricted as of September 30, 2025 represents cash that was withdrawn from the Trust Account to pay income taxes but was not utilized. Cash and investments held in Trust account As of March 31, 2026 and September 30, 2025, all of the assets held in the Trust Account were held in money market funds which are invested only in U.S. government securities. Investments in money market funds are presented on the balance sheet at fair value at the end of each reporting period. Interest and dividends earned from investments in these securities are included in the statements of operations. Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering”. Offering costs consist principally of professional and registration fees, cash underwriting discount, and deferred underwriting fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on relative fair value basis, compared to total proceeds received. Offering costs allocated to the Public Shares were charged against the carrying value of ordinary shares subject to possible redemption upon the completion of the Initial Public Offering and offering costs allocated to Public Rights (as defined in Note 3) were charged to additional paid in capital at the completion of the Initial Public Offering. <p id="xdx_843_eus-gaap--SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_zjn6iYOLpY3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Common Stock Subject to Possible Redemption The Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, or if there is a shareholder vote or tender offer in connection with the Company’s initial business combination. In accordance with ASC 480-10-S99, the Company classifies Public Shares subject to redemption outside of permanent equity as the redemption provisions are not solely within the control of the Company. The Public Shares sold as part of the Units in the Initial Public Offering were issued with other freestanding instruments (i.e., Public Rights) and as such, the initial carrying value of Public Shares classified as temporary equity are the allocated proceeds determined in accordance with ASC 470-20. The Company recognizes changes in redemption value immediately as it occurs and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable shares will result in charges against retained earnings or additional paid-in capital in the absence of retained earnings. Accordingly, as of March 31, 2026 and September 30, 2025, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable shares are affected by charges against retained earnings or additional paid-in capital in the absence of retained earnings. In connection with the Special Meeting held on September 22, 2025, stockholders holding 10,009,120 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.60 per share of the funds in the Trust Account. As a result, approximately $106.1 million was removed from the Trust Account to pay such holders, leaving approximately $15.8 million remaining in the Trust Account on the date of redemption. In connection with the Special Meeting held on March 25, 2026, stockholders holding 731,741 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.78 per share of the funds in the Trust Account. As a result, approximately $7.9 million was removed from the Trust Account to pay such holders, leaving approximately $8.2 million remaining in the Trust Account on the date of redemption. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) As of March 31, 2026 and September 30, 2025, the common stock subject to redemption reflected in the balance sheets are reconciled in the following table: SCHEDULE OF COMMON STOCK SUBJECT TO REDEMPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 82%; text-align: left">Common stock subject to possible redemption, September 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20251001__20251231_zpLxXAW3U52g" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common stock subject to possible redemption, September 30, 2025">15,983,315</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Plus:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20251001__20251231_zQkyeBTB3YT5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Remeasurement of carrying value to redemption value">121,098</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Common stock subject to possible redemption, December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20260101__20260331_zpNobhSiIe9i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance">16,104,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Less:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Redemptions of Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--RedemptionsOfCommonStock_c20260101__20260331_zkj9eGtQEk73" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Redemptions of common stock">(7,886,591</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Plus:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20260101__20260331_zaT63yUkjPN3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Remeasurement of carrying value to redemption value">108,311</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Common stock subject to possible redemption, March 31, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20260101__20260331_zaxGzypptBb1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance">8,326,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Income Taxes The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, Income Taxes, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of March 31, 2026 and September 30, 2025, the Company’s deferred tax asset had a full valuation allowance recorded against it. Our effective tax rate was (4.71)% and 24.16% for the three months ended March 31, 2026 and 2025, respectively, and (9.56)% and 24.13% for the six months ended March 31, 2026 and 2025, respectively. The effective tax rate differs from the statutory tax rate of 21% for the period ended March 31, 2026 and 2025, due to the valuation allowance on the deferred tax assets. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2026 and September 30, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) Net (Loss) Income Per Common Stock The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of shares of common stock outstanding for the period. Remeasurement associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted net (loss) income per share does not consider the effect of the rights issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the rights are contingent upon the occurrence of future events. As of March 31, 2026 and September 30, 2025, the rights are exercisable to purchase 605,525 shares of common stock in the aggregate. The weighted average of these shares was excluded from the calculation of diluted net (loss) income common stock since the inclusion of such rights would be anti-dilutive. The rights cannot be converted to shares of common stock prior to an initial Business Combination; therefore, they have been classified as anti-dilutive. The following table reflects the calculation of basic and diluted net (loss) income per common stock (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET LOSS INCOME PER COMMON STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Three Months Ended March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Six Months Ended March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net (loss) income per common share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Allocation of net (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z2SC65R4sFn6" title="Basic, Allocation of net income"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zf7huVViWCQ" title="Diluted, Allocation of net income">(162,136</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zt15whexz2fa" title="Basic, Allocation of net income"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zY2kzMC9Q1Zi" title="Diluted, Allocation of net income">(477,730</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z1kscNv7leL4" title="Basic, Allocation of net income"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zKgrelwwSWLb" title="Diluted, Allocation of net income">601,778</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_ztczxTI6pz05" title="Basic, Allocation of net income"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zOtYjQFlB51i" title="Diluted, Allocation of net income">222,348</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zdg5gIxZXtdh" title="Basic, Allocation of net income"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zUDaoLUp2p1" title="Diluted, Allocation of net income">(179,312</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zM9Sbay4xzL2" title="Basic, Allocation of net income"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z9Gcgdi33aRf" title="Diluted, Allocation of net income">(519,456</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zdzWm4WyvNZe" title="Basic, Allocation of net income"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zWvjyWuVThQc" title="Diluted, Allocation of net income">1,264,119</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zXv22MQMC9r1" title="Basic, Allocation of net income"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zOWsQoFzZEb6" title="Diluted, Allocation of net income">467,075</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Basic weighted-average shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zonSXnacJFnk" title="Basic weighted average common stock outstanding"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z4KwQo77N9k2" title="Diluted weighted average common stock outstanding">1,442,097</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zG28tZ2HEqle" title="Basic weighted average common stock outstanding"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zclbrWZqczc3" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zRIcLCAVwUV7" title="Basic weighted average common stock outstanding"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zoF25PRAnln8" title="Diluted weighted average common stock outstanding">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z0V66UCONg55" title="Basic weighted average common stock outstanding"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zavvMhtZmwj2" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zRpEm7lFPpXi" title="Basic weighted average common stock outstanding"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zjI0EvLywYV9" title="Diluted weighted average common stock outstanding">1,466,757</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zZsTOuZBfdbg" title="Basic weighted average common stock outstanding"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zhFdxW0cstd" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zMB7VhOfgDKh" title="Basic weighted average common stock outstanding"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z0nq8dL0ngE9" title="Diluted weighted average common stock outstanding">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zHNie8Uu4yYg" title="Basic weighted average common stock outstanding"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zeJyjjy0C0bi" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted net (loss) income per common share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zGps2CSi5tfg" title="Basic net (loss) income per common stock"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z5SLE7Z2OWi8" title="Diluted net (loss) income per common stock">(0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zi0IpCmN2zDc" title="Basic net (loss) income per common stock"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zm86rfQz2jd3" title="Diluted net (loss) income per common stock">(0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zygoii8iEyT7" title="Basic net (loss) income per common stock"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_ze4g3uS6KRWl" title="Diluted net (loss) income per common stock">0.05</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_znhdrvecSDd1" title="Basic net (loss) income per common stock"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zzlw3CLEVTS" title="Diluted net (loss) income per common stock">0.05</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zoK2fOZ6jJxa" title="Basic net (loss) income per common stock"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zytKe5WhCAOj" title="Diluted net (loss) income per common stock">(0.12</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zRxDIfc4e5Jc" title="Basic net (loss) income per common stock"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z2oDxDHnScwi" title="Diluted net (loss) income per common stock">(0.12</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zFOmTwNTmk47" title="Basic net (loss) income per common stock"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zwP17Kzdrj7c" title="Diluted net (loss) income per common stock">0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zA7ns1bBCiFk" title="Basic net (loss) income per common stock"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z3hs0od0grPc" title="Diluted net (loss) income per common stock">0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on the cash account and management believes that the Company is not exposed to significant risks on such account. Uninsured cash amounts as of March 31, 2026 and September 30, 2025, are $0 and $966,065, respectively. Fair value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) Recent Accounting Standards Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in unaudited financial statements prepared in accordance with GAAP have been omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended September 30, 2025, as filed with the SEC on December 29, 2025. The interim results for the three and six months ended March 31, 2026, are not necessarily indicative of the results to be expected for the year ending September 30, 2026 or for any future periods.

Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company had $4,634 and $428,700 in cash as of March 31, 2026, and September 30, 2025, respectively, and no cash equivalents. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited)

4634

428700

Cash – Restricted Cash that is encumbered or otherwise restricted as to its use is included in cash – restricted. As of March 31, 2026 and September 30, 2025, the balance was $0 and $787,365, respectively. Cash – restricted as of September 30, 2025 represents cash that was withdrawn from the Trust Account to pay income taxes but was not utilized.

787365

Cash and investments held in Trust account As of March 31, 2026 and September 30, 2025, all of the assets held in the Trust Account were held in money market funds which are invested only in U.S. government securities. Investments in money market funds are presented on the balance sheet at fair value at the end of each reporting period. Interest and dividends earned from investments in these securities are included in the statements of operations.

Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering”. Offering costs consist principally of professional and registration fees, cash underwriting discount, and deferred underwriting fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on relative fair value basis, compared to total proceeds received. Offering costs allocated to the Public Shares were charged against the carrying value of ordinary shares subject to possible redemption upon the completion of the Initial Public Offering and offering costs allocated to Public Rights (as defined in Note 3) were charged to additional paid in capital at the completion of the Initial Public Offering.

<p id="xdx_843_eus-gaap--SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_zjn6iYOLpY3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Common Stock Subject to Possible Redemption The Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, or if there is a shareholder vote or tender offer in connection with the Company’s initial business combination. In accordance with ASC 480-10-S99, the Company classifies Public Shares subject to redemption outside of permanent equity as the redemption provisions are not solely within the control of the Company. The Public Shares sold as part of the Units in the Initial Public Offering were issued with other freestanding instruments (i.e., Public Rights) and as such, the initial carrying value of Public Shares classified as temporary equity are the allocated proceeds determined in accordance with ASC 470-20. The Company recognizes changes in redemption value immediately as it occurs and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable shares will result in charges against retained earnings or additional paid-in capital in the absence of retained earnings. Accordingly, as of March 31, 2026 and September 30, 2025, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable shares are affected by charges against retained earnings or additional paid-in capital in the absence of retained earnings. In connection with the Special Meeting held on September 22, 2025, stockholders holding 10,009,120 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.60 per share of the funds in the Trust Account. As a result, approximately $106.1 million was removed from the Trust Account to pay such holders, leaving approximately $15.8 million remaining in the Trust Account on the date of redemption. In connection with the Special Meeting held on March 25, 2026, stockholders holding 731,741 shares of the Company’s shares of common stock exercised their right to redeem their shares for cash at an approximate price of $10.78 per share of the funds in the Trust Account. As a result, approximately $7.9 million was removed from the Trust Account to pay such holders, leaving approximately $8.2 million remaining in the Trust Account on the date of redemption. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) As of March 31, 2026 and September 30, 2025, the common stock subject to redemption reflected in the balance sheets are reconciled in the following table: SCHEDULE OF COMMON STOCK SUBJECT TO REDEMPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 82%; text-align: left">Common stock subject to possible redemption, September 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20251001__20251231_zpLxXAW3U52g" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common stock subject to possible redemption, September 30, 2025">15,983,315</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Plus:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20251001__20251231_zQkyeBTB3YT5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Remeasurement of carrying value to redemption value">121,098</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Common stock subject to possible redemption, December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20260101__20260331_zpNobhSiIe9i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance">16,104,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Less:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Redemptions of Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--RedemptionsOfCommonStock_c20260101__20260331_zkj9eGtQEk73" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Redemptions of common stock">(7,886,591</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Plus:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20260101__20260331_zaT63yUkjPN3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Remeasurement of carrying value to redemption value">108,311</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Common stock subject to possible redemption, March 31, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20260101__20260331_zaxGzypptBb1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance">8,326,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

10009120

10.60

106100000

15800000

731741

10.78

7900000

8200000

As of March 31, 2026 and September 30, 2025, the common stock subject to redemption reflected in the balance sheets are reconciled in the following table: SCHEDULE OF COMMON STOCK SUBJECT TO REDEMPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 82%; text-align: left">Common stock subject to possible redemption, September 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20251001__20251231_zpLxXAW3U52g" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common stock subject to possible redemption, September 30, 2025">15,983,315</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Plus:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20251001__20251231_zQkyeBTB3YT5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Remeasurement of carrying value to redemption value">121,098</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Common stock subject to possible redemption, December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20260101__20260331_zpNobhSiIe9i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance">16,104,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Less:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Redemptions of Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--RedemptionsOfCommonStock_c20260101__20260331_zkj9eGtQEk73" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Redemptions of common stock">(7,886,591</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Plus:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Remeasurement of carrying value to redemption value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--RemeasurementOfCarryingValueToRedemptionValue_c20260101__20260331_zaT63yUkjPN3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Remeasurement of carrying value to redemption value">108,311</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Common stock subject to possible redemption, March 31, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20260101__20260331_zaxGzypptBb1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance">8,326,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

15983315

121098

16104413

-7886591 108311

8326133

Income Taxes The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, Income Taxes, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of March 31, 2026 and September 30, 2025, the Company’s deferred tax asset had a full valuation allowance recorded against it. Our effective tax rate was (4.71)% and 24.16% for the three months ended March 31, 2026 and 2025, respectively, and (9.56)% and 24.13% for the six months ended March 31, 2026 and 2025, respectively. The effective tax rate differs from the statutory tax rate of 21% for the period ended March 31, 2026 and 2025, due to the valuation allowance on the deferred tax assets. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2026 and September 30, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited)

-0.0471

0.2416

-0.0956

0.2413

0.21

Net (Loss) Income Per Common Stock The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of shares of common stock outstanding for the period. Remeasurement associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates fair value. The calculation of diluted net (loss) income per share does not consider the effect of the rights issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the rights are contingent upon the occurrence of future events. As of March 31, 2026 and September 30, 2025, the rights are exercisable to purchase 605,525 shares of common stock in the aggregate. The weighted average of these shares was excluded from the calculation of diluted net (loss) income common stock since the inclusion of such rights would be anti-dilutive. The rights cannot be converted to shares of common stock prior to an initial Business Combination; therefore, they have been classified as anti-dilutive. The following table reflects the calculation of basic and diluted net (loss) income per common stock (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET LOSS INCOME PER COMMON STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Three Months Ended March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Six Months Ended March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net (loss) income per common share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Allocation of net (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z2SC65R4sFn6" title="Basic, Allocation of net income"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zf7huVViWCQ" title="Diluted, Allocation of net income">(162,136</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zt15whexz2fa" title="Basic, Allocation of net income"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zY2kzMC9Q1Zi" title="Diluted, Allocation of net income">(477,730</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z1kscNv7leL4" title="Basic, Allocation of net income"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zKgrelwwSWLb" title="Diluted, Allocation of net income">601,778</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_ztczxTI6pz05" title="Basic, Allocation of net income"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zOtYjQFlB51i" title="Diluted, Allocation of net income">222,348</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zdg5gIxZXtdh" title="Basic, Allocation of net income"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zUDaoLUp2p1" title="Diluted, Allocation of net income">(179,312</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zM9Sbay4xzL2" title="Basic, Allocation of net income"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z9Gcgdi33aRf" title="Diluted, Allocation of net income">(519,456</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zdzWm4WyvNZe" title="Basic, Allocation of net income"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zWvjyWuVThQc" title="Diluted, Allocation of net income">1,264,119</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zXv22MQMC9r1" title="Basic, Allocation of net income"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zOWsQoFzZEb6" title="Diluted, Allocation of net income">467,075</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Basic weighted-average shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zonSXnacJFnk" title="Basic weighted average common stock outstanding"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z4KwQo77N9k2" title="Diluted weighted average common stock outstanding">1,442,097</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zG28tZ2HEqle" title="Basic weighted average common stock outstanding"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zclbrWZqczc3" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zRIcLCAVwUV7" title="Basic weighted average common stock outstanding"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zoF25PRAnln8" title="Diluted weighted average common stock outstanding">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z0V66UCONg55" title="Basic weighted average common stock outstanding"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zavvMhtZmwj2" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zRpEm7lFPpXi" title="Basic weighted average common stock outstanding"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zjI0EvLywYV9" title="Diluted weighted average common stock outstanding">1,466,757</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zZsTOuZBfdbg" title="Basic weighted average common stock outstanding"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zhFdxW0cstd" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zMB7VhOfgDKh" title="Basic weighted average common stock outstanding"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z0nq8dL0ngE9" title="Diluted weighted average common stock outstanding">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zHNie8Uu4yYg" title="Basic weighted average common stock outstanding"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zeJyjjy0C0bi" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted net (loss) income per common share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zGps2CSi5tfg" title="Basic net (loss) income per common stock"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z5SLE7Z2OWi8" title="Diluted net (loss) income per common stock">(0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zi0IpCmN2zDc" title="Basic net (loss) income per common stock"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zm86rfQz2jd3" title="Diluted net (loss) income per common stock">(0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zygoii8iEyT7" title="Basic net (loss) income per common stock"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_ze4g3uS6KRWl" title="Diluted net (loss) income per common stock">0.05</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_znhdrvecSDd1" title="Basic net (loss) income per common stock"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zzlw3CLEVTS" title="Diluted net (loss) income per common stock">0.05</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zoK2fOZ6jJxa" title="Basic net (loss) income per common stock"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zytKe5WhCAOj" title="Diluted net (loss) income per common stock">(0.12</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zRxDIfc4e5Jc" title="Basic net (loss) income per common stock"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z2oDxDHnScwi" title="Diluted net (loss) income per common stock">(0.12</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zFOmTwNTmk47" title="Basic net (loss) income per common stock"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zwP17Kzdrj7c" title="Diluted net (loss) income per common stock">0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zA7ns1bBCiFk" title="Basic net (loss) income per common stock"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z3hs0od0grPc" title="Diluted net (loss) income per common stock">0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

605525

The following table reflects the calculation of basic and diluted net (loss) income per common stock (in dollars, except per share amounts): SCHEDULE OF BASIC AND DILUTED NET LOSS INCOME PER COMMON STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Three Months Ended March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Six Months Ended March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-redeemable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net (loss) income per common share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Allocation of net (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z2SC65R4sFn6" title="Basic, Allocation of net income"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zf7huVViWCQ" title="Diluted, Allocation of net income">(162,136</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zt15whexz2fa" title="Basic, Allocation of net income"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zY2kzMC9Q1Zi" title="Diluted, Allocation of net income">(477,730</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z1kscNv7leL4" title="Basic, Allocation of net income"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zKgrelwwSWLb" title="Diluted, Allocation of net income">601,778</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_ztczxTI6pz05" title="Basic, Allocation of net income"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zOtYjQFlB51i" title="Diluted, Allocation of net income">222,348</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zdg5gIxZXtdh" title="Basic, Allocation of net income"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zUDaoLUp2p1" title="Diluted, Allocation of net income">(179,312</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zM9Sbay4xzL2" title="Basic, Allocation of net income"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z9Gcgdi33aRf" title="Diluted, Allocation of net income">(519,456</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zdzWm4WyvNZe" title="Basic, Allocation of net income"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zWvjyWuVThQc" title="Diluted, Allocation of net income">1,264,119</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zXv22MQMC9r1" title="Basic, Allocation of net income"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zOWsQoFzZEb6" title="Diluted, Allocation of net income">467,075</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Basic weighted-average shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zonSXnacJFnk" title="Basic weighted average common stock outstanding"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z4KwQo77N9k2" title="Diluted weighted average common stock outstanding">1,442,097</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zG28tZ2HEqle" title="Basic weighted average common stock outstanding"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zclbrWZqczc3" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zRIcLCAVwUV7" title="Basic weighted average common stock outstanding"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zoF25PRAnln8" title="Diluted weighted average common stock outstanding">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z0V66UCONg55" title="Basic weighted average common stock outstanding"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zavvMhtZmwj2" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zRpEm7lFPpXi" title="Basic weighted average common stock outstanding"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zjI0EvLywYV9" title="Diluted weighted average common stock outstanding">1,466,757</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zZsTOuZBfdbg" title="Basic weighted average common stock outstanding"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zhFdxW0cstd" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zMB7VhOfgDKh" title="Basic weighted average common stock outstanding"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z0nq8dL0ngE9" title="Diluted weighted average common stock outstanding">11,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zHNie8Uu4yYg" title="Basic weighted average common stock outstanding"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zeJyjjy0C0bi" title="Diluted weighted average common stock outstanding">4,249,090</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted net (loss) income per common share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zGps2CSi5tfg" title="Basic net (loss) income per common stock"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z5SLE7Z2OWi8" title="Diluted net (loss) income per common stock">(0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zi0IpCmN2zDc" title="Basic net (loss) income per common stock"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zm86rfQz2jd3" title="Diluted net (loss) income per common stock">(0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zygoii8iEyT7" title="Basic net (loss) income per common stock"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_ze4g3uS6KRWl" title="Diluted net (loss) income per common stock">0.05</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_znhdrvecSDd1" title="Basic net (loss) income per common stock"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zzlw3CLEVTS" title="Diluted net (loss) income per common stock">0.05</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zoK2fOZ6jJxa" title="Basic net (loss) income per common stock"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zytKe5WhCAOj" title="Diluted net (loss) income per common stock">(0.12</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zRxDIfc4e5Jc" title="Basic net (loss) income per common stock"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20251001__20260331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z2oDxDHnScwi" title="Diluted net (loss) income per common stock">(0.12</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zFOmTwNTmk47" title="Basic net (loss) income per common stock"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_zwP17Kzdrj7c" title="Diluted net (loss) income per common stock">0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_zA7ns1bBCiFk" title="Basic net (loss) income per common stock"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--NonredeemableCommonStockMember_z3hs0od0grPc" title="Diluted net (loss) income per common stock">0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

-162136

-477730

601778

222348

-179312

-519456

1264119

467075

1442097

4249090

11500000

4249090

1466757

4249090

11500000

4249090

-0.11

0.05

-0.12

0.11

Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on the cash account and management believes that the Company is not exposed to significant risks on such account. Uninsured cash amounts as of March 31, 2026 and September 30, 2025, are $0 and $966,065, respectively.

250000

966065

Fair value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited)

Recent Accounting Standards Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

NOTE 3. INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units, which includes a full exercise by the underwriter of their over-allotment option in the amount of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zEH6rDxFtt3h" title="Number of units sold">1,500,000 Units, at a purchase price of $10.00 per Unit. <span id="xdx_90F_eus-gaap--SaleOfStockDescriptionOfTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zN1xT9fFoLOf" title="Sale of units, description">Each Unit consists of one share of the Company’s common stock, and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of one share of common stock upon the consummation of the Business Combination.

11500000

1500000

10.00

NOTE 4. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor has purchased an aggregate of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zrWnmnFlKMZ3" title="Number of units sold">610,500 Private Placement Units at a price of $10.00 per Private Placement Unit from the Company in a private placement. Each Private Unit will consist of one share of common stock (“Private Placement Share”) and one right (“Private Placement Right”). Each Private Placement Right will entitle the holder to receive one-twentieth of one share of common stock at the closing of a Business Combination. Certain proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placements Units and all underlying securities will expire worthless.

610500

10.00

Each Private Placement Right will entitle the holder to receive one-twentieth of one share of common stock at the closing of a Business Combination.

NOTE 5. RELATED PARTY TRANSACTIONS Founder Shares On September 2, 2020, the Sponsor subscribed to purchase an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200902__20200902__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_zhO8jcNjWzyc" title="Issuance of shares">4,312,500 shares (the “Founder Shares”) for a subscription price of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20200902__20200902__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_z0lAvKOSuk55" title="Subscription price">3,000. On October 26, 2023, the Sponsor agreed to surrender an aggregate of <span id="xdx_905_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20231026__20231026__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_zkp25TmpSrv2" title="Number of shares surrender">1,068,910 shares of the Company’s common stock for no consideration, which were cancelled, resulting in the Sponsor holding an aggregate of 3,243,590 Founder Shares. The subsequent cancellation is retrospectively reflected in the financial statements from day one. The Company maintains the ownership of Founder Shares by the initial stockholders at <span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20251001__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_z9UTFf3iP4Jh" title="Ownership percentage">22.0% of the Company’s issued and outstanding shares of common stock upon the consummation of the Initial Public Offering, not including the Private Placement Shares or the Representative Shares. Up to <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_zgbjk4FJayne" title="Common stock shares outstanding">423,077 Founder Shares held by the initial stockholders are no longer subject to forfeiture due to the underwriters’ over-allotment option exercised in full at the Initial Public Offering. The initial stockholders and the officers and directors have agreed not to transfer, assign or sell any of the Founder Shares until the earlier of (i) six months after the date of the consummation of the Business Combination or (ii) the date on which the Company completes a liquidation, merger, stock exchange or other similar transaction after its initial business combination that results in all of its public stockholders having the right to exchange their shares of common stock for cash, securities or other property. <span id="xdx_907_eus-gaap--SaleOfStockDescriptionOfTransaction_pid_c20241001__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember_zO5ieulV8by5" title="Sale of stock description">Notwithstanding the foregoing, if the last sale price of the Company’s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after its initial business combination, the Founder Shares will be released from the lock-up. Due to Sponsor During the quarterly period ended March 31, 2026, the Sponsor loaned the Company $10,000. During the annual period ended September 30, 2025, the Company incurred travel expenses amounting to $2,788, which are reimbursable by Su De Tang Global Corporation. The reimbursement was paid to the Company through the proceeds of the working capital loans. As of March 31, 2026 and September 30, 2025, the Company had due to Sponsor, non-interest bearing and due on demand, in the amount of $10,788 and $2,788, respectively. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited) Subscription Agreements From October 2023 through January 2024, the Company’s Sponsor entered into six subscription agreements to sell membership interests in the Sponsor to members of management, directors and director nominees. The membership interests represent the indirect equivalent of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231001__20240131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zGQnnud14jr" title="Number of shares issued">525,000 Founders Shares which equates to <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zdrqCU0RrFW8" title="Ownership percentage">16.19% of the 3,243,590 Founders Shares issued and outstanding. The total purchase price paid for the membership interests was $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20231001__20240131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z3YaQcLqmxO4" title="Value of shares issued">2,500. The Company modified the agreements in February 2024, with the intent to clarify that the Founder Shares are “earned upon the completion of a successful Business Combination” and the modified agreement is to be effective contemporaneously with the date and time of the initial subscription agreements. The sale of the membership interests to the Company’s management, directors and director’s nominees is in the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. On January 22, 2024, one of the subscription agreements representing an indirect equivalent of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240122__20240122__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zcVRwWoRBsI2" title="Number of shares terminted">100,000 Founders Shares or <span id="xdx_907_ecustom--PercentageOfSharesTerminated_pid_dp_uPure_c20240122__20240122__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zaSFA28exApd" title="Percentage of shares terminated">3.08% of the <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zRCaWA01D1ml" title="Common stock shares outstanding">3,243,590 Founders Shares (with over-allotment) issued and outstanding was terminated and $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_c20240122__20240122__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember_zz70EO8MepH6" title="Paid to subscriber">500 was paid to the subscriber as a result of the termination of the agreement. On September 11, 2024, one of the subscription agreements representing an indirect equivalent of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zpktppdqSoPb" title="Number of shares issued">100,000 Founders Shares or <span id="xdx_90C_ecustom--PercentageOfSharesTerminated_pid_dp_uPure_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zFduA3ebTZd2" title="Percentage of shares terminated">3.08% of the <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240911__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zNZNX3xRgXy7" title="Common stock shares outstanding">3,243,590 Founders Shares (with over-allotment) issued and outstanding was amended in which the Sponsor granted an additional <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zVqwWDpnl93a" title="Number of shares issued">50,000 Founder Shares bringing the total to <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zW9sGr8M1JX7" title="Number of shares terminted">150,000 Founder Shares or <span id="xdx_900_ecustom--PercentageOfSharesTerminated_pid_dp_uPure_c20240911__20240911__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zr6gLH5zUXAd" title="Percentage of shares terminated">4.62% of the <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240911__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FounderSharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zP0VasUoXRJi" title="Number of shares held">3,243,590 Founders Shares (with over-allotment) issued and outstanding. The total purchase price paid for the membership interest was $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240911__20240911__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--FounderSharesMember_zr1fZkMGvZA7" title="Paid to subscriber">750. The fair value of the <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240328__20240328__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zgJEMV51wWQl" title="Number of shares issued">425,000 shares granted through March 28, 2024, to the Company’s directors and director nominees was approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240328__20240328__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zm6TfIRT99H3" title="Number of shares issued, value">1,734,000 or approximately $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20240328__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zSCLdRVCZapl" title="Share price">4.08 per share. The fair value of the additional <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240911__20240911__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zDkiE0Dvpky1" title="Number of shares issued">50,000 shares granted on September 11, 2024, to the Company’s directors and director nominees was approximately $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240911__20240911__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zj4zo16VSzT7" title="Number of shares issued, value">499,000 or approximately $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20240911__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAndDirectorNomineesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zgbKBY0lBLJh" title="Share price">9.98 per share. The Founders Shares were granted subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of March 31, 2026, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of Founders Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founders Shares. <p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zQJn56GRVlH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Founder Shares issued to the directors and director nominees were valued using a Black-Scholes model. The following criteria presents the quantitative information regarding market assumptions used in the Founder Share valuations: SCHEDULE OF FAIR VALUE OF MARKET ASSUMPTIONS USED IN THE FOUNDER SHARE VALUATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231115__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember_zrUXh9kXwfv3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">November 15, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240115__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember_z65oEr9E0hia" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">January 15, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zsPZ2rGkoKcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAp0toyaZuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zLLFd8u1Y561" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Spot price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8.95</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9.32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountForLackOfMarketabilityMember_z8yh7I5ItDGe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Discount of lack of marketability (DLOM)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountForLackOfMarketabilityMember_zCb8dYq64JIa" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity measurement input</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> </table> Administrative Support Agreement The Company entered into an Administrative Services Agreement pursuant to which the Company agreed to pay the Chief Financial Officer a sum of $5,000 per month commencing on October 1, 2023. Upon completion of the initial business combination or the liquidation, the Company will cease paying these monthly fees. On January 22, 2024, the Company’s Chief Financial Officer resigned, and the Administrative Services Agreement was terminated. On January 22, 2024, the Company appointed a new Chief Financial Officer and entered into an Administrative Services Agreement dated January 24, 2024, pursuant to which the Company agreed to pay the Chief Financial Officer a sum of $5,000 per month commencing at the time of the Initial Public Offering closing. The agreement further specified that upon completion of the initial business combination or the liquidation, the Company will cease paying these monthly fees. For the three and six months ended March 31, 2026, the Company incurred $15,000 and $30,000 in fees for these services, respectively, of which $15,000 is recorded as accrued expenses in the balance sheet as of March 31, 2026. For the three and six months ended March 31, 2025, the Company incurred $15,000 and $30,000 in fees for these services, respectively, of which $15,000 is recorded as accounts payable and accrued expenses in the balance sheet as of March 31, 2025. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited)

4312500

3000

1068910

3243590

0.220

423077

10000

2788

10788

2788

525000

0.1619

3243590

2500

100000

0.0308

3243590

500

100000

0.0308

3243590

50000

150000

0.0462

3243590

750

425000

1734000

4.08

50000

499000

9.98

<p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zQJn56GRVlH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Founder Shares issued to the directors and director nominees were valued using a Black-Scholes model. The following criteria presents the quantitative information regarding market assumptions used in the Founder Share valuations: SCHEDULE OF FAIR VALUE OF MARKET ASSUMPTIONS USED IN THE FOUNDER SHARE VALUATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231115__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember_zrUXh9kXwfv3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">November 15, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240115__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember_z65oEr9E0hia" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">January 15, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zsPZ2rGkoKcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAp0toyaZuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zLLFd8u1Y561" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Spot price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8.95</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9.32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountForLackOfMarketabilityMember_z8yh7I5ItDGe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Discount of lack of marketability (DLOM)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountForLackOfMarketabilityMember_zCb8dYq64JIa" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity measurement input</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> </table>

5.0

4.8

4.1

8.95

9.32

0.2

0.4

0.2

0.4

5000

15000

30000

15000

30000

15000

NOTE 6. COMMITMENTS AND CONTINGENCY Registration Rights The holders of the Founder Shares, Private Placement Units (and their underlying securities) any Units that may be issued upon conversion of the Working Capital Loans (and underlying securities), and Representative Shares are entitled to registration rights pursuant to a registration rights agreement signed on the effective date of the Initial Public Offering requiring the Company to register such securities for resale. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement and Business Combination Marketing Agreement The Company engaged I-Bankers to act as Underwriters on the Initial Public Offering of the Company’s Units, for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251001__20260331__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zj8nletpIlpf" title="Stock issued during period value">115,000,000 and the simultaneous listing on the Nasdaq Global Market. The Underwriters had a 30-day option to purchase up to an additional <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251001__20260331__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDKjIORglxZb" title="Stock issued during period shares">1,500,000 Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. On March 28, 2024, simultaneously with the closing of the Initial Public Offering, the Underwriters elected to fully exercise the over-allotment option to purchase an additional <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zs5fCEw8PyMk" title="Number of units sold">1,500,000 Units at a price of $10.00 per Unit. The Underwriters were entitled to a cash underwriting discount of $<span id="xdx_901_ecustom--CashUnderwritingDiscountPerUnit_iI_pid_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_z08vGfgjswb1" title="Cash underwriting discount per unit">0.30 per Unit, or $<span id="xdx_900_eus-gaap--PaymentsForUnderwritingExpense_c20251001__20260331__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zyMX8bwfSjs" title="Cash underwriting fees">3,450,000 in the aggregate, paid upon the closing of the Initial Public Offering. In addition, under a business combination marketing agreement, the Company engaged I-Bankers to provide marketing services in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, <span id="xdx_908_eus-gaap--ManagementAndServiceFeesRate_pid_dp_uPure_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zamqKZR548Ja" title="Percentage of cash fee for service">3.5% of the gross proceeds of the Initial Public Offering (the “M&A fee”) or $<span id="xdx_90D_ecustom--MergersAndAcquisitionsCashFee_c20251001__20260331__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDbIc3fRnpYe" title="M&A cash fee">4,025,000 in the aggregate. If the Company doesn’t complete a business combination, no fee will be due. In addition, the Company will pay the I-Bankers a finder fee equal to <span id="xdx_90B_ecustom--PercentageOfFinderFee_pid_dp_uPure_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zTMMwJZ7fQNi" title="Percentage of finder fee">1.0% of the consideration issued to a target if the business combination is consummated with a target introduced by the I-Bankers. On the closing of the Initial Public Offering, pursuant to the underwriting agreement, the Company issued as compensation <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20251001__20260331__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2Og7Tg1N5re" title="Shares issued for compensation">395,000 shares of common stock for no cash consideration (the “Representative Shares”). Working Capital Loan On September 16, 2024, the Company issued an unsecured promissory note in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240916__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--SuDeTangGlobalCorporationMember_zJkslOunaeBb" title="Principal amount">150,000 to Su De Tang Global Corporation (the “Working Capital Loan”). The principal balance of this Promissory Note represents the first of potentially three instalments of the Working Capital Loan. The Working Capital Loan bears no interest and will be extinguished without any payment required at the consummation of a Business Combination with Su De Tang Global Corporation. The Company has borrowed a total of $<span id="xdx_90B_eus-gaap--OtherBorrowings_iI_c20260331__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--SuDeTangGlobalCorporationMember_zSZVcFSUggGi" title="Borrowings">147,629 under the Working Capital Loan. As of September 30, 2025, the Company repaid an amount of $<span id="xdx_908_eus-gaap--RepaymentsOfDebt_c20241001__20250930__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--SuDeTangGlobalCorporationMember_zsUDaZzrtTZ3" title="Repayment of loan">147,629. Borrowings under the note are no longer available.

115000000

1500000

10.00

0.30

3450000

0.035

4025000 0.010

395000

150000

147629

NOTE 7. STOCKHOLDERS’ (DEFICIT) EQUITY Preferred Stock — The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company’s board of directors. As of March 31, 2026 and September 30, 2025, there were no shares of preferred stock issued or outstanding. Common Stock — The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.0001 per share. Holders of common stock are entitled to one vote for each share. As of March 31, 2026 and September 30, 2025, there were 4,249,090 shares of common stock issued and outstanding, excluding 759,139 and 1,490,880 shares of common stock subject to possible redemption, respectively. IB ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2026 (Unaudited)

10000000

0.0001

100000000

0.0001

Holders of common stock are entitled to one vote for each share.

4249090

759139

1490880

NOTE 8. FAIR VALUE MEASUREMENTS The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</td></tr> </table> As of March 31, 2026, assets held in the Trust Account were comprised of $8,188,994 in a money market fund that is invested primarily in U.S. Treasury Securities. For the quarterly period ended March 31, 2026, the Company had withdrawn $105,000 of interest earned on the Trust Account to pay for income taxes and $7,886,591 from the Trust Account in connection with redemption. As of September 30, 2025, assets held in the Trust Account were comprised of $15,890,194 in a money market fund that is invested primarily in U.S. Treasury Securities. For the year ended September 30, 2025, the Company had withdrawn $1,711,366 of interest earned on the Trust Account to pay for income taxes and $106,131,025 from the Trust Account in connection with redemptions. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and September 30, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Description</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43%">Assets:</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Cash and investments held in Trust Account</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_982_eus-gaap--AssetsHeldInTrust_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQSoGrJqOm6b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and investments held in Trust Account">8,188,994</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98F_eus-gaap--AssetsHeldInTrust_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zdgNOW0Z50Rh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and investments held in Trust Account">15,890,194</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

8188994

105000

-7886591

15890194

1711366

-106131025

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and September 30, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Description</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43%">Assets:</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Cash and investments held in Trust Account</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_982_eus-gaap--AssetsHeldInTrust_iI_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQSoGrJqOm6b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and investments held in Trust Account">8,188,994</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98F_eus-gaap--AssetsHeldInTrust_iI_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zdgNOW0Z50Rh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and investments held in Trust Account">15,890,194</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

8188994

15890194

NOTE 9. SEGMENT INFORMATION ASC Topic 280, “Segment Reporting,” establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker, or group, in deciding how to allocate resources and assess performance. The Company’s chief operating decision maker has been identified as the Chief Financial Officer (“CODM”), who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment. When evaluating the Company’s performance and making key decisions regarding resource allocation, the CODM reviews key metrics, which includes general and administrative expenses and interest and dividends earned on cash and investments held in Trust Account which are included in the statements of operations. The key measures of segment profit or loss reviewed by our CODM are interest and dividends earned on cash and investments held in Trust Account and general and administrative expenses. The CODM reviews interest and dividends earned on cash and investments held in Trust Account to measure and monitor stockholder value and determine the most effective strategy of investment with the Trust Account funds while maintaining compliance with the trust agreement. General and administrative expenses are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination within the business combination period. The CODM also reviews general and administrative costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget.

NOTE 10. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

1222

29798

1222

3747

2254599

620636

3314235 1793058

371151

764769

5943732

3178463

5973530

3179685

761

1259116

243898

98001 49963 1149344 20000

1377878

1443205

26939850

21351250

13599823

8359353

72961

69498

13526862 8289855

176340

196515

-9304065

-6729715

4595652

1736480

5973530

3179685

60631

1460928

741414

44053

3449212

347933

687492

35964

21780

60000 60000

99338

7036

70896

2179743

4966934

-599

-12295

390 533

-393618

-1361481

-2574350

-6341243

-2574350

-6341243

-0.11

-0.37

22603000

17322917

10593220

403138

34643

-388472

49309

2503030 2760833 2760833 5870000 3449212 3449212 2385000 1746170 1746170 141697 141697 -69498 -69498

-6341243

21351250

8359353

-69498

176340

-6729715

1736480

5283000 4934870 4934870

305600

196515 196515 -3463 -3463

-2574350

26939850

13599823

-72961

176340

196515

-9304065

4595652

-2574350

-6341243

69553

1343

3449212

196515 -305600

-393618

-1361481

-599

-12295

-1607122

-1518255

29798

-529270

20000

1059955

18403

2649742

854386

1599585

306713

-3206707

-1824968

5090

1703516

620636

-1708606

-620636

-72650

4930091

2586979

-16000 -67503

4914091

2446826

-1222

1222

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td><td style="font: 10pt Times New Roman, Times, Serif">Organization and Nature of Operations</td></tr></table> DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS GNQ Insilico Inc. (the “Company” or “GNQ”) was incorporated under the Canada Business Corporations Act on August 23, 2023, with its registered office located at 40 Temperance Street, Suite 3200, Bay Adelaide Centre – North Tower, Toronto ON M5H 0B4. Its principal office is located at #101-2275 Upper Middle Road East, Oakville, Ontario, L6H 0C3. These consolidated financial statements include the accounts of GNQ Insilico Inc. and its wholly-owned subsidiary, GNQ Insilico Inc., incorporated under the laws of California, United States, collectively referred to herein as the “Company”. GNQ Insilico Inc. is a precision medicine tech-bio company whose principal business activity is the development and commercialization of proprietary software platforms that leverage multi-omics data, causal artificial intelligence, and emerging quantum computing technologies to accelerate and de-risk drug discovery and early clinical development. The Company’s product, the GNQ Drug Assessment Platform (the “DAP”), was successfully launched on September 13, 2025. GNQ’s DAP represents the first product release of the Company’s platform suite and marks the transition from the development stage to early revenue stage of operations. Revenues from DAP commenced in the first quarter of the fiscal year ending December 31, 2026. No revenues have been recognized in the financial statements for the year ended December 31, 2025. The Company also continues development of additional offerings within the GNQ platform suite as at December 31, 2025 (see Intangible under development, Note 6).

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2.</td><td style="font: 10pt Times New Roman, Times, Serif">Summary of Significant Accounting Policies</td></tr></table> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a)</td><td style="font: 10pt Times New Roman, Times, Serif">Basis of Presentation</td></tr></table> The consolidated financial statements have been prepared in accordance with US generally accepted accounting principles (“GAAP”) as defined by the Financial Accounting Standards Board (“FASB”). The consolidated financial statements are presented in United States dollars, which is the Company’s functional and reporting currency. All intercompany balances and transactions have been eliminated on consolidation. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b)</td><td style="font: 10pt Times New Roman, Times, Serif">Emerging Growth Company</td></tr></table> The Company qualifies as an “Emerging Growth Company” as defined under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As an Emerging Growth Company, the Company is permitted to take advantage of certain reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Presenting only two years of audited financial statements and related Management’s Discussion and Analysis.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Reduced disclosure obligations regarding executive compensation.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exemption from the requirement to obtain an auditor’s attestation on internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.</td></tr></table> The Company has elected to use the extended transition period for adopting new or revised accounting standards, as permitted under the JOBS Act. This means that the Company will adopt such standards on the dates applicable to private companies. The Company may choose to forgo these exemptions in the future, but any such decision will be irrevocable. The Company will remain an Emerging Growth Company until the earliest of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The last day of the fiscal year in which it reaches $1.235 billion in annual gross revenues;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The last day of the fiscal year following the fifth anniversary of its first sale of common equity securities under an effective registration statement;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The date on which it becomes a “large accelerated filer”; or</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The date on which it issues more than $1 billion in non-convertible debt over a three-year period.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c)</td><td style="font: 10pt Times New Roman, Times, Serif">Use of Estimates</td></tr></table> The preparation of the consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect certain reported amounts and related disclosures. Such estimates include, but are not limited to, the fair value of stock-based compensation and investments in a related party and income tax valuation allowances. Actual results could differ from those estimates. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d)</td><td style="font: 10pt Times New Roman, Times, Serif">Going Concern</td></tr></table> These financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at December 31, 2025, the Company is a pre-revenue development stage enterprise in the process of being commercialized. For the year ended December 31, 2025, the Company had a net loss of $2,574,350 (2024: $6,341,243). As at December 31, 2025 there was an accumulated deficit of $9,304,065 (2024: $6,729,715), and a bank overdraft of $761 (2024: Cash balance of $1,222). The Company had a positive total shareholders’ equity as at December 31, 2025 of $4,595,652 (2024: $1,736,480). The Company signed a revenue contract worth $10,750,000 during the year ended December 31, 2025, with revenue of $750,000 earned in the first quarter of 2026, with the balance to be over three years starting in 2026. In addition, the Company is in the process of signing additional revenue contracts of $<span id="xdx_908_eus-gaap--FinancialGuaranteeInsuranceContractsFutureExpectedPremiumRevenueToBeRecognized_iI_c20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxnxE4fYz9J1" title="Additional revenue contracts">99,300,000 in the first quarter of 2026. The Company is also in discussions with other potential customers for securing other revenue contracts which are expected to be signed in 2026. The Company continues to attract equity investments in the Company. The Company is in the process of doing a de-SPAC transaction for listing on Nasdaq. The transaction is expected to be finalized in the third quarter of 2026. In this connection, PIPE and bridge financing are being arranged. The Company’s ability to continue as a going concern is dependent upon obtaining additional equity or debt financing, generating revenues sufficient to cover operating costs, and continuing to execute on its commercialization strategy. The Company is aggressively pursuing its business leads to execute additional revenue contracts and deliver to customers. While the company has substantial doubt about its ability to continue as a going concern provided the financing is not obtained or the revenue is not earned, management considers that, with financings arranged and revenue contracts signed, it is appropriate to treat the Company as a going concern over the foreseeable future. Accordingly, these consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">e)</td><td style="font: 10pt Times New Roman, Times, Serif">Cash and Cash Equivalents</td></tr></table> The Company considers all highly liquid investments with an original maturity date of three months or less to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking and interest-bearing accounts. Bank overdrafts, if any, are classified as current liabilities in the balance sheet and are presented net within cash and cash equivalents for purposes of the statement of cash flows. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">f)</td><td style="font: 10pt Times New Roman, Times, Serif">Other Receivables</td></tr></table> Other receivables consist of amounts due from third parties, including vendor overpayments and other short-term amounts collectible within one year. Receivables are stated at their net realizable value. Management evaluates the collectability of receivables and records an allowance for credit losses when collection is not probable. No allowance for credit losses has been recognized as of December 31, 2025, or 2024. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">g)</td><td style="font: 10pt Times New Roman, Times, Serif">Subscription Receivables</td></tr></table> The Company recognizes share subscription receivables in cases where shares are issued but consideration has not yet been received. Where subscription obligations are to be settled through non-cash consideration, the receivable is recorded at the agreed upon fair value of the consideration to be received. Subscription receivables denominated in foreign currencies are translated into US dollars at the closing exchange rate at each balance sheet date, in accordance with ASC 830, Foreign Currency Matters. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">h)</td><td style="font: 10pt Times New Roman, Times, Serif">Property, Plant and Equipment</td></tr></table> Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses. Additions and improvements to property and equipment are capitalized. The cost of maintenance and repairs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives are as follows: SCHEDULE OF ESTIMATED PROPERTY PLANT AND EQUIPMENT USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 49%; text-align: left">Asset Category</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">Useful Life</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ9ET2ycerof" title="Property plant and equipment useful life">3 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxis3I5PZLV8" title="Property plant and equipment useful life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg4q5QMrXsah" title="Property plant and equipment useful life">3 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zqf4TWMCWzX8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember">Lesser of useful life or lease term</td></tr> </table> When assets are sold or disposed of, the cost and related accumulated depreciation is removed from their respective accounts, and the resulting gain or loss is reported in the consolidated statement of operations. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">i)</td><td style="font: 10pt Times New Roman, Times, Serif">Investments</td></tr></table> The Company’s investment in a related party is accounted for under the fair value option elected pursuant to ASC 825, Financial Instruments, or under the equity method pursuant to ASC 323, Investments – Equity Method and Joint Ventures, depending on the nature of the Company’s ownership interest and ability to exercise significant influence. Depending on the nature of the instrument held, fair value is determined using inputs that may be classified within different levels of the fair value hierarchy established under ASC 820, Fair Value Measurement. The level of the hierarchy applied reflects the observability of the inputs used in the valuation if the investment includes more than one component, each component is evaluated separately and me be classified within a different level of hierarchy, depending on the observability of inputs used to value it. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">j)</td><td style="font: 10pt Times New Roman, Times, Serif">Intangible Assets under Development</td></tr></table> Costs associated with the development of products in GNQ’s platform suite are capitalized as intangible assets under development in accordance with ASC 350-40, Internal-Use Software, and ASC 985-20, Costs of Software to be Sold, Leased or Marketed, as applicable. Costs incurred prior to the establishment of technological feasibility are expensed as research and development cost in the period incurred. Technological feasibility is established when the Company has completed all planning, designing, coding and testing necessary to confirm that the product can be produced to meet its design specifications, as evidence by the completion of a working model. Capitalization of development costs commence when management determines that the technological feasibility of the specific platform has been established and it is probable that the project will be completed and the software will be used to perform the intended function. Costs eligible for capitalization include direct labor, directly attributable third-party consulting and professional fees, and other direct incremental costs incurred during the application development stage. Capitalization ceases when the product is available for general release. Costs incurred during the preliminary project stage and post-implementation/operational stage are expensed as incurred. Once the asset is available for its intended use, it is amortized on a straight-line basis over its estimated useful life. Intangible assets are assessed for impairment at each reporting date. Capitalized costs are recorded at cost less accumulated amortization and any impairment write-downs. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">k)</td><td style="font: 10pt Times New Roman, Times, Serif">Impairment of Long-Lived Assets</td></tr></table> The Company reviews long-lived assets, including property, plant and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable in accordance with ASC 360, Property, Plant and Equipment. Recoverability is assessed by comparing the carrying amount of the asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount exceeds the estimated undiscounted future cash flows, an impairment loss is recognized for the excess of the carrying amount over the fair value of the asset. No impairment loss was recognized during the years ended December 31, 2025 or 2024. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">l)</td><td style="font: 10pt Times New Roman, Times, Serif">Accounts Payable and Accrued Liabilities</td></tr></table> Accounts payable and accrued liabilities represent obligations arising from goods and services rendered to the Company during the reporting period. These amounts are unsecured, non-interest-bearing, and generally due within one year. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">m)</td><td style="font: 10pt Times New Roman, Times, Serif">Short-Term Loan</td></tr></table> Short-term loans are recognized initially at the proceeds received, net of transaction costs, if any. Borrowings are subsequently measured at amortized cost. The loan is classified as a current liability if due within twelve months of the balance sheet date. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">n)</td><td style="font: 10pt Times New Roman, Times, Serif">Related-Party Transactions</td></tr></table> Related-party transactions are measured and recorded at the exchange amount, which is the consideration agreed upon by the related parties. The Company follows the guidance of ASC 850, Related Party Disclosures, in identifying related parties and disclosing material transactions and balances. Due to/from related parties are unsecured and non-interest-bearing unless otherwise indicated. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">o)</td><td style="font: 10pt Times New Roman, Times, Serif">Common Shares</td></tr></table> Common shares are classified as equity. Incremental costs directly attributable to the issuance of common shares and warrants are recognized as a deduction from equity, net of any tax effects. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">p)</td><td style="font: 10pt Times New Roman, Times, Serif">Warrants</td></tr></table> Warrants issued as part of equity financings are classified as equity instruments and measured at fair value at the date of issuance. Warrants are assessed for equity vs. liability. Equity warrants are fair valued once whereas liability warranted fair valued at each reporting period. For the years ended December 31, 2025 and 2024, there were no liability warrants. The fair value allocated to warrants is credited to the warrants component within shareholders’ equity, with the residual amount allocated to share capital. The Company uses the Black-Scholes-Merton (“BSM”) option-pricing model to estimate the fair value of warrants on the date of grant. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">q)</td><td style="font: 10pt Times New Roman, Times, Serif">Share-Based Compensation</td></tr></table> The Company accounts for share-based compensation in accordance with ASC 718, Compensation – Stock Compensation. The Company measures the cost of employee and non-employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Share-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company uses the BSM option pricing model to estimate the fair value of stock options on the date of grant. The calculation of fair value included several assumptions that require management’s judgement. The Company accounts for forfeitures as they occur. Compensation expense is recognized in the period in which the options vest, based on the number of options vesting during that period. For awards with graded vesting, each tranche is treated as a separate award. For grants where the vesting commencement date precedes the grant date, the cost attributable to pre-grant service is recognized on the grant date. Since the expense is recognized only for options that vest, no adjustment arises upon forfeiture of unvested options. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">r)</td><td style="font: 10pt Times New Roman, Times, Serif">Income Taxes</td></tr></table> The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company evaluates the likelihood of realization of deferred tax assets based on available evidence, including projected future taxable income, reversal of existing temporary differences, and available tax planning strategies. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the position will be sustained upon examination by tax authorities. Interest and penalties related to uncertain tax positions are included in income tax expense. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">s)</td><td style="font: 10pt Times New Roman, Times, Serif">Research and development expenses</td></tr></table> All research and development expenses relating to inception of the project through to technological feasibility, including planning, architecture, design, data source identification and prototype development is expensed and included in the statement of operations. Costs incurred after technological feasibility is established until the product is available for general release to customers are capitalized as an intangible asset. These costs include coding, testing and other direct costs of bringing the product to completion. Costs related to production, training, maintenance, and customer support activities after the product is available for general release to customers are expensed as incurred and included in the statement of operations. Research and development expenses include personnel-related costs (comprised of salaries, benefits and share-based compensation), consulting and professional fees and certain technology costs. These expenses are exclusive of depreciation and amortization. Research and development activities consist of continued development of the Company’s platform suite. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">t)</td><td style="font: 10pt Times New Roman, Times, Serif">Foreign Currency Translation</td></tr></table> The Company’s functional and reporting currency is the U.S. dollar. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expense items are translated at the sport rate for the transaction day or average exchange rates for the period, whichever is easily available. Foreign exchange gains and losses are recognized in the statement of operations in the period incurred. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">u)</td><td style="font: 10pt Times New Roman, Times, Serif">Loss Per Share</td></tr></table> Basic net loss per share is computed by dividing net loss applicable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the treasury stock method and reflects the dilutive effect of outstanding stock options and warrants. In periods of net loss, all potentially dilutive securities are excluded from the computation of diluted earnings per share as their effect is antidilutive. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">v)</td><td style="font: 10pt Times New Roman, Times, Serif">Fair Value Measurements</td></tr></table> The Company measures certain financial instruments at fair value in accordance with ASC 820, Fair Value Measurement, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three-level hierarchy for fair value inputs: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif">Level 1: Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif">Level 3: Unobservable inputs supported by little or no market activity that are significant to the fair value of the assets or liabilities.</td></tr></table> The carrying values of cash, other receivables, accounts payable and accrued liabilities, short-term loans, and due to/from related parties approximate their fair values given their short-term nature. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">w)</td><td style="font: 10pt Times New Roman, Times, Serif">Segment Information</td></tr></table> The Company currently operates and is managed as a single operating segment. The Company’s chief operating decision maker is its Chief Executive Officer, who allocates resources and assesses performance at the consolidated level. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">x)</td><td style="font: 10pt Times New Roman, Times, Serif">Recently Adopted Accounting Standards</td></tr></table> The Company reviews new accounting pronouncements as they are issued by FASB. There were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements for the year ended December 31, 2025 and 2024. In June 2022, FASB issued Accounting Standard Update (“ASU”) 2022-03, ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. This guidance was issued to clarify the guidance in Topic 820, Fair Value Measurement when measuring the fair value of an open equity security subject to contractual restrictions that prohibit the sale of an equity security and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. These amendments are effective for fiscal years beginning after December 15, 2023. The adoption of this standard did not have a significant impact on the company’s consolidated financial statements. In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to improve reportable segments disclosure requirements primarily through enhanced disclosures about significant segment expenses. The adoption of this standard did not have a significant impact on the company’s consolidated financial statements. In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which amends the codification to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate of an entity and of income taxes paid. For public business entities, the amendments are effective for annual years beginning after December 15, 2024. The Company adopted the ASU prospectively for the year ended December 31, 2025, the effect being only related to the disclosures with no impact on the results of operations or financial condition. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">y)</td><td style="font: 10pt Times New Roman, Times, Serif">Recently Issued Accounting Standards Not Yet Adopted</td></tr></table> Management has reviewed all recently issued accounting standards and does not expect any of the issued but not yet effective standards to have a material effect on the Company’s financial statements. In November 2024, FASB issued ASU 2024-03, Expense Disaggregation Disclosures (Subtopic 220-40), which requires additional disclosure of the nature of expenses included in the income statement as well as disclosures about specific types of expenses included in the expense captions presented in the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026. The Company is currently evaluating the impact of the ASU on its consolidated financial statements. In July 2025, FASB issued ASU No. 2025-05, Financial Instruments—Credit Losses (Topic 326) — Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient for estimating expected credit losses. The amendments are effective for annual reporting periods beginning after December 15, 2025. The Company has not yet adopted ASU 2025-05 and is still evaluating the impact of the adoption on its consolidated financial statements. In September 2025, the FASB issued ASU No. 2025-06, Accounting for internal-use software costs (Topic 350). The new standard amends specific aspects of the accounting for internal-use software costs including the criteria for capitalizing software costs. It also amends the related disclosure requirements. This standard will be effective starting the year 2029. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements. In September 2025, FASB issued ASU No. 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The new standard refines the scope of the guidance on derivatives in Topic 815 and clarifies the guidance on shared-based payments from a customer in ASC 606. This standard will be effective for the Company starting the year 2027. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements. In December 2025, FASB issued ASU No. 2025-10, Government Grants (Topic 832). The new standard adds guidance to ASC 832 on the recognition, measurement, and presentation of government grants. This standard will be effective for the Company starting the year 2029. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a)</td><td style="font: 10pt Times New Roman, Times, Serif">Basis of Presentation</td></tr></table> The consolidated financial statements have been prepared in accordance with US generally accepted accounting principles (“GAAP”) as defined by the Financial Accounting Standards Board (“FASB”). The consolidated financial statements are presented in United States dollars, which is the Company’s functional and reporting currency. All intercompany balances and transactions have been eliminated on consolidation.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b)</td><td style="font: 10pt Times New Roman, Times, Serif">Emerging Growth Company</td></tr></table> The Company qualifies as an “Emerging Growth Company” as defined under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As an Emerging Growth Company, the Company is permitted to take advantage of certain reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Presenting only two years of audited financial statements and related Management’s Discussion and Analysis.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Reduced disclosure obligations regarding executive compensation.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exemption from the requirement to obtain an auditor’s attestation on internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.</td></tr></table> The Company has elected to use the extended transition period for adopting new or revised accounting standards, as permitted under the JOBS Act. This means that the Company will adopt such standards on the dates applicable to private companies. The Company may choose to forgo these exemptions in the future, but any such decision will be irrevocable. The Company will remain an Emerging Growth Company until the earliest of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The last day of the fiscal year in which it reaches $1.235 billion in annual gross revenues;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The last day of the fiscal year following the fifth anniversary of its first sale of common equity securities under an effective registration statement;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The date on which it becomes a “large accelerated filer”; or</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The date on which it issues more than $1 billion in non-convertible debt over a three-year period.</td></tr></table>

1235000000

1000000000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c)</td><td style="font: 10pt Times New Roman, Times, Serif">Use of Estimates</td></tr></table> The preparation of the consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect certain reported amounts and related disclosures. Such estimates include, but are not limited to, the fair value of stock-based compensation and investments in a related party and income tax valuation allowances. Actual results could differ from those estimates.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d)</td><td style="font: 10pt Times New Roman, Times, Serif">Going Concern</td></tr></table> These financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at December 31, 2025, the Company is a pre-revenue development stage enterprise in the process of being commercialized. For the year ended December 31, 2025, the Company had a net loss of $2,574,350 (2024: $6,341,243). As at December 31, 2025 there was an accumulated deficit of $9,304,065 (2024: $6,729,715), and a bank overdraft of $761 (2024: Cash balance of $1,222). The Company had a positive total shareholders’ equity as at December 31, 2025 of $4,595,652 (2024: $1,736,480). The Company signed a revenue contract worth $10,750,000 during the year ended December 31, 2025, with revenue of $750,000 earned in the first quarter of 2026, with the balance to be over three years starting in 2026. In addition, the Company is in the process of signing additional revenue contracts of $<span id="xdx_908_eus-gaap--FinancialGuaranteeInsuranceContractsFutureExpectedPremiumRevenueToBeRecognized_iI_c20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxnxE4fYz9J1" title="Additional revenue contracts">99,300,000 in the first quarter of 2026. The Company is also in discussions with other potential customers for securing other revenue contracts which are expected to be signed in 2026. The Company continues to attract equity investments in the Company. The Company is in the process of doing a de-SPAC transaction for listing on Nasdaq. The transaction is expected to be finalized in the third quarter of 2026. In this connection, PIPE and bridge financing are being arranged. The Company’s ability to continue as a going concern is dependent upon obtaining additional equity or debt financing, generating revenues sufficient to cover operating costs, and continuing to execute on its commercialization strategy. The Company is aggressively pursuing its business leads to execute additional revenue contracts and deliver to customers. While the company has substantial doubt about its ability to continue as a going concern provided the financing is not obtained or the revenue is not earned, management considers that, with financings arranged and revenue contracts signed, it is appropriate to treat the Company as a going concern over the foreseeable future. Accordingly, these consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

-2574350

-6341243

-9304065

-6729715

761

1222

4595652

1736480

10750000

750000

99300000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">e)</td><td style="font: 10pt Times New Roman, Times, Serif">Cash and Cash Equivalents</td></tr></table> The Company considers all highly liquid investments with an original maturity date of three months or less to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking and interest-bearing accounts. Bank overdrafts, if any, are classified as current liabilities in the balance sheet and are presented net within cash and cash equivalents for purposes of the statement of cash flows.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">f)</td><td style="font: 10pt Times New Roman, Times, Serif">Other Receivables</td></tr></table> Other receivables consist of amounts due from third parties, including vendor overpayments and other short-term amounts collectible within one year. Receivables are stated at their net realizable value. Management evaluates the collectability of receivables and records an allowance for credit losses when collection is not probable. No allowance for credit losses has been recognized as of December 31, 2025, or 2024.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">g)</td><td style="font: 10pt Times New Roman, Times, Serif">Subscription Receivables</td></tr></table> The Company recognizes share subscription receivables in cases where shares are issued but consideration has not yet been received. Where subscription obligations are to be settled through non-cash consideration, the receivable is recorded at the agreed upon fair value of the consideration to be received. Subscription receivables denominated in foreign currencies are translated into US dollars at the closing exchange rate at each balance sheet date, in accordance with ASC 830, Foreign Currency Matters.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">h)</td><td style="font: 10pt Times New Roman, Times, Serif">Property, Plant and Equipment</td></tr></table> Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses. Additions and improvements to property and equipment are capitalized. The cost of maintenance and repairs are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives are as follows: SCHEDULE OF ESTIMATED PROPERTY PLANT AND EQUIPMENT USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 49%; text-align: left">Asset Category</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">Useful Life</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ9ET2ycerof" title="Property plant and equipment useful life">3 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxis3I5PZLV8" title="Property plant and equipment useful life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg4q5QMrXsah" title="Property plant and equipment useful life">3 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zqf4TWMCWzX8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember">Lesser of useful life or lease term</td></tr> </table> When assets are sold or disposed of, the cost and related accumulated depreciation is removed from their respective accounts, and the resulting gain or loss is reported in the consolidated statement of operations.

SCHEDULE OF ESTIMATED PROPERTY PLANT AND EQUIPMENT USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 49%; text-align: left">Asset Category</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">Useful Life</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ9ET2ycerof" title="Property plant and equipment useful life">3 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxis3I5PZLV8" title="Property plant and equipment useful life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zg4q5QMrXsah" title="Property plant and equipment useful life">3 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zqf4TWMCWzX8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23UsefulLifeTermOfLeaseMember">Lesser of useful life or lease term</td></tr> </table>

P3Y

P5Y

P3Y

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">i)</td><td style="font: 10pt Times New Roman, Times, Serif">Investments</td></tr></table> The Company’s investment in a related party is accounted for under the fair value option elected pursuant to ASC 825, Financial Instruments, or under the equity method pursuant to ASC 323, Investments – Equity Method and Joint Ventures, depending on the nature of the Company’s ownership interest and ability to exercise significant influence. Depending on the nature of the instrument held, fair value is determined using inputs that may be classified within different levels of the fair value hierarchy established under ASC 820, Fair Value Measurement. The level of the hierarchy applied reflects the observability of the inputs used in the valuation if the investment includes more than one component, each component is evaluated separately and me be classified within a different level of hierarchy, depending on the observability of inputs used to value it.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">j)</td><td style="font: 10pt Times New Roman, Times, Serif">Intangible Assets under Development</td></tr></table> Costs associated with the development of products in GNQ’s platform suite are capitalized as intangible assets under development in accordance with ASC 350-40, Internal-Use Software, and ASC 985-20, Costs of Software to be Sold, Leased or Marketed, as applicable. Costs incurred prior to the establishment of technological feasibility are expensed as research and development cost in the period incurred. Technological feasibility is established when the Company has completed all planning, designing, coding and testing necessary to confirm that the product can be produced to meet its design specifications, as evidence by the completion of a working model. Capitalization of development costs commence when management determines that the technological feasibility of the specific platform has been established and it is probable that the project will be completed and the software will be used to perform the intended function. Costs eligible for capitalization include direct labor, directly attributable third-party consulting and professional fees, and other direct incremental costs incurred during the application development stage. Capitalization ceases when the product is available for general release. Costs incurred during the preliminary project stage and post-implementation/operational stage are expensed as incurred. Once the asset is available for its intended use, it is amortized on a straight-line basis over its estimated useful life. Intangible assets are assessed for impairment at each reporting date. Capitalized costs are recorded at cost less accumulated amortization and any impairment write-downs.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">k)</td><td style="font: 10pt Times New Roman, Times, Serif">Impairment of Long-Lived Assets</td></tr></table> The Company reviews long-lived assets, including property, plant and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable in accordance with ASC 360, Property, Plant and Equipment. Recoverability is assessed by comparing the carrying amount of the asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount exceeds the estimated undiscounted future cash flows, an impairment loss is recognized for the excess of the carrying amount over the fair value of the asset. No impairment loss was recognized during the years ended December 31, 2025 or 2024.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">l)</td><td style="font: 10pt Times New Roman, Times, Serif">Accounts Payable and Accrued Liabilities</td></tr></table> Accounts payable and accrued liabilities represent obligations arising from goods and services rendered to the Company during the reporting period. These amounts are unsecured, non-interest-bearing, and generally due within one year.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">m)</td><td style="font: 10pt Times New Roman, Times, Serif">Short-Term Loan</td></tr></table> Short-term loans are recognized initially at the proceeds received, net of transaction costs, if any. Borrowings are subsequently measured at amortized cost. The loan is classified as a current liability if due within twelve months of the balance sheet date.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">n)</td><td style="font: 10pt Times New Roman, Times, Serif">Related-Party Transactions</td></tr></table> Related-party transactions are measured and recorded at the exchange amount, which is the consideration agreed upon by the related parties. The Company follows the guidance of ASC 850, Related Party Disclosures, in identifying related parties and disclosing material transactions and balances. Due to/from related parties are unsecured and non-interest-bearing unless otherwise indicated.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">o)</td><td style="font: 10pt Times New Roman, Times, Serif">Common Shares</td></tr></table> Common shares are classified as equity. Incremental costs directly attributable to the issuance of common shares and warrants are recognized as a deduction from equity, net of any tax effects.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">p)</td><td style="font: 10pt Times New Roman, Times, Serif">Warrants</td></tr></table> Warrants issued as part of equity financings are classified as equity instruments and measured at fair value at the date of issuance. Warrants are assessed for equity vs. liability. Equity warrants are fair valued once whereas liability warranted fair valued at each reporting period. For the years ended December 31, 2025 and 2024, there were no liability warrants. The fair value allocated to warrants is credited to the warrants component within shareholders’ equity, with the residual amount allocated to share capital. The Company uses the Black-Scholes-Merton (“BSM”) option-pricing model to estimate the fair value of warrants on the date of grant.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">q)</td><td style="font: 10pt Times New Roman, Times, Serif">Share-Based Compensation</td></tr></table> The Company accounts for share-based compensation in accordance with ASC 718, Compensation – Stock Compensation. The Company measures the cost of employee and non-employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Share-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company uses the BSM option pricing model to estimate the fair value of stock options on the date of grant. The calculation of fair value included several assumptions that require management’s judgement. The Company accounts for forfeitures as they occur. Compensation expense is recognized in the period in which the options vest, based on the number of options vesting during that period. For awards with graded vesting, each tranche is treated as a separate award. For grants where the vesting commencement date precedes the grant date, the cost attributable to pre-grant service is recognized on the grant date. Since the expense is recognized only for options that vest, no adjustment arises upon forfeiture of unvested options.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">r)</td><td style="font: 10pt Times New Roman, Times, Serif">Income Taxes</td></tr></table> The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company evaluates the likelihood of realization of deferred tax assets based on available evidence, including projected future taxable income, reversal of existing temporary differences, and available tax planning strategies. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the position will be sustained upon examination by tax authorities. Interest and penalties related to uncertain tax positions are included in income tax expense.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">s)</td><td style="font: 10pt Times New Roman, Times, Serif">Research and development expenses</td></tr></table> All research and development expenses relating to inception of the project through to technological feasibility, including planning, architecture, design, data source identification and prototype development is expensed and included in the statement of operations. Costs incurred after technological feasibility is established until the product is available for general release to customers are capitalized as an intangible asset. These costs include coding, testing and other direct costs of bringing the product to completion. Costs related to production, training, maintenance, and customer support activities after the product is available for general release to customers are expensed as incurred and included in the statement of operations. Research and development expenses include personnel-related costs (comprised of salaries, benefits and share-based compensation), consulting and professional fees and certain technology costs. These expenses are exclusive of depreciation and amortization. Research and development activities consist of continued development of the Company’s platform suite.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">t)</td><td style="font: 10pt Times New Roman, Times, Serif">Foreign Currency Translation</td></tr></table> The Company’s functional and reporting currency is the U.S. dollar. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expense items are translated at the sport rate for the transaction day or average exchange rates for the period, whichever is easily available. Foreign exchange gains and losses are recognized in the statement of operations in the period incurred.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">u)</td><td style="font: 10pt Times New Roman, Times, Serif">Loss Per Share</td></tr></table> Basic net loss per share is computed by dividing net loss applicable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the treasury stock method and reflects the dilutive effect of outstanding stock options and warrants. In periods of net loss, all potentially dilutive securities are excluded from the computation of diluted earnings per share as their effect is antidilutive.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">v)</td><td style="font: 10pt Times New Roman, Times, Serif">Fair Value Measurements</td></tr></table> The Company measures certain financial instruments at fair value in accordance with ASC 820, Fair Value Measurement, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three-level hierarchy for fair value inputs: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif">Level 1: Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif">Level 3: Unobservable inputs supported by little or no market activity that are significant to the fair value of the assets or liabilities.</td></tr></table> The carrying values of cash, other receivables, accounts payable and accrued liabilities, short-term loans, and due to/from related parties approximate their fair values given their short-term nature.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">w)</td><td style="font: 10pt Times New Roman, Times, Serif">Segment Information</td></tr></table> The Company currently operates and is managed as a single operating segment. The Company’s chief operating decision maker is its Chief Executive Officer, who allocates resources and assesses performance at the consolidated level.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">x)</td><td style="font: 10pt Times New Roman, Times, Serif">Recently Adopted Accounting Standards</td></tr></table> The Company reviews new accounting pronouncements as they are issued by FASB. There were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements for the year ended December 31, 2025 and 2024. In June 2022, FASB issued Accounting Standard Update (“ASU”) 2022-03, ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. This guidance was issued to clarify the guidance in Topic 820, Fair Value Measurement when measuring the fair value of an open equity security subject to contractual restrictions that prohibit the sale of an equity security and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. These amendments are effective for fiscal years beginning after December 15, 2023. The adoption of this standard did not have a significant impact on the company’s consolidated financial statements. In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to improve reportable segments disclosure requirements primarily through enhanced disclosures about significant segment expenses. The adoption of this standard did not have a significant impact on the company’s consolidated financial statements. In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which amends the codification to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate of an entity and of income taxes paid. For public business entities, the amendments are effective for annual years beginning after December 15, 2024. The Company adopted the ASU prospectively for the year ended December 31, 2025, the effect being only related to the disclosures with no impact on the results of operations or financial condition.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">y)</td><td style="font: 10pt Times New Roman, Times, Serif">Recently Issued Accounting Standards Not Yet Adopted</td></tr></table> Management has reviewed all recently issued accounting standards and does not expect any of the issued but not yet effective standards to have a material effect on the Company’s financial statements. In November 2024, FASB issued ASU 2024-03, Expense Disaggregation Disclosures (Subtopic 220-40), which requires additional disclosure of the nature of expenses included in the income statement as well as disclosures about specific types of expenses included in the expense captions presented in the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026. The Company is currently evaluating the impact of the ASU on its consolidated financial statements. In July 2025, FASB issued ASU No. 2025-05, Financial Instruments—Credit Losses (Topic 326) — Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient for estimating expected credit losses. The amendments are effective for annual reporting periods beginning after December 15, 2025. The Company has not yet adopted ASU 2025-05 and is still evaluating the impact of the adoption on its consolidated financial statements. In September 2025, the FASB issued ASU No. 2025-06, Accounting for internal-use software costs (Topic 350). The new standard amends specific aspects of the accounting for internal-use software costs including the criteria for capitalizing software costs. It also amends the related disclosure requirements. This standard will be effective starting the year 2029. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements. In September 2025, FASB issued ASU No. 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The new standard refines the scope of the guidance on derivatives in Topic 815 and clarifies the guidance on shared-based payments from a customer in ASC 606. This standard will be effective for the Company starting the year 2027. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements. In December 2025, FASB issued ASU No. 2025-10, Government Grants (Topic 832). The new standard adds guidance to ASC 832 on the recognition, measurement, and presentation of government grants. This standard will be effective for the Company starting the year 2029. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3.</td><td style="font: 10pt Times New Roman, Times, Serif">Cash and Cash Equivalents</td></tr></table> CASH AND CASH EQUIVALENTS As of December 31, 2025, the Company had a bank overdraft of $761 (2024: cash balance of $1,222). The overdraft balance reflects a timing difference between outstanding disbursements and available funds at the reporting date and was cleared in the normal course subsequent to year end.

761

1222

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">4.</td><td style="font: 10pt Times New Roman, Times, Serif">Other Receivables</td></tr></table> ACCOUNTS RECEIVABLE Other receivables are comprised of the following: SCHEDULE OF OTHER RECEIVABLES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_491_20251231_z5XWgqiLKaed" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_497_20241231_zfAdsa2SeKIj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherReceivablesNetCurrent_iI_hus-gaap--SubsidiarySaleOfStockAxis__custom--VendorReceivableMember_zfK81CCsfAv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Vendor receivable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">29,120</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_hus-gaap--SubsidiarySaleOfStockAxis__custom--EmployeeReceivableMember_zaX6DSKqMdjl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Employee receivables</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">678</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherReceivablesNetCurrent_iI_zWVqUig8r97f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">29,798</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> As at December 31, 2025, the vendor overpayment receivable of $29,120 represented an overpayment made to a third-party service provider in connection with an invoice discrepancy identified during the year. The amount was received as a cash refund subsequent to year-end and has been fully recovered. Employee receivables represent amounts advanced to employees or reclassified from accounts payable in respect of employee expense settlements. These amounts are non-interest bearing and are expected to be settled against future expense reimbursements in the normal course.

Other receivables are comprised of the following: SCHEDULE OF OTHER RECEIVABLES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_491_20251231_z5XWgqiLKaed" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_497_20241231_zfAdsa2SeKIj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherReceivablesNetCurrent_iI_hus-gaap--SubsidiarySaleOfStockAxis__custom--VendorReceivableMember_zfK81CCsfAv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Vendor receivable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">29,120</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_hus-gaap--SubsidiarySaleOfStockAxis__custom--EmployeeReceivableMember_zaX6DSKqMdjl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Employee receivables</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">678</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherReceivablesNetCurrent_iI_zWVqUig8r97f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">29,798</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

29120

678

29798

29120

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">5.</td><td style="font: 10pt Times New Roman, Times, Serif">Property, Plant and Equipment</td></tr></table> PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zXs5TTiKrPx3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241231_zBfHMJXfBZu4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--MachineryAndEquipmentGross_iI_maPPAENzCha_zwGeAOV51jo4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5,090</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzCha_zagy8ci3a1il" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,343</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzCha_zljB1WjY0cob" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,747</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> During the year ended December 31, 2025, the Company acquired computer equipment at a cost of $5,090 (2024: nil). The asset is depreciated on a straight-line basis over a useful life of three years. The depreciation expense for the year ended December 31, 2025 was $1,343 (2024: nil).

Property, plant and equipment consisted of the following: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zXs5TTiKrPx3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241231_zBfHMJXfBZu4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--MachineryAndEquipmentGross_iI_maPPAENzCha_zwGeAOV51jo4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5,090</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzCha_zagy8ci3a1il" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,343</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzCha_zljB1WjY0cob" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,747</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

5090

1343

3747

5090

P3Y

1343

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">6.</td><td style="font: 10pt Times New Roman, Times, Serif">Intangible Under Development</td></tr></table> INTANGIBLE UNDER DEVELOPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt">a)</td><td style="font: 10pt Times New Roman, Times, Serif">Continuity of Capitalized Software Development Costs</td></tr></table> The following table summarizes intangible assets: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DrugAssessmentPlatformMember_ziWWmPUtSosg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Drug Assessment Platform</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DigitalTwinsPlatformMember_zNUSKIexXQjg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Digital Twins Platform</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B4_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DrugSimulationPlatformMember_zVv9HCpTTf9g" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Drug Simulation Platform</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--FiniteLivedIntangibleAssetsNetMember_zZO1wEbII7g2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_432_c20240101__20241231_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zcZTf5Q7lgDl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinitelivedIntangibleAssetsAcquired1_zpbHN1ObTuGd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Additions: Capitalized costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">605,830</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">14,806</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">620,636</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AmortizationOfIntangibleAssets_iN_di_zDbP2fQBlSc9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43E_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_ztBh0sLcGsg5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Balance, December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">605,830</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14,806</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">620,636</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_438_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zCsBspvhmDkb" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Intangible assets beginning balance</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">605,830</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14,806</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">620,636</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_z4jWfgpgA3jd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additions: Capitalized costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,070,327</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">448,962</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">184,227</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,703,516</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AmortizationOfIntangibleAssets_iN_di_z9JNwHGZexh3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(69,553</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(69,553</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_436_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_z5YLWvcEVhX3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,606,604</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">463,768</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">184,227</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,254,599</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_434_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_z6IGQhIA2Hd7" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Intangible assets ending balance</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,606,604</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">463,768</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">184,227</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,254,599</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b)</td><td style="font: 10pt Times New Roman, Times, Serif">Amortization:</td></tr></table> Capitalized software costs are amortized on a product-by-product basis commencing upon general release, using the greater of: (i) the ratio of current gross revenues to current and anticipated future gross revenues from the product; or (ii) the straight-line method over the remaining estimated economic life of the product. For the product, Drug Assessment Platform, the estimated useful life has been determined to be five years from the general release date of September 13, 2025. This platform is being enhanced, and the customers will be transitioned to the enhanced updated version. The amortization expense for the year ended December 31, 2025 was $69,553 (2024: nil). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c)</td><td style="font: 10pt Times New Roman, Times, Serif">Impairment:</td></tr></table> At each balance sheet date, the Company compares the unamortized capitalized cost of each software product to its net realizable value (“NRV”), defined as estimated future gross revenues less estimated future costs of completing and disposing of the product. Any excess of unamortized cost over NRV is written off immediately and may not be subsequently restored.

The following table summarizes intangible assets: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DrugAssessmentPlatformMember_ziWWmPUtSosg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Drug Assessment Platform</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DigitalTwinsPlatformMember_zNUSKIexXQjg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Digital Twins Platform</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B4_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DrugSimulationPlatformMember_zVv9HCpTTf9g" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Drug Simulation Platform</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--FiniteLivedIntangibleAssetsNetMember_zZO1wEbII7g2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_432_c20240101__20241231_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zcZTf5Q7lgDl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinitelivedIntangibleAssetsAcquired1_zpbHN1ObTuGd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Additions: Capitalized costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">605,830</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">14,806</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">620,636</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AmortizationOfIntangibleAssets_iN_di_zDbP2fQBlSc9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43E_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_ztBh0sLcGsg5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Balance, December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">605,830</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14,806</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">620,636</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_438_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zCsBspvhmDkb" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif">Intangible assets beginning balance</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">605,830</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14,806</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">620,636</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_z4jWfgpgA3jd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additions: Capitalized costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,070,327</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">448,962</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">184,227</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,703,516</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AmortizationOfIntangibleAssets_iN_di_z9JNwHGZexh3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(69,553</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(69,553</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_436_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_z5YLWvcEVhX3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,606,604</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">463,768</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">184,227</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,254,599</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_434_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_z6IGQhIA2Hd7" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Intangible assets ending balance</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,606,604</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">463,768</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">184,227</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,254,599</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

605830

14806

620636

605830

14806

620636

605830

14806

620636

1070327

448962

184227

1703516

69553

1606604

463768

184227

2254599

1606604

463768

184227

2254599

P5Y

69553

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">7.</td><td style="font: 10pt Times New Roman, Times, Serif">Accounts Payable and Accrued Liabilities</td></tr></table> ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zjcsK2jg7uAj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zRELG9GJe6y7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableCurrent_iI_maAPAOAz1CP_zhlRmENBiqYh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">618,622</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">148,145</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedPayrollTaxesCurrent_iI_maAPAOAz1CP_zJu10WcswRTa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Payroll liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">225,334</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AuditAndLegalFeesAccrual_iI_maAPAOAz1CP_zs4tGW8ehmi1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Audit and legal fees accrual</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">404,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">95,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_maAPAOAz1CP_zbik39fxkAE4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other accrued liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,277</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">750</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ConvertibleNoteInterestAccrual_iI_maAPAOAz1CP_zfa6fAJr4Q8b" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Convertible note interest accrual</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_mtAPAOAz1CP_z98AZLAU7y79" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,259,116</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">243,898</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> All trade accounts payable amounts are unsecured, non-interest bearing and are generally payable within 30-90 days. The significant increase in trade accounts payable during the year ended December 31, 2025 is primarily attributable to professional and consulting fees payable as the Company advances its development efforts and commercialization strategy. Payroll liabilities represent statutory source deductions withheld from employee compensation and remitted subsequent to year end.

Accounts payable and accrued liabilities consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zjcsK2jg7uAj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zRELG9GJe6y7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableCurrent_iI_maAPAOAz1CP_zhlRmENBiqYh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">618,622</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">148,145</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedPayrollTaxesCurrent_iI_maAPAOAz1CP_zJu10WcswRTa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Payroll liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">225,334</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AuditAndLegalFeesAccrual_iI_maAPAOAz1CP_zs4tGW8ehmi1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Audit and legal fees accrual</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">404,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">95,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_maAPAOAz1CP_zbik39fxkAE4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other accrued liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,277</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">750</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ConvertibleNoteInterestAccrual_iI_maAPAOAz1CP_zfa6fAJr4Q8b" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Convertible note interest accrual</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_mtAPAOAz1CP_z98AZLAU7y79" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,259,116</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">243,898</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

618622

148145

225334

404883 95000

10277

750

1259116

243898

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">8.</td><td style="font: 10pt Times New Roman, Times, Serif">Shareholder’s Equity</td></tr></table> SHAREHOLDER’S EQUITY Common Shares: The Company is authorized to issue an unlimited number of no par value common shares. During the year ended December 31, 2023, the Company issued: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif">10,000,000 shares to its parent company, My Next Health Inc.; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">593,220 shares against cash received $529,270, less share issue expenses of $126,132 to Trenchant, a related party.</td></tr></table> During the year ended December 31, 2024, the Company issued: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">2,503,030 shares against cash and non-cash consideration of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20241231__dei--LegalEntityAxis__custom--TrenchantTechnologiesCapitalCorpMember_ztx7Y5XhUmBh" title="Cash and non-cash consideration">2,970,030, less share issue expenses of $209,199 to Trenchant;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">2,385,000 shares against private placements of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zz930dnmtmcl" title="Cash and non-cash consideration">1,746,170 against cash and non-cash consideration received; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">5,870,000 founder shares to its executives. These shares were valued at $3,449,212 which amount was charged as share compensation expense.</td></tr></table> During the year ended December 31, 2025, the Company issued: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">5,283,000 shares against private placements of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoktufHt2buj" title="Cash and non-cash consideration">4,950,870 against cash and non-cash consideration received, less share issue expenses of $16,000; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">305,600 shares to consultants for providing advisory services to the Company. These shares were valued at $305,600 which amount was charged as expense.</td></tr></table> Subsequent to the year end, on February 5, 2026, GNQ affected a 10-for-1 forward stock split of its common shares. In accordance with ASC 260, Earnings Per Share, where the number of common shares outstanding increases due to a stock split (or decreases via reverse split), the weighted-average number of shares, earnings per share, and option and warrant exercise prices, have been retroactively restated on a post-split basis as if the split had occurred at the beginning of the earliest period presented. Accordingly, the number of common shares outstanding as of December 31, 2025 on a post-split basis was 26,939,850 shares (2024: 21,351,250 shares). Warrants: During the year ended December 31, 2024, the Company issued 360,880 finder warrants to 2809539 Ontario Inc., a director of Trenchant, a related party, in respect of investment in the Company by Trenchant. These warrants were valued at $176,340 using the Black-Scholes valuation method. Subscription Receivable: As part of the Company’s 2024 private placement issuance of common shares, two subscribers each subscribed for <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z7EPW1Do9Geh">150,000 common shares of the Company at a price of C$<span id="xdx_90A_eus-gaap--SharePrice_iI_uCADPShares_c20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zv3xNmPzNRId" title="Share price">1 (equivalent to US$<span id="xdx_909_eus-gaap--SharePrice_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zqYJbp4TaDr1" title="Share price">0.7265) per share, for an aggregate subscription of C$<span id="xdx_908_ecustom--AggregateSubscriptionPrice_uCAD_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCqNUvPBF5kh" title="Aggregate subscription price">150,000 (equivalent to US$<span id="xdx_90A_ecustom--AggregateSubscriptionPrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXrm7212Oo6a" title="Aggregate subscription price">108,975) per subscriber. In respect of each subscription, <span id="xdx_909_ecustom--NumberOfSharesSettledByWayOfCashProceeds_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z5trn8zNp299" title="Number of shares settled by way of cash proceeds">100,000 shares were settled by way of cash proceeds, with the remaining <span id="xdx_90A_ecustom--NumberOfRemainingSharesSettledByWayOfCashProceeds_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zyaCNMQCMqE8" title="Number of remaining shares settled by way of cash proceeds">50,000 shares representing an obligation of C$<span id="xdx_909_ecustom--NumberOfSharesSettledByWayOfCashProceedsValue_uCAD_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zmVjh7F2Knh1" title="Number of shares settled by way of cash proceeds, value">50,000 (equivalent to US$<span id="xdx_905_ecustom--NumberOfSharesSettledByWayOfCashProceedsValue_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zgC3XtcQxXea" title="Number of shares settled by way of cash proceeds, value">36,325) per subscriber. This obligation was to be satisfied through the transfer of common shares of Green Sky Labs Inc. (“GSL”), a related party, at an agreed upon price of C$<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_uCADPShares_c20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOHIfiKTG3r3">1.35 (equivalent to approximately US$<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6ONmyJ2BJP5">0.985) per GSL share, resulting in an aggregate obligation to transfer <span id="xdx_90E_ecustom--NumberOfSharesTransferred_c20260401__20260401__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8qiBDinmfK8" title="Number of shares transferred">74,074 GSL common shares to the Company that was settled on April 1, 2026. The subscription receivable, denominated in Canadian dollars, was initially recognized as at December 31, 2024, and has been translated into US dollars at the closing exchange rate at each balance sheet date in accordance with ASC 830, Foreign Currency Matters. Foreign exchange gains or losses arising from remeasurement at each period end are recognized in the Consolidated Statement of Operations. As at December 31, 2025, the share subscription receivable amounted to $72,961 (2024: $69,498). Subscription receivable as at December 31, 2025 and 2024 has been shown as deduction in the Statement of Equity. These amounts were settled subsequent to the year end.

10000000

593220

529270

126132

2503030

2970030

209199

2385000

1746170

5870000

3449212

5283000

4950870

16000

305600

26939850

21351250

360880

176340

150000

0.7265

150000 108975 100000 50000 50000 36325

1.35

0.985

74074

72961

69498

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">9.</td><td style="font: 10pt Times New Roman, Times, Serif">Related-Party Transactions and Balances</td></tr></table> RELATED-PARTY TRANSACTIONS AND BALANCES Related-party relationships and transactions are identified and disclosed in accordance with ASC 850, Related Party Disclosures. Related parties include affiliates, principal owners (holders of 10% or more of the voting interest), management (including persons serving in management capacities as consultants and all members of the Board of Directors), immediate family members of management and entities controlled by or under common control with those parties. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a)</td><td style="font: 10pt Times New Roman, Times, Serif">Board Member(s)</td></tr></table> The Company did not pay any compensation to its sole director for services rendered in their capacity as director during the years ended December 31, 2025 and 2024. Subsequent to year-end, on February 5, 2026, the Company granted stock options to certain new board members (see Note 17, Subsequent Events). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Green Sky Labs Inc. (“GSL”)</td></tr></table> <span id="xdx_909_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zuZlfqb9Gmkh" title="Related party transactions description">GSL is the ultimate parent of the Company, primarily due to its ability to exercise control through management. GSL directly owns over 50% of My Next Health Inc., which holds approximately 37% of the Company’s issued and outstanding shares. Pursuant to a management support and administrative services agreement dated September 1, 2023, GSL provides management and administrative services to the Company. During the year ended December 31, 2025, $<span id="xdx_900_eus-gaap--AdministrativeFeesExpense_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zMl9ioj4QqIa" title="Management and administrative services">60,000 was charged under this arrangement (2024: $<span id="xdx_904_eus-gaap--AdministrativeFeesExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zkFOm05r8ZJ" title="Management and administrative services">60,000). The Company and GSL are also parties to a revolving loan agreement, dated August 23, 2023, pursuant to which funds may be advanced and repaid between the parties from time-to-time on an unsecured, non-interest-bearing basis with no fixed terms of repayment. During the year ended December 31, 2025, an amount of $<span id="xdx_908_eus-gaap--RepaymentsOfRelatedPartyDebt_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zvgut1URRRx6" title="Repayment from related party">60,000 was charged as payable to GSL, while during the year ended December 31, 2024, net advances of $<span id="xdx_905_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_z9uquHo5uSk2" title="Advances from related party">1,606,000 was made by the Company to GSL. As at December 31, 2025, $1,612,672 was due from GSL (2024: $1,672,672). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">My Next Health Inc.</td></tr></table> My Next Health Inc. (“MNH”) is a direct owner of approximately 37% of the Company’s issued and outstanding shares. The Company and MNH entered into an IP license agreement dated November 30, 2023, whereby MNH granted the Company an exclusive, perpetual, royalty-free license to its intellectual property in consideration for shares of the Company. MNH and the Company are also parties to a technical services agreement dated November 30, 2023, pursuant to which MNH may provide technical services upon request. No services were provided under this agreement for the years ending December 31, 2024, and 2025. The Company and MNH are also parties to a revolving loan agreement pursuant to which funds may be advanced and repaid between the parties from time to time. During the year ended December 31, 2025, the Company advanced a net of $<span id="xdx_907_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncMember__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanAgreementMember_zdLwx7npkwM8" title="Advance from related party">2,730,521 to MNH, while during the year ended December 31, 2024, net advances of $<span id="xdx_90B_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncMember__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanAgreementMember_zwa4j0OhB6Qi" title="Advance from related party">884,958 were made by MNH to the Company. As at December 31, 2025, $1,701,563 was due from MNH, while as at December 31, 2024, an amount of $1,028,958 was due to MNH. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Bearco Investments Ltd.</td></tr></table> Bearco Investments Ltd. (“Bearco”) is a company controlled by a Director and President of GSL. Bearco provided an unsecured non-interest-bearing short-term loan of $<span id="xdx_907_eus-gaap--UnsecuredDebt_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BearcoInvestmentsLtdMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zd7ofj7Mkmab" title="Unsecured debt">20,000 to the Company on January 15, 2025, with no fixed terms of repayment. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">e)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trenchant Technologies Capital Corp. (“Trenchant”)</td></tr></table> Trenchant owns approximately <span id="xdx_909_ecustom--IssuedAndOutstandingSharesPercentage_iI_dp_uPure_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrenchantTechnologiesCapitalCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6g68Lhmqd7" title="Issued and outstanding shares percentage">11.5% of the Company’s issued and outstanding shares. Pursuant to a management agreement dated November 30, 2023, entered into as a condition of Trenchant’s equity investment, Trenchant was appointed manager of the Company, with no additional fees payable for services within scope (out-of-pocket expenses are reimbursable). Trenchant is entitled to attend all Board meetings and to nominate one member to the Board of Directors. Subsequent to year end, effective February 5, 2026, Trenchant’s nominee, Tom English, was appointed to the Board. Other than the cash, stocks and warrants received from Trenchant, no amounts were paid or outstanding to Trenchant during the year ended December 31, 2025, and 2024. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">f)</td><td style="font: 10pt Times New Roman, Times, Serif">2809539 Ontario Inc.</td></tr></table> 2809539 Ontario Inc. is owned by Tom English, who is a director of Trenchant (which owns approximately <span id="xdx_90E_ecustom--IssuedAndOutstandingSharesPercentage_iI_dp_uPure_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OntarioInc2809539Member__srt--TitleOfIndividualAxis__srt--DirectorMember_zyZM1LW9lQc5" title="Issued and outstanding shares percentage">11.5% of the Company’s issued and outstanding shares and is appointed a manager of the Company). Tom English was appointed a director of the Company subsequent to the year end, effective February 5, 2026. In connection with the Trenchant equity investment, 2809539 Ontario Inc., acted as a finder and received cash finder’s fees of $109,844 (being equal to 8% of the cash proceeds raised) and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OntarioInc2809539Member_zzSPYheFeEe9" title="Warrants shares">360,880 broker warrants, each exercisable to acquire one common share of the Company at C$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uCADPShares_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OntarioInc2809539Member_zgPcw9b8okc4" title="Exercise price">1 (US$<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OntarioInc2809539Member_zfhu5dFwmGN7" title="Exercise price">0.7296) exercise price, expiring <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OntarioInc2809539Member_zOpPyvRHyK4e" style="display: none" title="Expring years">5five years from the date of issuance. The finder’s fee arrangement and Trenchant’s investment were negotiated and executed as an integrated transaction. The warrants issued had a fair value of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OntarioInc2809539Member_z4DJSiQ6WuS6" title="Fair value adjustment of warrants">176,340. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">g)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">5 Palisades Plaza LLC</td></tr></table> During the year ended December 31, 2025, in connection with certain private placement investments, the Company paid cash commissions of $9,000 and issued 7,000 common shares of the Company (valued at US$10 per share) as sales commission to 5 Palisades Place LLC, an entity owned by an executive of MNH. During the year ended December 31, 2025, $1,500 was paid to Tsamutalis & Company, LLC, a company at which the MNH executive’s spouse is an employee in connection with the preparation of the Company’s US tax returns and related filings (2024: $1,500). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">h)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Compensation of key management personnel</td></tr></table> The Company entered into consulting arrangements with certain members of executive management and affiliated entities. During the year ended December 31, 2025, the Company incurred consulting fees of $1,016,000 (2024: $1,016,000) related to these arrangements and share-based compensation of nil (2024: $3,449,212). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">i)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Compensation of immediate family members</td></tr></table> The Company employed Nimish Saxena, the son of the CTO of the Company, as Data Lead. Compensation expense recognized in connection with this employment arrangement amounted to $170,366 (includes share-based compensation and other employee benefits) for the year ended December 31, 2025. During the year ended December 31, 2024, Nimish Saxena provided consulting services to the Company, for which consulting fees of $14,805 were incurred. Effective January 1, 2025, Nimish Saxena transitioned from a consulting arrangement to full-time employment with the Company. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">i.</td><td style="font: 10pt Times New Roman, Times, Serif">Due from Related Parties</td></tr></table> Amounts due from related parties consisted of the following: SCHEDULE OF AMOUNTS DUE FROM RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20251231_zTlTWZ4ADfy1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231_zcp2nDHjAySk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_ecustom--DueFromRelatedParty_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zTuRYVUbWgY7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Due from Green Sky Labs Inc. (“GSL”)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,612,672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,672,672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DueFromRelatedParty_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncCanadaMember_zH1Lqv14j1f9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Due from My Next Health Inc. – Canada</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">887,132</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">120,386</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DueFromRelatedParty_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncUSMember_zvtOAhPDyUi8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Due from My Next Health Inc. – US</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">814,431</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DueFromRelatedParty_iI_zfjp6WZMv5Ij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,314,235</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,793,058</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> Amounts due from related parties are governed by revolving loan agreements dated August 23, 2023 entered into with both GSL and MNH. The arrangement operates on a non-interest bearing basis with no fixed terms of repayment and permits the netting of balances between the parties. Under these agreements, the net balance with each counterparty reflects cumulative advances made between the parties, reduced by expenses paid by GSL or MNH on behalf of the Company, and increased by expenses paid by the Company on behalf of GSL or MNH. These balances are not intended to be settled in full within twelve months and are therefore classified as non-current assets. The Company has assessed the recoverability of these balances and determined that no impairment is required as at December 31, 2025 or 2024. As at December 31, 2024, the net position with MNH represented a payable from the Company to MNH and was classified within due to related parties. As at December 31, 2025, the net position with MNH-US reversed to a receivable and has been reclassified accordingly to due from related parties. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">ii.</td><td style="font: 10pt Times New Roman, Times, Serif">Due to Related Parties</td></tr></table> Amounts due to related parties consisted of the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zkNlzPJre2p3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zxsyZflBvIc6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--OtherLiabilities_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncUSMember_zAZpdvESA606" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1pt">Due to My Next Health Inc.-US</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,149,344</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherLiabilities_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncUSMember_zvXbTTjQ4jyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,149,344</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> As at December 31, 2025, there were no net amounts due to related parties (2024: $1,149,344). The prior year balance included amounts due to MNH under the revolving loan agreement, which was reversed to a net receivable position as at December 31, 2025 and has been reclassified to due from related parties. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">iii.</td><td style="font: 10pt Times New Roman, Times, Serif">Accounts Payable to Related Parties</td></tr></table> Amounts due to related parties in respect of accounts payable consisted of the following: SCHEDULE OF AMOUNTS DUE TO RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zrhnJIoICUH2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zFJugqdraMb9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_ecustom--ConsultingFeesPayable_iI_maAPCANz85c_z8lnjBBPZYld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Consulting fees payable to CTO</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">88,022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndConsultingFeesPayable_iI_maAPCANz85c_zvepmeVOO0Id" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Payroll and consulting fees payable to Nimish Saxena</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,587</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,416</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ExpenseReimbursement_iI_maAPCANz85c_zhDI8iey10Yf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expense reimbursement to the CEO</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,892</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FeePayable_iI_maAPCANz85c_z3bUH3oK8jDj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Fee payable to Tsamutalis & Company, LLC</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrentAndNoncurrent_iTI_mtAPCANz85c_zwMGgADHXwFd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">98,001</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">49,963</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">iv.</td><td style="font: 10pt Times New Roman, Times, Serif">Short-term Loan</td></tr></table> On January 15, 2025, the Company received an unsecured loan of $20,000 from Bearco. The loan has no fixed terms of repayment. In the absence of a contractual right to defer settlement for at least one year after the reporting date, and consistent with management’s intent to settle the obligation within the next twelve months, the loan is classified as a current liability as at December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">v.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investment in a Related Party</td></tr></table> The Company holds an investment in Trenchant. The continuity of this investment is as follows: SCHEDULE OF INVESTMENT RELATED PARTY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--RelatedPartyTransactionsByRelatedPartyAxis_custom--TrenchantCommonSharesMember_zOL2RlM1D82l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trenchant Common Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--RelatedPartyTransactionsByRelatedPartyAxis_custom--TrenchantWarrantsMember_zDkGy2zH44mf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trenchant Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_zCJlwYS2kxv9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_435_c20240429__20241231_eus-gaap--LongTermInvestments_iS_zURYW4ElkXTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Initial recognition (April 29, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,848,805</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">277,445</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,126,250</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GainLossOnInvestments_zWsWGwZNDIEe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss on fair value of investment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,146,855</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(214,626</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,361,481</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43A_c20250101__20251231_eus-gaap--LongTermInvestments_iS_zJgLY2sQzkRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Balance, December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">701,950</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">62,819</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">764,769</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GainLossOnInvestments_zCViyyBgJka8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss on fair value of investment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(333,502</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(60,116</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(393,618</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_430_c20250101__20251231_eus-gaap--LongTermInvestments_iE_zJwmYwce3ki8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">368,448</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,703</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">371,151</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> On April 29, 2024, the Company received <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240429__20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrenchantWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXBfpQ4g6K2k" title="Common shares issued">10,100,000 common shares and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrenchantWarrantsMember_zFO2actlbVPl" title="Warrant shares issued">2,600,000 warrants of Trenchant, as non-cash consideration forming part of a broader investment arrangement in the common shares of GNQ. Trenchant’s common shares are listed on the Canadian Securities Exchanges (“CSE”). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(a)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trenchant Common shares</td></tr></table> The Trenchant common shares were initially recognized at a fair value of $1,848,800 determined by reference to Trenchant’s quoted market price of C$0.25 (equivalent to approximately US$0.18) per share on the transaction date. The shares are subject to a voluntary lock-up agreement whereby 50% were restricted from transfer until April 29, 2025, and the remaining 50% until April 29, 2026. No discount for lack of marketability was applied as the transfer restriction is a characteristic of the Company as holder and not the underlying shares themselves. Accordingly, the Level 1 quoted market price was used without adjustment. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(b)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trenchant Warrants</td></tr></table> The <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrenchantWarrantsMember_z9h1PVOlHFS5" title="Warrants shares">2,600,000 warrants of Trenchant, exercisable at C$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uCADPShares_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrenchantWarrantsMember_zAlYNBJ8FKod" title="Exercisable share">0.50 (equivalent to approximately US$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrenchantWarrantsMember_z0IVSYqyQDL" title="Exercisable share">0.36) per share are expiring two years from the date of issuance. The warrants are classified as an equity investment and measured at fair value. The initial fair value of $277,445 was determined using the BSM option pricing model, with key inputs including a stock price of C$0.25 (equivalent to approximately US$0.18), an exercise price of C$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uCADPShares_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zcRSOt5QonD8" title="Exercise price">0.50 (equivalent to approximately US$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zYMqNVLmrvga" title="Exercise price">0.36), implied volatility of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zAinjuiFJdl4" title="Volatility">142%, a risk-free rate of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8kfQpCsv2oe" title="Risk-free rate">4.25% and a 2 two-year term. The Company has not exercised any of the warrants. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(c)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Subsequent measurement</td></tr></table> The investment is carried at fair value at each reporting date, with changes recognized in the statement of operations as loss on fair value of investment. The common shares are classified within Level 1 of the fair value hierarchy based on the quoted market price of the Trenchant shares on the CSE at each measurement date. The warrants are classified within Level 3 given the use of unobservable inputs in the BSM option-pricing model. During the year ended December 31, 2025, the Company recognized a loss on fair value of investments of $393,618 (2024: $1,361,481), reflecting the decline in Trenchant’s quoted share price over the respective periods.

GSL is the ultimate parent of the Company, primarily due to its ability to exercise control through management. GSL directly owns over 50% of My Next Health Inc., which holds approximately 37% of the Company’s issued and outstanding shares

60000

1606000

1612672

1672672

2730521

884958

1701563

1028958

20000

0.115 0.115

109844

360880

0.7296

P5Y

176340

9000

7000

1500

1016000

3449212

170366

14805

Amounts due from related parties consisted of the following: SCHEDULE OF AMOUNTS DUE FROM RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20251231_zTlTWZ4ADfy1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231_zcp2nDHjAySk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_ecustom--DueFromRelatedParty_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zTuRYVUbWgY7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Due from Green Sky Labs Inc. (“GSL”)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,612,672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,672,672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DueFromRelatedParty_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncCanadaMember_zH1Lqv14j1f9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Due from My Next Health Inc. – Canada</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">887,132</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">120,386</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DueFromRelatedParty_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncUSMember_zvtOAhPDyUi8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Due from My Next Health Inc. – US</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">814,431</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DueFromRelatedParty_iI_zfjp6WZMv5Ij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,314,235</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,793,058</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> Amounts due from related parties are governed by revolving loan agreements dated August 23, 2023 entered into with both GSL and MNH. The arrangement operates on a non-interest bearing basis with no fixed terms of repayment and permits the netting of balances between the parties. Under these agreements, the net balance with each counterparty reflects cumulative advances made between the parties, reduced by expenses paid by GSL or MNH on behalf of the Company, and increased by expenses paid by the Company on behalf of GSL or MNH. These balances are not intended to be settled in full within twelve months and are therefore classified as non-current assets. The Company has assessed the recoverability of these balances and determined that no impairment is required as at December 31, 2025 or 2024. As at December 31, 2024, the net position with MNH represented a payable from the Company to MNH and was classified within due to related parties. As at December 31, 2025, the net position with MNH-US reversed to a receivable and has been reclassified accordingly to due from related parties. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">ii.</td><td style="font: 10pt Times New Roman, Times, Serif">Due to Related Parties</td></tr></table> Amounts due to related parties consisted of the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zkNlzPJre2p3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zxsyZflBvIc6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--OtherLiabilities_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncUSMember_zAZpdvESA606" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1pt">Due to My Next Health Inc.-US</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,149,344</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherLiabilities_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncUSMember_zvXbTTjQ4jyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,149,344</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1612672 1672672 887132 120386 814431 3314235 1793058

1149344

Amounts due to related parties in respect of accounts payable consisted of the following: SCHEDULE OF AMOUNTS DUE TO RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zrhnJIoICUH2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zFJugqdraMb9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_ecustom--ConsultingFeesPayable_iI_maAPCANz85c_z8lnjBBPZYld" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Consulting fees payable to CTO</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">88,022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndConsultingFeesPayable_iI_maAPCANz85c_zvepmeVOO0Id" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Payroll and consulting fees payable to Nimish Saxena</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,587</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,416</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ExpenseReimbursement_iI_maAPCANz85c_zhDI8iey10Yf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expense reimbursement to the CEO</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,892</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FeePayable_iI_maAPCANz85c_z3bUH3oK8jDj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Fee payable to Tsamutalis & Company, LLC</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrentAndNoncurrent_iTI_mtAPCANz85c_zwMGgADHXwFd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">98,001</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">49,963</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> 88022 40000 1587 5416 6892 4547 1500

98001

49963

20000

The Company holds an investment in Trenchant. The continuity of this investment is as follows: SCHEDULE OF INVESTMENT RELATED PARTY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--RelatedPartyTransactionsByRelatedPartyAxis_custom--TrenchantCommonSharesMember_zOL2RlM1D82l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trenchant Common Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--RelatedPartyTransactionsByRelatedPartyAxis_custom--TrenchantWarrantsMember_zDkGy2zH44mf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trenchant Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_zCJlwYS2kxv9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_435_c20240429__20241231_eus-gaap--LongTermInvestments_iS_zURYW4ElkXTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Initial recognition (April 29, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,848,805</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">277,445</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,126,250</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GainLossOnInvestments_zWsWGwZNDIEe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss on fair value of investment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,146,855</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(214,626</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,361,481</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43A_c20250101__20251231_eus-gaap--LongTermInvestments_iS_zJgLY2sQzkRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Balance, December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">701,950</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">62,819</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">764,769</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GainLossOnInvestments_zCViyyBgJka8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss on fair value of investment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(333,502</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(60,116</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(393,618</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_430_c20250101__20251231_eus-gaap--LongTermInvestments_iE_zJwmYwce3ki8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">368,448</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,703</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">371,151</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1848805

277445

2126250

-1146855

-214626

-1361481

701950

62819

764769

-333502

-60116

-393618

368448

2703

371151

10100000

2600000

1848800

0.25

0.18

2600000

0.50

0.36

277445

0.25

0.18

0.50

0.36

142

4.25

P2Y

-393618

1361481

<p id="xdx_806_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zVCwThhtYTp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">10.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Share-based Compensation</td></tr></table> SHARE-BASED COMPENSATION During the year ended December 31, 2025, the Company recognized total share-based compensation of $196,515 (2024: $3,449,212). The components of share-based compensation are as follows: SCHEDULE OF SHARE-BASED COMPENSATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250101__20251231_z2YIfF63QJF4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231_zvMxwdGWzGn8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity incentive plan (“EIP”):</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zV8DeinOc78l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Share-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">44,053</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zP74j7rBoJK7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--CapitalizedToIntangibleAssetsUnderDevelopment_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zUJuCitU6cD2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Capitalized to intangible assets under development</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--SharebasedCompensationGross_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zhpQe62Wp1w7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Share-based compensation, gross</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">196,515</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--SharesIssuedToManagement_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zz0PW3BWxhDg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Shares issued to management</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,449,212</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--SharesBasedCompensation_iT_z9aDOx1RUHKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total share-based compensation</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">196,515</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,449,212</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> Of the total share-based compensation incurred during the year ended December 31, 2025, a portion was capitalized as part of the cost of the GNQ intangible asset under development in accordance with ASC 350-40, as it relates directly to employees engaged in the application development stage of the platform. The allocation between amounts expensed and capitalized is provided in the table above. During the year ended December 31, 2024, $3,449,212 in share-based compensation was recognized as expense in connection with the issuance of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5Xi76oCEzmh" title="Shares issued">5,870,000 common shares to founding management team members (Chief Executive Officer and Chief Technology Officer) for services rendered. The fair value of the shares issued was determined based on the estimated fair value of the Company’s common shares on the date of issuance, adjusted for a 20% discount for lack of marketability. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(a)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Equity Incentive Plan description</td></tr></table> Effective January 1, 2025, the Company adopted the 2025 Equity Incentive Plan (the “EIP”), which authorized the Board of Directors to grant stock options, restricted share units, and other equity-based awards to the Company’s employees, officers, directors and consultants. The maximum number of shares issuable under the EIP is 10% of the issued and outstanding shares of the Company. As at December 31, 2025 there were <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zfqXKfcEeUT6" title="Issuance of shares">2,693,985 common shares issuable under the plan (2024: <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_dxL_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zDXhaWM02iii" title="Issuance of shares::XDX::-">nil). Under the EIP, the Board has the authority to determine the recipients, number of awards, exercise price, vesting conditions, and expiry dates of each grant, subject to the terms of the EIP and applicable securities regulations. During the year ended December 31, 2025, the Company granted 1,060,000 stock options across eleven separate grants at exercise prices ranging from US$2.00 to US$7.50 per option. All options are exercisable into common shares of the Company on a one-to-one basis and expire between August 18, 2028, and November 1, 2035. No options were outstanding at the beginning of the year 2025. Adjusted for 1,060,000 issuances during the year ended December 31, 2025, the shares available for grant under the plan as at December 31, 2025 were 1,633,985 (2024: <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_dxL_c20240101__20241231_zrnWxnzOAXi1" title="Stock options grant fair value::XDX::-">nil). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(b)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock Option Activity:</td></tr></table> Stock option activity for the year was as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average contractual term remaining</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate intrinsic value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif">Beginning January 1, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_zSLZIq4O0Uih" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Beginning">-</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zox15x9WQfT7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Beginning balance">- </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231_zjZTvEY9ms41" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of options, Granted">1,060,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231_zwptQ5NonV53" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted average exercise price, Granted">4.68</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20250101__20251231_zD9lcfClTIQd" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate intrinsic value, Granted">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250101__20251231_zvkETZh4x8I9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20251231_zCKuhPDDNdx9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20250101__20251231_zrhZAc9TrY6j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231_zTWKsTK9FOj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Forfeited">(81,666</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zP9XnJZ32S8a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited">4.94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_c20250101__20251231_zwyWJIjJVRJk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Forfeited">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20250101__20251231_zkmLpnXkkKo4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Expired">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231_zT2uAM4ScRC3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Expired">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_c20250101__20251231_zDdjb9T4hV5h" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Aggregate intrinsic value, Expired">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231_ztMsibm2DYUl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Ending">978,334</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zV0qLF1o7tL6" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Ending">4.66</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_z3O0766noLI7" title="Weighted average contractual term remaining, Ending">8.00 years</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_zERZkfeuImGh" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Aggregate intrinsic value, Ending balance">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Exercisable, December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231_z94X2IyIYc62" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Exercisable">978,334</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> The aggregate intrinsic value of options outstanding and exercisable at December 31, 2025 is nil, as the exercise prices of all outstanding options (US$2 - US$7.50 per share) exceed the Company’s share price of US$10 as at that date. The weighted-average grant-date fair value of options granted during the year was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231_zylIk5hsCr7h" title="Weighted-average grant-date fair value of options granted">4.87. As of December 31, 2025, there was $289,676 (2024: nil) of unrecognized compensation cost related to unvested stock options granted under the EIP, which is expected to be recognized over a weighted average period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zT8mFxiBKOs1" title="Weighted average period expected term">1.79 years. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(c)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of Fair Value</td></tr></table> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zptYSLtz2tp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">EIP options are valued using the BSM Option Pricing model. The following are the weighted average valuation assumptions used for EIP awards granted during the periods presented: SCHEDULE OF DETERMINATION OF FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20251231_z0efH2TU5Tk8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20241231_z6PdZeH33Kma" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Valuation assumptions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_z25D1A9QThFe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zjFBvRU60yUa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">82.10</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Expected term</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.78 years</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_z07RC6ez3Elc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The risk-free rate is the Bank of Canada zero-yield bond rate matching the contractual life of each grant. The contractual term is used as the expected term in the absence of sufficient historical exercise data. Expected volatility is based on the historical volatility of a comparable peer group of publicly traded companies over a period matching the expected term. No dividend yield is applied.

196515

3449212

SCHEDULE OF SHARE-BASED COMPENSATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250101__20251231_z2YIfF63QJF4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231_zvMxwdGWzGn8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity incentive plan (“EIP”):</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zV8DeinOc78l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Share-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">44,053</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zP74j7rBoJK7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--CapitalizedToIntangibleAssetsUnderDevelopment_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zUJuCitU6cD2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Capitalized to intangible assets under development</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--SharebasedCompensationGross_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zhpQe62Wp1w7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Share-based compensation, gross</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">196,515</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--SharesIssuedToManagement_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zz0PW3BWxhDg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Shares issued to management</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,449,212</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--SharesBasedCompensation_iT_z9aDOx1RUHKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total share-based compensation</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">196,515</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,449,212</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

44053

17440

135022 196515 3449212 196515 3449212

3449212

5870000

2693985

1060000

2.00

7.50

1060000

1633985

Stock option activity for the year was as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted average contractual term remaining</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate intrinsic value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif">Beginning January 1, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_zSLZIq4O0Uih" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Beginning">-</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zox15x9WQfT7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Beginning balance">- </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231_zjZTvEY9ms41" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of options, Granted">1,060,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231_zwptQ5NonV53" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted average exercise price, Granted">4.68</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_c20250101__20251231_zD9lcfClTIQd" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate intrinsic value, Granted">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250101__20251231_zvkETZh4x8I9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20251231_zCKuhPDDNdx9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20250101__20251231_zrhZAc9TrY6j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231_zTWKsTK9FOj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Forfeited">(81,666</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zP9XnJZ32S8a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited">4.94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_c20250101__20251231_zwyWJIjJVRJk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, Forfeited">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20250101__20251231_zkmLpnXkkKo4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Expired">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231_zT2uAM4ScRC3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Expired">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_c20250101__20251231_zDdjb9T4hV5h" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Aggregate intrinsic value, Expired">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231_ztMsibm2DYUl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Ending">978,334</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zV0qLF1o7tL6" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Ending">4.66</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_z3O0766noLI7" title="Weighted average contractual term remaining, Ending">8.00 years</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_zERZkfeuImGh" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Aggregate intrinsic value, Ending balance">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Exercisable, December 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231_z94X2IyIYc62" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, Exercisable">978,334</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1060000

4.68

81666

4.94

978334

4.66

P8Y

978334

7.50

4.87

289676

P1Y9M14D

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zptYSLtz2tp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">EIP options are valued using the BSM Option Pricing model. The following are the weighted average valuation assumptions used for EIP awards granted during the periods presented: SCHEDULE OF DETERMINATION OF FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20251231_z0efH2TU5Tk8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20241231_z6PdZeH33Kma" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Valuation assumptions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_z25D1A9QThFe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zjFBvRU60yUa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">82.10</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Expected term</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.78 years</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_z07RC6ez3Elc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

0.8210

P7Y9M10D

0.0310

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">11.</td><td style="font: 10pt Times New Roman, Times, Serif">Employee benefit plans – 401(k) Plan</td></tr></table> EMPLOYEE BENEFIT PLANS – 401(K) PLAN SCHEDULE OF EMPLOYEE BENEFIT PLANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20251231_zc6dI9jvC4m4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zTIyIRckHcTe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_ecustom--CapitalizedToIntangibleAssetsUnderDevelopment_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_zxLcSnMakfo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Capitalized to intangible assets under development</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">9,172</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_zaa0jsMcLt7k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,713</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_z3jkkeSEsHWe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,672</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_z1Vzlx8jFWw1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">12,557</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> Effective January 1, 2025, the Company entered into a defined contribution Pooled Employer 401(k) tax-deferred savings plan administered by a third-party service provider for all U.S. employees who meet certain eligibility requirements. Employees may contribute, on a pre-tax or post-tax basis, a percentage of their annual compensation, not to exceed a maximum contribution amount pursuant to Section 401(k) of the Internal Revenue Code. The Company matches up two-thirds (662/3%) of the employee’s contributions, up to a maximum match of <span id="xdx_904_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pid_dp_uPure_c20250101__20250101__srt--RangeAxis__srt--MaximumMember_zwRp4R9itoz8" title="Employees contributions">3.5% of gross wages for each employee. During the year ended December 31, 2025, the Company contributed $12,557 to the plan (2024: nil).

SCHEDULE OF EMPLOYEE BENEFIT PLANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20251231_zc6dI9jvC4m4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zTIyIRckHcTe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_ecustom--CapitalizedToIntangibleAssetsUnderDevelopment_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_zxLcSnMakfo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Capitalized to intangible assets under development</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">9,172</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_zaa0jsMcLt7k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,713</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_z3jkkeSEsHWe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,672</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_z1Vzlx8jFWw1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">12,557</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

9172

1713

1672

12557

the Company entered into a defined contribution Pooled Employer 401(k) tax-deferred savings plan administered by a third-party service provider for all U.S. employees who meet certain eligibility requirements. Employees may contribute, on a pre-tax or post-tax basis, a percentage of their annual compensation, not to exceed a maximum contribution amount pursuant to Section 401(k) of the Internal Revenue Code.

0.035

12557

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">12.</td><td style="font: 10pt Times New Roman, Times, Serif">Research and Development</td></tr></table> RESEARCH AND DEVELOPMENT The Company incurred the following research and development expenses: SCHEDULE OF RESEARCH AND DEVELOPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20251231_zfgsbNA3dvrh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240101__20241231_ztuTyus4VbMh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_ecustom--ConsultingAndProfessionalFees_zQTFhGgRBzP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Consulting and professional fees</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">147,496</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">687,492</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CostDirectLabor_zTbsnX1WXUhf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Direct labor costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">198,724</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EmployeeBenefitsPlanExpenses_zJBBLOBAc5w" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Employee benefits plan expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,713</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_zViP4hpmdNbh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total research and development</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">347,933</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">687,492</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

The Company incurred the following research and development expenses: SCHEDULE OF RESEARCH AND DEVELOPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20251231_zfgsbNA3dvrh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240101__20241231_ztuTyus4VbMh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_ecustom--ConsultingAndProfessionalFees_zQTFhGgRBzP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Consulting and professional fees</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">147,496</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">687,492</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CostDirectLabor_zTbsnX1WXUhf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Direct labor costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">198,724</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EmployeeBenefitsPlanExpenses_zJBBLOBAc5w" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Employee benefits plan expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,713</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_zViP4hpmdNbh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total research and development</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">347,933</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">687,492</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> 147496 687492

198724

1713

347933

687492

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">13.</td><td style="font: 10pt Times New Roman, Times, Serif">Loss per Share</td></tr></table> LOSS PER SHARE The following table sets forth the computation of basic and diluted net loss per share: SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20251231_zwmBZIwFGaZk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zl8oy0e6GA8d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_zQPqbZUqgXnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(2,574,350</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(6,341,243</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Weighted-average number of common shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,603,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17,322,917</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Basic and diluted net loss per share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.37</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> </table> Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. The Company was in a loss position for all periods presented, therefore basic net loss per share and diluted net loss per share are the same for all periods as the inclusion of all potential common securities outstanding would have been anti-dilutive.

The following table sets forth the computation of basic and diluted net loss per share: SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20251231_zwmBZIwFGaZk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zl8oy0e6GA8d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_zQPqbZUqgXnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(2,574,350</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(6,341,243</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Weighted-average number of common shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,603,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17,322,917</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Basic and diluted net loss per share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(0.11</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.37</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> </table>

-2574350

-6341243

22603000

17322917

-0.11

-0.37

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">14.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income Taxes</td></tr></table> INCOME TAXES The Company files income tax returns in Canada and the United States. The Company is in a net loss position for both accounting and tax purposes. No tax expense or benefit is booked as the realization of any tax loss carryforwards cannot be more likely than not to be realized, based on available evidence, including projected future taxable income. There were no uncertain tax positions as at December 31, 2025 and 2024.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">15.</td><td style="font: 10pt Times New Roman, Times, Serif">Commitments and Contingencies</td></tr></table> COMMITMENTS AND CONTINGENCIES Purchase of Equipment The Company has commitment to purchase multi-omics testing equipment amounting to $318,000 from a third-party supplier. Indemnification The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company’s request in such capacity. The Company has purchased directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company’s exposure and enable it to recover a portion of any amounts it pays under its indemnification obligations. The Company had no liabilities recorded for these agreements as of December 31, 2025 and December 31, 2024, as no amounts were probable. Employee Agreements The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including accelerated vesting of shares under EIP.

318000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">16.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Concentration of Credit Risk</td></tr></table> CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, subscription receivable, other receivables and revolving loan receivables from related parties. The subscription receivable from two equity investors and other receivable were settled subsequent to the year ended December 31, 2025 The revolving loan receivables are from Company’s parent and ultimate parent companies and are expected to be settled in 2026.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">17.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Subsequent Events</td></tr></table> SUBSEQUENT EVENTS Management has evaluated events subsequent to the year ended December 31, 2025 up to June 1, 2026, for transactions and other events that may require adjustment of and/or disclosure in the consolidated financial statements. Business combination agreement On March 16, 2026, the Company entered into a Business Combination Agreement (“BCA”) with IB Acquisition Corp. (“IBAC”), a Nevada based special purpose acquisition company (“SPAC”). Pursuant to the BCA, the transaction will be affected by way of a plan of arrangement under Section 192 of the Canada Business Corporations Act, subject to approval by the Ontario Superior Court of Justice (Commercial List). Under the terms of the BCA, the aggregate arrangement consideration is valued at $<span id="xdx_902_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20260316__20260316__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxGEe38r92Pi" title="Consideration value">500 million, subject to potential upward adjustment pursuant to revenue earnout and share price earnout provisions as outlined in the BCA. Upon closing, the shareholders of the Company will receive either Class A common shares of IBAC or exchangeable shares of a Canadian subsidiary of IBAC, in each case based on an exchange ratio derived by dividing <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7vHxs4JcnFa" title="Common stock, shares outstanding diluted">50,000,000 by the fully-diluted company common shares outstanding immediately prior to closing. Consummation of the transaction is subject to customary closing conditions, including, among others, approval by the Company’s shareholders and IBAC’s stockholders, receipt of required regulatory approvals, effectiveness of a registration statement Form S-4 to be filed with the U.S. Securities and Exchange Commission, approval for listing of the combined company’s Class A common stock on Nasdaq, and a minimum available cash condition of $<span id="xdx_903_eus-gaap--Cash_iI_pn6n6_c20260316__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXCPFRfS5bU" title="Cash">15 million at closing. The BCA contains customary termination rights for both parties. If closing does not occur before the 270-day anniversary of the BCA (subject to a potential 60-day extension), either party may terminate the agreement. A break-up fee of $<span id="xdx_90F_ecustom--BreakUpFee_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUlayvWswvL5" title="Break up fee">10,000,000 is payable by the breaching party in the event of termination resulting from a material uncured willful breach or actual fraud. The Company is unable to predict the outcome of the proposed transaction at this time. The financial statements do not reflect any adjustments that might result from the consummation of the arrangement. Shareholder Support Agreement Contemporaneously with the execution of the BCA, certain shareholders of the Company collectively holding sufficient number of votes to approve the arrangement, entered into a Shareholder Support Agreement pursuant to which they agreed, among other things, to vote in favor of the arrangement and to waive any dissent rights in connection therewith. Bridge financing Concurrently with the execution of the BCA, the Company entered into a side letter agreement with IBAC pursuant to which the Company is authorized to complete a bridge financing of up to $<span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember_z2m8asQKJp2i" title="Secured convertible promissory note amount">2,000,000 through the issuance of secured convertible promissory notes and accompanying common share purchase warrants. <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateTerms_c20260316__20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember_zORnKzeY7tti" title="Convertible notes bear interest rate description">The convertible notes bear interest at 10% per annum, mature six months from issuance, and are convertible at the option of the holder into the Company’s common shares at a price equal to 80% of the deemed per-share value of the Company’s common shares, as adjusted pursuant to the exchange ratio set forth in the BCA. Each convertible note is accompanied by a <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8LZl8BNO9Fj" title="Warrant exercisable term">5-year warrant exercisable at the same conversion price, with the number of the Company’s underlying common shares determined on a discount to the $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zRaBs27nWsy5" title="Common shares price per share">10 reference value of IBAC’s Class A common shares. Secured promissory note On March 16, 2026, the Company issued a $<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--SecuredPromissoryNoteMember_zAAojprZDaV9" title="Convertible notes issued amount">250,000 convertible note and related warrants to an investor introduced by IBAC as the initial draw under the bridge financing. Concurrently with this issuance, the Company entered into a General Security Agreement (“GSA”) with the convertible note holder. Pursuant to the GSA, GNQ granted the holder a general and continuing security interest over substantially all of GNQ’s present and after-acquired personal property and assets, including intellectual property, to secure all obligations owing under the convertible note. The GSA contains customary covenant and enforcement rights and remains in effect until all secured obligations have been discharged in full. On May 4, 2026, the Company issued a secured convertible promissory note for $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260504__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--SecuredPromissoryNoteMember_z1eXEDYXbZqa" title="Convertible notes issued amount">50,000 at an interest rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20260504__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--SecuredPromissoryNoteMember_zIimml9ljrV8" title="Interest rate percentage">10% per annum. South Carolina Laboratory Lease On May 5, 2026, the Company entered into a sublease agreement with Clemson University, South Carolina for approximately <span id="xdx_90D_eus-gaap--AreaOfLand_iI_uArea_c20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTxTUQww9yW7" title="Area of land">1,671 square feet of laboratory space located in Greenville, SC. The sublease has an initial term of <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXzZplxi36A2" title="Initial term">one year commencing June 1, 2026, with up to three consecutive one-year<span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20260601__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zj2pNqpg87Sl" style="display: none" title="Initial term">1 renewal options. Either party may terminate upon 90-days written notice. Base rent is $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20260505__20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zegOSCC9qKt1" title="Rent">40,104 per year ($<span id="xdx_905_eus-gaap--PaymentsForRent_c20260505__20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zyEJe6LfZIVf" title="Rent">3,342 per month), plus a monthly equipment access fee of $<span id="xdx_900_ecustom--EquipmentAccessFee_c20260505__20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMmiUIgVrFJ4" title="Equipment access fee">975, resulting in total committed payments of approximately $<span id="xdx_90E_ecustom--CommittedPayments_c20260505__20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZWMIIJ9DBfd" title="Total committed payments">51,804 over the initial term. Since the <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDescription_c20260505__20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKOVirfmIzDk" title="Initial lease term">initial lease term is 12 months or less, the Company will utilize the short-term lease practical expedient under ASC 842, Leases, and will not recognize a right-of-use asset or lease liability in connection with this arrangement. New Director Appointments Effective February 5, 2026, the shareholders of the Company appointed three new directors to the Board of the company: Tom English, who is a director of Trenchant, Maliha Hashmi and Dave Johnson. In exchange for services provided, share-based compensation was issued. See Share Capital and Warrants below. Share Capital and Warrants Stock split As described in note 8, on February 5, 2026, the Company affected a <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20260205__20260205__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6r2QWzwuOM9" title="Reverse stock split">10-for-1 forward stock split of its common shares. Equity Incentive Plan (“EIP”) On February 5, 2026, the Company granted <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260205__20260205__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--TomEnglishMember_zlZep9DUdf35" title="Shares granted"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260205__20260205__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--DrMalihaHashmiMember_zZyFhOJGf0Hi" title="Shares granted"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260205__20260205__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--DaveJohnsonMember_zbczIOB2Kh9k" title="Shares granted">10,600 options to each of the three newly appointed directors (<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260205__20260205__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWnFFKpz7Tej" title="Shares granted">31,800 options in aggregate) at a nominal exercise price, with a three-year expiry. On April 1, 2026, the Company granted a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260401__20260401__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zrefe7lvCXvj" title="Shares granted">160,000 options to newly hired employees under its EIP at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260401__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_ziNijrZPTSWi" title="Exercise price">10 per share with a ten-year term. <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20260401__20260401__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zZ3Pnp4ReYb9" title="Vesting period description">The grant will follow the customary vesting schedule for employee EIP grants, with 25% vesting upon the 6-month anniversary of the grant date, and the remaining vesting over the following 18 months. The fair value of these options will be recognized as compensation expense over the applicable service period in accordance with ASC 718, Compensation – Stock Compensation. Private Placement Subsequent to year-end, the Company is in the process of completing a series of private placement subscriptions resulting in the issuance of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZOXJSCTsvmb" title="Shares issued">398,500 common shares for total aggregate consideration of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zFbsD7vwmrV2" title="Shares value">408,500, as described below. <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5rMVaiGfdH6" title="Shares issued">250,000 common shares to be issued to a subscriber at $<span id="xdx_907_eus-gaap--SharePrice_iI_c20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zK6lq8qVrmo2" title="Price per share">1.00 per share for aggregate consideration of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZfLbdJbwwP9" title="Shares value">250,000. This subscriber is a convertible noteholder of MNH and is settling this transaction through assignment of his MNH promissory note to the Company in satisfaction of the purchase price. As a result of this transaction, MNH will be indebted to the Company in the amount of $<span id="xdx_905_eus-gaap--OtherReceivables_iI_c20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNNPZwOX9Ixd" title="Indebted amount receivables">250,000, which will be recognized as a note receivable by the Company. Further, <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--GreenSkyLabsIncMember_zrc7NrMjcLL4" title="Shares issued">116,000 common shares were issued at $<span id="xdx_909_eus-gaap--SharePrice_iI_c20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--GreenSkyLabsIncMember_zXuKbxVxcceh" title="Price per share">1.00 per share for aggregate consideration of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--GreenSkyLabsIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSamTbdi2BJc" title="Shares value">116,000, settled by way of non-cash consideration through the transfer of <span id="xdx_901_eus-gaap--SharesIssued_iI_c20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--GreenSkyLabsIncMember_z7QhHK4ESMRf" title="Shares transfer">110,476 common shares of GSL, at an agreed upon value of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--GreenSkyLabsIncMember_zuwCx0poZTyk" title="Price per share">1.05 per GSL share. An additional <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zefm2CRasjYb" title="Shares issued">20,000 common shares were issued at $<span id="xdx_904_eus-gaap--SharePrice_iI_c20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXQLJVQ50NC8" title="Price per share">1.50 per share for aggregate cash consideration of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBj8yJtara1f" title="Shares value">30,000. As part of the Company’s 2024 private placement issuances, two subscribers each retained an outstanding obligation of C$<span id="xdx_907_eus-gaap--ContractualObligation_iI_uCAD_c20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourPrivatePlacementMember_z93VvdSjLLMi" title="Outstanding obligation">50,000 (equivalent to US$<span id="xdx_90B_eus-gaap--ContractualObligation_iI_c20260101__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandTwentyFourPrivatePlacementMember_z8uPKvowncya" title="Outstanding obligation">36,480) to be satisfied through the transfer of GSL common shares at an agreed upon price of C$<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_uCADPShares_c20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwvKiiB2r9s9">1.35 (equivalent to US$<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zfG7z3jEHoB1">0.985) per share, resulting in an aggregate obligation to transfer <span id="xdx_90E_ecustom--NumberOfSharesTransferred_c20260401__20260401__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z41alISsKIg4" title="Number of shares transferred">74,074 GSL common shares to the Company, which was effected on April 13, 2026, in full settlement of the obligation. Related Party Loan Agreement On March 9, 2026, the Company entered into a loan agreement with GNQI Holdings Inc. (“GNQI”), a related party, pursuant to which GNQI agreed to make available up to $<span id="xdx_90F_eus-gaap--DebtCurrent_iI_c20260309__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--RelatedPartyLoanAgreementMember_zIVwvDD7mula" title="General corporate and working capital amount">2,500,000 to the Company for general corporate and working capital purposes. The facility is interest-free with no fixed repayment date and the amounts outstanding may be repaid in whole or in part at any time without penalty. To date, no amounts have been drawn under this facility. Revenue Agreements On September 25, 2025, the Company entered into a consulting services agreement with a customer, an unrelated private company, to provide AI-powered digital twin modeling and clinical trial support services in connection with the customer’s drug development program. The agreement has a two<span id="xdx_90A_ecustom--AgreementTermOfContract_dtY_c20250925__20250925__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--RevenueAgreementMember_z552ZWsGdndd" style="display: none" title="Agreement term of contract">2-year term and a total contract value of $<span id="xdx_901_ecustom--ContractAgreementAmount_iI_c20250925__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--RevenueAgreementMember_zmTb7nXX549a" title="Contract value">750,000, with $<span id="xdx_902_eus-gaap--OtherLiabilitiesCurrent_iI_c20250925__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--RevenueAgreementMember_zXgpiyoZVSwj" title="Payable in equity">250,000 payable in equity, and the remaining $<span id="xdx_907_eus-gaap--Cash_iI_c20250925__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--RevenueAgreementMember_zFxFwpFzvGYj" title="Cash">500,000 payable in either equity or cash at the discretion of the customer. No revenue was recognized under this contract during the year ended December 31, 2025. Subsequent to year-end, the Company recognized the full contract value of $<span id="xdx_904_ecustom--ContractAgreementAmount_iI_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--RevenueAgreementMember_zAj92caqnHff" title="Contract value">250,000 in the first quarter of 2026, to be settled through the issuance of the customer’s shares. On November 20, 2025, the Company entered into a software services agreement with a hospital group to provide its DT platform to approximately 5,000 of the group’s employees. The agreement has a total contract value of $<span id="xdx_90C_ecustom--ContractAgreementAmount_iI_c20251120__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SoftwareServicesAgreementMember_zcEGXmAhnBG7" title="Contract value">10,000,000 <span id="xdx_902_ecustom--ContractAgreementDescription_c20251120__20251120__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SoftwareServicesAgreementMember_zpGDyuKumv07" title="Contract agreement description">over three years, with year 1 fees of $<span id="xdx_904_eus-gaap--FeeIncome_c20251120__20251120__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SoftwareServicesAgreementMember_zM5eXzwVyA65" title="Service agreement fee">5,000,000 structured across five milestone-based payments. No revenue has been recognized under this contract to date and management anticipates commencing this arrangement in the third or fourth quarter of 2026. On March 11, 2026, the Company entered into an exclusive software license agreement with a company for use of the Company’s DT platform in the functional health clinic channel across North America. Fees are structured as a <span id="xdx_900_ecustom--RoyaltyPercentage_pid_dp_uPure_c20260311__20260311__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SoftwareServicesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zq1a8j6okVhf" title="Royalty percentage">4% royalty on net retail price per paying customer annually, plus $<span id="xdx_905_eus-gaap--FeeIncome_c20260311__20260311__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SoftwareServicesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBw10ifVi10h" title="Service agreement fee">500 per genetic testing fee. The agreement has an initial three-year term with automatic renewal. No revenue has been recognized under this agreement as implementation has not yet commenced. On April 22, 2026, the Company entered into a consulting agreement with a customer to provide its DAP services in connection with the customer’s lead drug development program. The agreement has a two <span id="xdx_906_ecustom--AgreementTermOfContract_dtY_c20260422__20260422__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCwnFe5QF4Xl" style="display: none" title="Agreement term of contract">2-year term and a total contract value of $<span id="xdx_90A_ecustom--ContractAgreementAmount_iI_c20260422__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOOjoAV7yFmh" title="Contract value">3,300,000 payable entirely in the customer’s equity. The Company commenced recognition of revenues related to this contract in in the first quarter of 2026.

500000000

50000000

15000000

10000000

2000000

P5Y

250000

50000

0.10

1671

P1Y

40104

3342

975 51804

initial lease term is 12 months or less, the Company will utilize the short-term lease

10-for-1

10600

31800

160000

The grant will follow the customary vesting schedule for employee EIP grants, with 25% vesting upon the 6-month anniversary of the grant date, and the remaining vesting over the following 18 months.

398500

408500

250000

1.00

250000

116000

1.00

116000

110476

1.05

20000

1.50

30000

50000

36480

1.35

0.985

74074

2500000

P2Y 750000

250000

500000

250000 10000000 over three years, with year 1 fees

5000000

0.04

500

P2Y 3300000

405632

250000

1322

29798

10875

1686335

2354164

29798

20000

3323

3747

2548509

2254599

3314235

398524

371151

2970356

5943732

5324520

5973530

761

1871151

1259116

23131 98001

170577

20000 20000

2084859

1377878

95487

2180346

1377878

26939850

22271250

13599823

19925

71740

72961

13548008 13526862

176340

255349 196515

-10835523

-9304065

3144174

4595652

5324520

5973530

250000

139470

80567 483

1214836

149573

34297

200254

39831

9921

18224

9500

15000 15000

88454

12800

424

1542723

235982

-85

170

1001

147

27373

-168965

-15022

-1531458

-404924

-1531458

-404924

-0.06

-0.02

26939850

21351250

26939850

13599823

-72961

176340

196515

-9304065

4595652

19925 19925 58834 58834 1221 1221

-1531458

26939850

13599823

19925

-71740

176340

255349

-10835523

3144174

21351250

8359353

-69498

176340

-6729715

1736480

21351250

8359353

-69498

176340

-6729715

1736480

1017000

858593

21876 21876 21876 21876 -62 -62

-404924

22368250

9217946

-69560

176340

21876

-7134639

2211963

22368250

9217946

-69560

176340

21876

-7134639

2211963

10-for-1

-1531458

-404924

-1531458

-404924

69547

424

58834 21876

27373

-168965

-15022

1042

-85

170

-1413877

-214182

232399

20000

537540

84068

-1627900

389669

-1913041

285601

499164

-499783

5091

363457

354189

-363457

-359280

30000

858593

10075

250000

269925

858593

405632

-470

1222

405632

752

<p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zykGAKudHGe5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: -0.25in"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td><td style="font: 10pt Times New Roman, Times, Serif">Organization and Nature of Operations</td></tr></table> DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS GNQ Insilico Inc. (the “Company” or “GNQ”) was incorporated under the Canada Business Corporations Act on August 23, 2023, with its registered office located at 40 Temperance Street, Suite 3200, Bay Adelaide Centre – North Tower, Toronto ON M5H 0B4. Its principal office is located at #101-2275 Upper Middle Road East, Oakville, Ontario, L6H 0C3. These consolidated financial statements include the accounts of GNQ Insilico Inc. and its wholly-owned subsidiary, GNQ Insilico Inc., incorporated under the laws of California, United States, collectively referred to herein as the “Company” or “GNQ”. GNQ is a precision medicine tech-bio company whose principal business activity is the development and commercialization of proprietary software platforms that leverage multi-omics data, causal artificial intelligence, and emerging quantum computing technologies to accelerate and de-risk drug discovery and early clinical development. The Company’s product, the GNQ Drug Assessment Platform, was successfully launched on September 13, 2025. This platform represents the first product release of the Company’s platform suite and marks the transition from the development stage to early revenue stage of operations. Revenues from the Drug Assessment Platform commenced during the three months ended March 31, 2026. The Company also continues development of additional offerings within the GNQ platform suite as at March 31, 2026 (see Note 9 – Intangible Under Development).

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2.</td><td style="font: 10pt Times New Roman, Times, Serif">Business Combination Agreement</td></tr></table> BUSINESS COMBINATION AGREEMENT On March 16, 2026, the Company entered into a Business Combination Agreement (“BCA”) with IB Acquisition Corp. (“IBAC”), a Nevada based special purpose acquisition company (“SPAC”). Pursuant to the BCA, the transaction will be affected by way of a plan of arrangement under Section 192 of the Canada Business Corporations Act, subject to approval by the Ontario Superior Court of Justice (Commercial List). Under the terms of the BCA, the aggregate arrangement consideration is valued at $<span id="xdx_902_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20260316__20260316__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4gzEo2eH0l5" title="Consideration value">500 million, subject to potential upward adjustment pursuant to revenue earnout and share price earnout provisions as outlined in the BCA. Upon closing, the shareholders of the Company will receive either Class A common shares of IBAC or exchangeable shares of a Canadian subsidiary of IBAC, in each case based on an exchange ratio derived by dividing <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDoYC0ZNvsr8" title="Common stock, shares outstanding diluted">50,000,000 by the fully-diluted company common shares outstanding immediately prior to closing. Consummation of the transaction is subject to customary closing conditions, including, among others, approval by the Company’s shareholders and IBAC’s stockholders, receipt of required regulatory approvals, effectiveness of a registration statement Form S-4 to be filed with the U.S. Securities and Exchange Commission, approval for listing of the combined company’s Class A common stock on Nasdaq, and a minimum available cash condition of $<span id="xdx_903_eus-gaap--Cash_iI_pn6n6_c20260316__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbsKnI8XJIn8" title="Cash">15 million at closing. The BCA contains customary termination rights for both parties. If closing does not occur before the 270-day anniversary of the BCA (subject to a potential 60-day extension), either party may terminate the agreement. A break-up fee of $<span id="xdx_90C_ecustom--BreakUpFee_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVxLTQUQCbI8" title="Break up fee">10,000,000 is payable by the breaching party in the event of termination resulting from a material uncured willful breach or actual fraud. Contemporaneously with the execution of the BCA, certain shareholders of the Company collectively holding sufficient number of votes to approve the arrangement, entered into a Shareholder Support Agreement pursuant to which they agreed, among other things, to vote in favor of the arrangement and to waive any dissent rights in connection therewith. The Company is unable to predict the outcome of the proposed transaction at this time. The financial statements do not reflect any adjustments that might result from the consummation of the arrangement.

500000000

50000000

15000000

10000000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3.</td><td style="font: 10pt Times New Roman, Times, Serif">Summary of Significant Accounting Policies</td></tr></table> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a)</td><td style="font: 10pt Times New Roman, Times, Serif">Basis of Presentation</td></tr></table> The unaudited interim condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), as defined by the Financial Accounting Standards Board (“FASB”), and pursuant to the rules and regulations of the SEC. Accordingly, certain information and footnote disclosures normally included in the annual financial statements have been condensed or omitted. There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes for the year ended December 31, 2025. The interim financial information presented is unaudited and reflects all normal adjustments that are, in the Company’s opinion, necessary to provide a fair statement of the financial position, results of operations and cash flows for the periods presented. These unaudited condensed interim consolidated financial statements are presented in United States dollars, which is the Company’s functional and reporting currency. All intercompany balances and transactions have been eliminated on consolidation. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b)</td><td style="font: 10pt Times New Roman, Times, Serif">Going Concern</td></tr></table> These financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at March 31, 2026, the Company had a net loss of $1,531,458 (March 31, 2025: net loss of $404,924), an accumulated deficit of $10,835,523 (December 31, 2025: $9,304,065), and a cash balance of $405,632 (December 31, 2025: bank overdraft of $761). The Company had total shareholder’s equity as at March 31, 2026 of $3,144,174 (December 31, 2025: $4,595,652). During the three months ended March 31, 2026, the Company transitioned from a pre-revenue development stage enterprise to an early-stage revenue generating company. The Company recognized $250,000 during the period, which will be settled through the issuance of the customer’s equity securities (private company) rather than cash and, accordingly, does not provide immediate liquidity to fund operations. During the year ended December 31, 2025, the Company also entered into a software services agreement with a total contract value of $10,000,000 anticipated to be earned over three years with year 1 fees anticipated to be $5,000,000. No revenue has been recognized under this contract to date and management anticipates commencing this engagement during the second half of 2026. During the three months ended March 31, 2026, the Company also entered into an exclusive software license agreement for the use of its digital health platform in the functional health clinic channel across North America, structured as a royalty on net retail price per paying customer annually plus a per-unit genetic testing fee, with an initial three-year term and automatic renewal. Subsequent to the three months ended March 31, 2026, on April 22, 2026, the Company also entered into a consulting agreement to provide its Drug Assessment Platform services in connection with the customer’s lead drug development program. The agreement has a two-year term and a total contract value of $3,300,000 payable entirely in the customer’s equity. The Company is also in discussions with other potential customers for securing other revenue contracts which are expected to be signed in 2026. As described in Note 2 – Business Combination Agreement, the Company’s de-SPAC transaction is expected to be finalized in the third quarter of 2026. In connection with this transaction, the Company is arranging Private Investment in Public Entity (“PIPE”) and Bridge Financing and continues to attract investments in the Company. The Company’s ability to continue as a going concern is dependent upon obtaining additional equity or debt financing, generating revenues sufficient to cover operating costs, and continuing to execute on its commercialization strategy. The Company is aggressively pursuing its business leads to execute additional revenue contracts and deliver to customers. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. However, management is of the view that taking into consideration the revenue contracts signed, the pending de-SPAC transaction, and the financing arrangements being put in place, it is appropriate to prepare these financial statements on a going concern basis. Accordingly, these consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c)</td><td style="font: 10pt Times New Roman, Times, Serif">Revenue Recognition</td></tr></table> The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, using a five-step model to identify contracts, performance obligations, transaction price, allocation and recognition. For the three months ended March 31, 2026, the Company’s revenue consists solely of consulting services. Consulting revenue is recognized over time or at a point in time as control of the promised services is transferred to customers, depending on the specific terms of the contract. For arrangements recognized over time, progress toward completion is measured using either input methods (such as time incurred) or output methods (such as the achievement of contractually defined phases, milestones or deliverables), depending on the contract terms. For contracts containing multiple performance obligations, the transaction price is allocated to each obligation based on its relative standalone selling price. Non-cash consideration received from customers, including equity issued in lieu of cash fees, is generally measured at fair value at contract inception. If the fair value of the non-cash consideration cannot be reasonably estimated, it is measured indirectly by reference to the standalone selling price of the services promised. Upon formal issuance of the equity securities, the amount is reclassified to equity investments, with subsequent changes in fair value recognized within the consolidated statement of operations. Amounts received or billed in advance of performance are recorded as deferred revenue. Amounts invoiced but not yet settled are recorded as receivables, while amounts earned but not yet invoiced are recorded as contract assets. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d)</td><td style="font: 10pt Times New Roman, Times, Serif">Convertible promissory note & warrants</td></tr></table> The Company elected the Fair Value Option (“FVO”) under ASC 825-10, Financial Instruments to accounts for its convertible promissory note (and embedded conversion feature) as a single combined unit of account. This irrevocable election, made at issuance, precludes the bifurcation of the embedded conversion feature under ASC 815-15, Derivatives and Hedging. The convertible promissory note and embedded conversion feature are recorded at fair value upon initial recognition and remeasured at each balance sheet date, with changes in fair value recognized in earnings. Consequently, no debt proceeds are allocated to the conversion feature, and no debt discount is established or amortized. The detachable warrants are freestanding financial instruments. Based on the Company’s evaluation under ASC 480, Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Heding – Contracts in Entity’s Own Equity, the warrants did not qualify for equity classification. They are recorded as liabilities at fair value upon issuance and remeasured to fair value at each subsequent balance sheet date, with changes in fair value recognized in earnings. The Company presents interest expense on the convertible promissory note separately form the fair value remeasurement line, using the stated coupon rate applied to outstanding principal. The residual change in fair value is presented as a single line within other income (expense). All issuance costs, including cash commissions and the fair value of broker warrants, are expensed as incurred within the statement of operations. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">e)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recently Adopted Accounting Standards</td></tr></table> In July 2025, FASB issued ASU No. 2025-05, Financial Instruments—Credit Losses (Topic 326) — Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient for estimating expected credit losses. The ASU provides a practical expedient permitting entities to assume that current conditions as of the balance sheet date remain unchanged for the remaining life of current accounts receivable and contract assets arising from revenue transactions when estimating expected credit losses. The amendments are effective for annual reporting periods beginning after December 15, 2025. The Company adopted ASU 2025-05 effective January 1, 2026. For the three months ended March 31, 2026, the Company had no credit losses on its accounts receivable or contract assets, and accordingly, no allowance for credit losses was required. The adoption of ASU 2025-05 had no impact on the Company’s consolidated financial statements. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">f)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recently Issued Accounting Standards Not Yet Adopted</td></tr></table> Management has reviewed all recently issued accounting standards and does not expect any of the issued but not yet effective standards to have a material effect on the Company’s financial statements. In November 2024, FASB issued ASU 2024-03, Expense Disaggregation Disclosures (Subtopic 220-40), which requires additional disclosure of the nature of expenses included in the income statement as well as disclosures about specific types of expenses included in the expense captions presented in the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026. The Company is currently evaluating the impact of the ASU on its consolidated financial statements. In September 2025, the FASB issued ASU No. 2025-06, Accounting for internal-use software costs (Topic 350). The new standard amends specific aspects of the accounting for internal-use software costs including the criteria for capitalizing software costs. It also amends the related disclosure requirements. This standard will be effective starting the year 2029. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements. In September 2025, FASB issued ASU No. 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The new standard refines the scope of the guidance on derivatives in Topic 815 and clarifies the guidance on shared-based payments from a customer in ASC 606, Revenue from Contracts with Customers. This standard will be effective for the Company starting the year 2027. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements. In December 2025, FASB issued ASU No. 2025-10, Government Grants (Topic 832). The new standard adds guidance to ASC 832, Government Grants on the recognition, measurement, and presentation of government grants. This standard will be effective for the Company starting the year 2029. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a)</td><td style="font: 10pt Times New Roman, Times, Serif">Basis of Presentation</td></tr></table> The unaudited interim condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), as defined by the Financial Accounting Standards Board (“FASB”), and pursuant to the rules and regulations of the SEC. Accordingly, certain information and footnote disclosures normally included in the annual financial statements have been condensed or omitted. There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes for the year ended December 31, 2025. The interim financial information presented is unaudited and reflects all normal adjustments that are, in the Company’s opinion, necessary to provide a fair statement of the financial position, results of operations and cash flows for the periods presented. These unaudited condensed interim consolidated financial statements are presented in United States dollars, which is the Company’s functional and reporting currency. All intercompany balances and transactions have been eliminated on consolidation.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b)</td><td style="font: 10pt Times New Roman, Times, Serif">Going Concern</td></tr></table> These financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at March 31, 2026, the Company had a net loss of $1,531,458 (March 31, 2025: net loss of $404,924), an accumulated deficit of $10,835,523 (December 31, 2025: $9,304,065), and a cash balance of $405,632 (December 31, 2025: bank overdraft of $761). The Company had total shareholder’s equity as at March 31, 2026 of $3,144,174 (December 31, 2025: $4,595,652). During the three months ended March 31, 2026, the Company transitioned from a pre-revenue development stage enterprise to an early-stage revenue generating company. The Company recognized $250,000 during the period, which will be settled through the issuance of the customer’s equity securities (private company) rather than cash and, accordingly, does not provide immediate liquidity to fund operations. During the year ended December 31, 2025, the Company also entered into a software services agreement with a total contract value of $10,000,000 anticipated to be earned over three years with year 1 fees anticipated to be $5,000,000. No revenue has been recognized under this contract to date and management anticipates commencing this engagement during the second half of 2026. During the three months ended March 31, 2026, the Company also entered into an exclusive software license agreement for the use of its digital health platform in the functional health clinic channel across North America, structured as a royalty on net retail price per paying customer annually plus a per-unit genetic testing fee, with an initial three-year term and automatic renewal. Subsequent to the three months ended March 31, 2026, on April 22, 2026, the Company also entered into a consulting agreement to provide its Drug Assessment Platform services in connection with the customer’s lead drug development program. The agreement has a two-year term and a total contract value of $3,300,000 payable entirely in the customer’s equity. The Company is also in discussions with other potential customers for securing other revenue contracts which are expected to be signed in 2026. As described in Note 2 – Business Combination Agreement, the Company’s de-SPAC transaction is expected to be finalized in the third quarter of 2026. In connection with this transaction, the Company is arranging Private Investment in Public Entity (“PIPE”) and Bridge Financing and continues to attract investments in the Company. The Company’s ability to continue as a going concern is dependent upon obtaining additional equity or debt financing, generating revenues sufficient to cover operating costs, and continuing to execute on its commercialization strategy. The Company is aggressively pursuing its business leads to execute additional revenue contracts and deliver to customers. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. However, management is of the view that taking into consideration the revenue contracts signed, the pending de-SPAC transaction, and the financing arrangements being put in place, it is appropriate to prepare these financial statements on a going concern basis. Accordingly, these consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

-1531458

-404924

-10835523

-9304065

405632

761

3144174

4595652

250000

10000000

5000000

3300000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c)</td><td style="font: 10pt Times New Roman, Times, Serif">Revenue Recognition</td></tr></table> The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, using a five-step model to identify contracts, performance obligations, transaction price, allocation and recognition. For the three months ended March 31, 2026, the Company’s revenue consists solely of consulting services. Consulting revenue is recognized over time or at a point in time as control of the promised services is transferred to customers, depending on the specific terms of the contract. For arrangements recognized over time, progress toward completion is measured using either input methods (such as time incurred) or output methods (such as the achievement of contractually defined phases, milestones or deliverables), depending on the contract terms. For contracts containing multiple performance obligations, the transaction price is allocated to each obligation based on its relative standalone selling price. Non-cash consideration received from customers, including equity issued in lieu of cash fees, is generally measured at fair value at contract inception. If the fair value of the non-cash consideration cannot be reasonably estimated, it is measured indirectly by reference to the standalone selling price of the services promised. Upon formal issuance of the equity securities, the amount is reclassified to equity investments, with subsequent changes in fair value recognized within the consolidated statement of operations. Amounts received or billed in advance of performance are recorded as deferred revenue. Amounts invoiced but not yet settled are recorded as receivables, while amounts earned but not yet invoiced are recorded as contract assets.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d)</td><td style="font: 10pt Times New Roman, Times, Serif">Convertible promissory note & warrants</td></tr></table> The Company elected the Fair Value Option (“FVO”) under ASC 825-10, Financial Instruments to accounts for its convertible promissory note (and embedded conversion feature) as a single combined unit of account. This irrevocable election, made at issuance, precludes the bifurcation of the embedded conversion feature under ASC 815-15, Derivatives and Hedging. The convertible promissory note and embedded conversion feature are recorded at fair value upon initial recognition and remeasured at each balance sheet date, with changes in fair value recognized in earnings. Consequently, no debt proceeds are allocated to the conversion feature, and no debt discount is established or amortized. The detachable warrants are freestanding financial instruments. Based on the Company’s evaluation under ASC 480, Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Heding – Contracts in Entity’s Own Equity, the warrants did not qualify for equity classification. They are recorded as liabilities at fair value upon issuance and remeasured to fair value at each subsequent balance sheet date, with changes in fair value recognized in earnings. The Company presents interest expense on the convertible promissory note separately form the fair value remeasurement line, using the stated coupon rate applied to outstanding principal. The residual change in fair value is presented as a single line within other income (expense). All issuance costs, including cash commissions and the fair value of broker warrants, are expensed as incurred within the statement of operations.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">e)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recently Adopted Accounting Standards</td></tr></table> In July 2025, FASB issued ASU No. 2025-05, Financial Instruments—Credit Losses (Topic 326) — Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient for estimating expected credit losses. The ASU provides a practical expedient permitting entities to assume that current conditions as of the balance sheet date remain unchanged for the remaining life of current accounts receivable and contract assets arising from revenue transactions when estimating expected credit losses. The amendments are effective for annual reporting periods beginning after December 15, 2025. The Company adopted ASU 2025-05 effective January 1, 2026. For the three months ended March 31, 2026, the Company had no credit losses on its accounts receivable or contract assets, and accordingly, no allowance for credit losses was required. The adoption of ASU 2025-05 had no impact on the Company’s consolidated financial statements.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">f)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recently Issued Accounting Standards Not Yet Adopted</td></tr></table> Management has reviewed all recently issued accounting standards and does not expect any of the issued but not yet effective standards to have a material effect on the Company’s financial statements. In November 2024, FASB issued ASU 2024-03, Expense Disaggregation Disclosures (Subtopic 220-40), which requires additional disclosure of the nature of expenses included in the income statement as well as disclosures about specific types of expenses included in the expense captions presented in the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026. The Company is currently evaluating the impact of the ASU on its consolidated financial statements. In September 2025, the FASB issued ASU No. 2025-06, Accounting for internal-use software costs (Topic 350). The new standard amends specific aspects of the accounting for internal-use software costs including the criteria for capitalizing software costs. It also amends the related disclosure requirements. This standard will be effective starting the year 2029. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements. In September 2025, FASB issued ASU No. 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The new standard refines the scope of the guidance on derivatives in Topic 815 and clarifies the guidance on shared-based payments from a customer in ASC 606, Revenue from Contracts with Customers. This standard will be effective for the Company starting the year 2027. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements. In December 2025, FASB issued ASU No. 2025-10, Government Grants (Topic 832). The new standard adds guidance to ASC 832, Government Grants on the recognition, measurement, and presentation of government grants. This standard will be effective for the Company starting the year 2029. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash and Cash Equivalents</td></tr></table> CASH AND CASH EQUIVALENTS Cash consists of deposits held with financial institutions. As of March 31, 2026, the Company had a cash balance of $405,632. As of December 31, 2025, the Company had an overdraft balance of $761, presented as Bank overdraft on the Consolidated Statement of Financial Position.

405632

761

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">5.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts Receivable</td></tr></table> ACCOUNTS RECEIVABLE During the three months ended March 31, 2026, the Company commenced delivery under a consulting services agreement representing its first revenue generating activity. The agreement is governed by ASC 606, Revenue from Contracts with Customers. In connection with this agreement, during the three months ended March 31, 2026, the Company earned revenues of $250,000 (three months ended March 31, 2025: nil). In accordance with the contract terms, this revenue is fixed as a dollar amount but contracted to be settled in equity securities of the customer. No allowance for credit losses has been established as of the balance sheet date. Management has assessed the collectability of these balances and considers them fully recoverable. Management will re-evaluate collectability at each subsequent reporting date.

250000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">6.</td><td style="font: 10pt Times New Roman, Times, Serif">Other Receivables</td></tr></table> OTHER RECEIVABLES Other receivables are comprised of the following: SCHEDULE OF OTHER RECEIVABLES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260331_z6RjahoEFkj" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_zJbKNr7jAbl1" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherReceivablesNetCurrent_iI_hus-gaap--SubsidiarySaleOfStockAxis__custom--VendorReceivableMember_ziMynKjrICLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Vendor receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">29,120</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherReceivablesNetCurrent_iI_hus-gaap--SubsidiarySaleOfStockAxis__custom--EmployeeReceivableMember_zLRWaYhiOl7a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Employee receivables</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">678</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_z7WUvZM0kYK1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">29,798</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Employee receivables represent amounts advanced to employee or reclassified from accounts payable in respect of employee expense settlements. These amounts are non-interest bearing and are expected to be settled against future expense reimbursements in the normal course. As at December 31, 2025, the vendor overpayment receivable of $29,120 represented an overpayment made to a third-party service provider in connection with an invoice discrepancy identified during the year. During the three months ended March 31, 2026, the Company received full repayment of this amount, and accordingly, no vendor receivable balance remains outstanding as at March 31, 2026.

Other receivables are comprised of the following: SCHEDULE OF OTHER RECEIVABLES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260331_z6RjahoEFkj" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_zJbKNr7jAbl1" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherReceivablesNetCurrent_iI_hus-gaap--SubsidiarySaleOfStockAxis__custom--VendorReceivableMember_ziMynKjrICLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Vendor receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">29,120</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherReceivablesNetCurrent_iI_hus-gaap--SubsidiarySaleOfStockAxis__custom--EmployeeReceivableMember_zLRWaYhiOl7a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Employee receivables</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">678</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_iI_z7WUvZM0kYK1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">29,798</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

29120

1322

678

1322

29798

29120

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">7.</td><td style="font: 10pt Times New Roman, Times, Serif">Prepaid Expenses</td></tr></table> PREPAID EXPENSES Prepaid expenses comprise of the following: SCHEDULE OF PREPAID EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260331_zcveQ1xYOlw4" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_z0lbL0LbX1L2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--PrepaidSoftwareSubscription_iI_z8VcwkJEyDhd" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Software subscription</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">10,875</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PrepaidExpenseCurrent_iI_zyrIbpfGWpRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total current</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,875</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PayrollTaxDeposit_iI_ziTyj0ROodX8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Payroll tax deposit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PrepaidExpenseNoncurrent_iI_zDE20zOrSZKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total non-current</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> The software subscription balance represents the unamortized portion of a prepaid annual subscription commencing January 1, 2026. The subscription is amortized on a straight-line basis over the twelve-month term, with $3,625 recognized in operating expenses during the three months ended March 31, 2026 (March 31, 2025: nil). The payroll tax deposit represents funds held on deposit with the Company’s payroll services provider to facilitate payroll tax remittance services. This deposit is non-interest bearing and is expected to be held for the duration of the service arrangement, which has no fixed end date. Accordingly, this amount has been classified as a long-term asset.

Prepaid expenses comprise of the following: SCHEDULE OF PREPAID EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260331_zcveQ1xYOlw4" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_z0lbL0LbX1L2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--PrepaidSoftwareSubscription_iI_z8VcwkJEyDhd" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Software subscription</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">10,875</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PrepaidExpenseCurrent_iI_zyrIbpfGWpRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total current</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,875</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PayrollTaxDeposit_iI_ziTyj0ROodX8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Payroll tax deposit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PrepaidExpenseNoncurrent_iI_zDE20zOrSZKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total non-current</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 10875

10875

20000

3625

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">8.</td><td style="font: 10pt Times New Roman, Times, Serif">Property, Plant and Equipment</td></tr></table> PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260331_ztgYo1GeT8A" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zsl8CeenOrGa" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--MachineryAndEquipmentGross_iI_maPPAENzCha_zlfUyA0lpQRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computer equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,090</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,090</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzCha_zW1M8sFKfQK6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,767</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,343</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzCha_zPRdcJX7i515" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,323</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,747</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Computer equipment is depreciated on a straight-line basis over a useful life of three years. Depreciation expense for the three months ended March 31, 2026 was $424 (March 31, 2025: $71).

Property, plant and equipment consisted of the following: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260331_ztgYo1GeT8A" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zsl8CeenOrGa" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--MachineryAndEquipmentGross_iI_maPPAENzCha_zlfUyA0lpQRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computer equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,090</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,090</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzCha_zW1M8sFKfQK6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,767</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,343</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzCha_zPRdcJX7i515" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,323</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,747</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

5090

1767

1343

3323

3747

P3Y

424

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">9.</td><td style="font: 10pt Times New Roman, Times, Serif">Intangible Under Development</td></tr></table> INTANGIBLE UNDER DEVELOPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a)</td><td style="font: 10pt Times New Roman, Times, Serif">Continuity of Capitalized Software Development Costs</td></tr></table> The following table summarizes intangible assets: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DrugAssessmentPlatformMember_zaUNDxmGHywb" style="border-bottom: Black 1pt solid; text-align: center">Drug Assessment Platform</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DigitalTwinsPlatformMember_zA2fdyclHTy1" style="border-bottom: Black 1pt solid; text-align: center">Bio Avatar (formerly Digital Twins Platform)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B4_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DrugSimulationPlatformMember_z1oxKfzjcOPi" style="border-bottom: Black 1pt solid; text-align: center">Drug Simulation Platform</td><td style="padding-bottom: 1pt"> </td><td style="font-style: italic; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--FiniteLivedIntangibleAssetsNetMember_zgf9bXcAWZkb" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt; font-style: italic"> </td></tr> <tr id="xdx_433_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zEDFJ3sakjC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance, January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">605,830</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">14,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">620,636</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinitelivedIntangibleAssetsAcquired1_zQL8emfxOzIh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions: Capitalized costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,070,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">448,962</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,703,516</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AmortizationOfIntangibleAssets_iN_di_zE2hLgslnqId" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,553</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,553</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43C_c20260101__20260331_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zpd8WSYXrOxf" style="vertical-align: bottom; background-color: White"> <td>Balance, December 31, 2025</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">463,768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">184,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,254,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_430_c20260101__20260331_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zJ30bOJTt6we" style="display: none; vertical-align: bottom; background-color: White"> <td>Intangible assets beginning balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">463,768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">184,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,254,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_zr06ycV9Vnx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additions: Capitalized costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186,401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">363,457</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AmortizationOfIntangibleAssets_iN_di_zd7nEPEUEEY5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,547</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,547</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43A_c20260101__20260331_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_zgQlzle72jE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Balance, March 31, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,687,113</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">650,169</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">211,227</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,548,509</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_435_c20260101__20260331_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_zyDzxrifS2zc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Intangible assets ending balance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,687,113</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">650,169</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">211,227</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,548,509</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b)</td><td style="font: 10pt Times New Roman, Times, Serif">Amortization:</td></tr></table> The amortization expense for the Drug Assessment Platform for the three months ended March 31, 2026 was $69,547 (March 31, 2025: nil). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c)</td><td style="font: 10pt Times New Roman, Times, Serif">Impairment:</td></tr></table> At each balance sheet date, the Company compares the unamortized capitalized cost of each software product to its net realizable value (“NRV”), defined as estimated future gross revenues less estimated future costs of completing and disposing of the product. Any excess of unamortized cost over NRV is written off immediately and may not be subsequently restored. No impairment loss was recognized during the three months ended March 31, 2026 or the year ended December 31, 2025.

The following table summarizes intangible assets: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DrugAssessmentPlatformMember_zaUNDxmGHywb" style="border-bottom: Black 1pt solid; text-align: center">Drug Assessment Platform</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DigitalTwinsPlatformMember_zA2fdyclHTy1" style="border-bottom: Black 1pt solid; text-align: center">Bio Avatar (formerly Digital Twins Platform)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B4_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--DrugSimulationPlatformMember_z1oxKfzjcOPi" style="border-bottom: Black 1pt solid; text-align: center">Drug Simulation Platform</td><td style="padding-bottom: 1pt"> </td><td style="font-style: italic; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis_custom--FiniteLivedIntangibleAssetsNetMember_zgf9bXcAWZkb" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt; font-style: italic"> </td></tr> <tr id="xdx_433_c20250101__20251231_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zEDFJ3sakjC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance, January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">605,830</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">14,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">620,636</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinitelivedIntangibleAssetsAcquired1_zQL8emfxOzIh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions: Capitalized costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,070,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">448,962</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,703,516</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AmortizationOfIntangibleAssets_iN_di_zE2hLgslnqId" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,553</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,553</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43C_c20260101__20260331_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zpd8WSYXrOxf" style="vertical-align: bottom; background-color: White"> <td>Balance, December 31, 2025</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">463,768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">184,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,254,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_430_c20260101__20260331_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_zJ30bOJTt6we" style="display: none; vertical-align: bottom; background-color: White"> <td>Intangible assets beginning balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">463,768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">184,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,254,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_zr06ycV9Vnx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additions: Capitalized costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186,401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">363,457</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AmortizationOfIntangibleAssets_iN_di_zd7nEPEUEEY5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,547</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,547</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43A_c20260101__20260331_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_zgQlzle72jE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Balance, March 31, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,687,113</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">650,169</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">211,227</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,548,509</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_435_c20260101__20260331_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_zyDzxrifS2zc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Intangible assets ending balance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,687,113</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">650,169</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">211,227</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,548,509</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

605830

14806

620636

1070327

448962

184227

1703516

69553

1606604

463768

184227

2254599

1606604

463768

184227

2254599

150056

186401

27000

363457

69547

1687113

650169

211227

2548509

1687113

650169

211227

2548509

69547

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">10.</td><td style="font: 10pt Times New Roman, Times, Serif">Accounts Payable and Accrued Liabilities</td></tr></table> ACCOUNTS PAYABLE AND ACCRUED LIABILITIES <p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zjMTKSxmdFD7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Accounts payable and accrued liabilities consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260331_znCc1zRZcoM5" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zqdD2dckrhp" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableCurrent_iI_maAPAOAz1CP_zCd07a3yB4ve" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,157,555</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">618,622</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AuditAndLegalFeesAccrual_iI_maAPAOAz1CP_zdQx2j2NEfBj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Audit and legal fees accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">661,388</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">404,883</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedPayrollTaxesCurrent_iI_maAPAOAz1CP_zdDqzmjQ0Yj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payroll liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,334</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_maAPAOAz1CP_zHxeqpd0A9m5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,277</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_mtAPAOAz1CP_z3FusW4wSQ7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,871,151</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,259,116</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> All trade accounts payable amounts are unsecured, non-interest bearing and are generally payable within 30-90 days. The significant increase in trade accounts payable during the three months ended March 31, 2026 is primarily attributable to professional fees payable as the Company advances its capital markets efforts. Payroll liabilities represent statutory source deductions withheld from employee compensation and remitted subsequent to the period end.

<p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zjMTKSxmdFD7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Accounts payable and accrued liabilities consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260331_znCc1zRZcoM5" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20251231_zqdD2dckrhp" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableCurrent_iI_maAPAOAz1CP_zCd07a3yB4ve" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,157,555</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">618,622</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AuditAndLegalFeesAccrual_iI_maAPAOAz1CP_zdQx2j2NEfBj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Audit and legal fees accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">661,388</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">404,883</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedPayrollTaxesCurrent_iI_maAPAOAz1CP_zdDqzmjQ0Yj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payroll liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,334</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_maAPAOAz1CP_zHxeqpd0A9m5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,277</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_mtAPAOAz1CP_z3FusW4wSQ7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,871,151</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,259,116</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1157555

618622

661388 404883

52057

225334

151

10277

1871151

1259116

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">11.</td><td style="font: 10pt Times New Roman, Times, Serif">Convertible Promissory Note</td></tr></table> CONVERTIBLE PROMISSORY NOTE Concurrently with the execution of the BCA with IBAC, the Company entered into a side letter agreement with IBAC pursuant to which the Company is authorized to complete a bridge financing of up to $<span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember_zlRRgs6kS7e3" title="Secured convertible promissory note amount">2,000,000 through the issuance of secured convertible promissory notes and accompanying common share purchase warrants (the “Warrants”). On March 16, 2026, the Company issued a $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--SecuredPromissoryNoteMember_zaO8MoooxxCj">250,000 note with an embedded conversion feature (the “Note”) and accompanying Warrants to an investor (the “Holder”) as the initial draw under the bridge financing. The Note bears interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--SecuredPromissoryNoteMember_z5y9lSb5DTHe">10% per annum with all accrued interest payable in a single lump sum at maturity. The Note matures six months from the date of issuance. The Note is convertible into shares of the Company’s common stock at the option of the Holder under the terms of the note purchase agreement. The Company also entered into a General Security Agreement (“GSA”) with the Holder. Pursuant to the GSA, the Company granted the holder a general and continuing security interest over substantially all of the Company’s present and after-acquired personal property and assets, including intellectual property, to secure all obligations owing under the Note. The GSA contains customary covenant and enforcement rights and remains in effect until all secured obligations have been discharged in full. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">a)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounting treatment</td></tr></table> The Company elected the FVO under ASC 825, Financial Instruments for the Note. Accordingly, the Note, inclusive of its embedded conversion feature and the detachable Warrants are classified as liabilities and carried at fair value, with changes in fair value recognized in earnings each period. At issuance, the aggregate uncalibrated fair value of the Note (including the embedded derivative) and Warrants yielded by the underlying baseline models was $443,984, which exceeded cash proceeds of $250,000. To align the model with the transaction price at inception, the Company applied a calibration discount rate to both the Note and the Warrants. Using the Monte Carlo simulation, the discount rate was iteratively solved for the level at which the sum of the fair value of the Note and Warrants equaled total cash proceeds of $250,000, resulting in a calibrated discount rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--NoteAndWarrantsMember_zikQNbTkS6wh" title="Calibrated discount rate percentage">43.69% at issuance. As a result, no day-one gain or loss was recognized. For subsequent measurement, the selected discount rate considers the initial <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--NoteAndWarrantsMember_ztQZfmag8chi" title="Calibrated discount rate percentage">43.69% calibrated rate as of the issuance date, adjusted for subsequent changes in the risk-free rate and the credit risk of the Company. For the period from issuance (March 16, 2026) through to March 31, 2026, the change in fair value (excluding $1,042 of contractual interest separately recognized as interest expense) resulted in a net loss of $15,022 recognized within the Statement of Operations. As of March 31, 2026, the excess of the outstanding principal amount of the Note over its fair value was $80,465 ($251,042 principal and interest less $170,577 fair value). The following table represents the fair value at issuance (March 16, 2026) and as at March 31, 2026: SCHEDULE OF FAIR VALUE ISSUANCE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260316_zjZlqV7HdFJ1" style="border-bottom: Black 1pt solid; text-align: center">March 16, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_zy2QQB7kKIfe" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_maCDzIye_zZvg5lMTTbZf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Convertible note payable, at fair value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">160,194</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">170,577</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DerivativeLiabilities_iI_maCDzIye_zCZn7rVA2Se7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrant liability, at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">89,806</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">95,487</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleDebt_iTI_mtCDzIye_zs0KrvWPob2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">250,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">266,064</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> The following table represents the roll-forward of the Note and Warrant liabilities from the date of issuance (March 16, 2026) through March 31, 2026: SCHEDULE OF NOTE AND WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260101__20260331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeNA7Om7dsg1" style="border-bottom: Black 1pt solid; text-align: center">Convertible Note (incl. conversion feature)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260101__20260331__us-gaap--ShortTermDebtTypeAxis__us-gaap--WarrantMember_zWCSmzsJU2ki" style="border-bottom: Black 1pt solid; text-align: center">Warrant</td><td style="padding-bottom: 1pt"> </td><td style="font-style: italic; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260101__20260331_zZtgYPGNecab" style="border-bottom: Black 1pt solid; font-style: italic; text-align: center">Total</td><td style="padding-bottom: 1pt; font-style: italic"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleDebt_iS_zjMcrzOtW9o9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Opening Fair Value, January 1, 2026</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--FairValueAtIssuance_z7wdCFfzrSQg" style="vertical-align: bottom; background-color: White"> <td style="width: 46%">Fair Value at Issuance (March 16, 2026)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">160,194</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">89,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtSecuritiesTradingUnrealizedGainLoss_iN_di_zuHpNVxPEXcb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in Fair Value (recognized in earnings)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,341</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,681</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,022</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedInterestOnPromissoryNote_z4SEIeVBxtsg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense accrual</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,042</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,042</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleDebt_iE_z7F5tjJZKZB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Ending Fair Value, March 31, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">170,577</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">95,487</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">266,064</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> The following table indicates the fair value compared to the unpaid principal balance: SCHEDULE OF UNPAID PRINCIPAL BALANCE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260316_z5Lau5TuMcCj" style="border-bottom: Black 1pt solid; text-align: center">March 16, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260331_zXeum7dhGbLj" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentFaceAmount_iI_zwuD688fhTGg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Unpaid principal and accrued interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">251,042</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_zXkTFkIDMWfi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">160,194</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">170,577</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentFairValue_iNTI_di_zvFT9GGJ8jqh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Fair value over/(under) unpaid principal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(89,806</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(80,465</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b)</td><td style="font: 10pt Times New Roman, Times, Serif">Determination of Fair Value</td></tr></table> The fair value of the Note and Warrants are classified as Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. The fair values of the Note and Warrants were estimated with the assistance of an independent third-party valuation specialist. To value the Note, the specialist utilized a Monte Carlo simulation that incorporated a market-based discount rate applied to the debt host component alongside an option pricing model for the embedded conversion features. This model projects contractual cash flows based on management’s probability assessments of future milestone events. The underlying stock price of $18.5461 was derived from the $500 million target valuation in the BCA, divided by a fully diluted share count of 26,959,850 (includes unissued shares). Expected volatility was based on an annualized term-matched analysis of a guideline public company peer group. The debt discount rate was benchmarked against CCC-rated corporate bond yields. The fair value of the detachable Warrants was calculated using a standard option-pricing model. The significant quantitative inputs used under these valuation methods were as follows: SCHEDULE OF VALUATION OF CONVERTIBLE NOTE AND WARRANT Convertible Note (including embedded conversion feature): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260316__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zCpzwUwpj5Cd" style="border-bottom: Black 1pt solid; text-align: center">March 16, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zjHt3G8muyI" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Valuation assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zq4JbuGX7IOc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%">Stock Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.5461</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.5461</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zrKgz7Ppup07" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59.54</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62.63</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zFjl7xkq7Oz6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.72</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.72</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zyNk1MQEJq8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Debt discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18.75</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19.12</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zlQoJI1It5Tk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Expected term remaining</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.50 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.46 years</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__custom--MeasurementInputDiscountRateCalibratedMember_z3bfA2FiOWk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Note discount rate (calibrated)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43.69</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40.13</td><td style="text-align: left">%</td></tr> </table> Warrants: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260316__us-gaap--ShortTermDebtTypeAxis__us-gaap--WarrantMember_z1Hs3ZezFAsl" style="border-bottom: Black 1pt solid; text-align: center">March 16, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260331__us-gaap--ShortTermDebtTypeAxis__us-gaap--WarrantMember_zMPOZOI5CAoi" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Valuation assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zYS3hBUN5kyb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%">Stock Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.5461</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.5461</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zb5n8e66X7Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63.10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62.41</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2b27Rml5Elf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.92</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zT7U1uiu4Jej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_ziFYwD8ZsQPl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Expected term remaining</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.96 years</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z8L6ImDVdyo1" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.96 years</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c)</td><td style="font: 10pt Times New Roman, Times, Serif">Interest expense</td></tr></table> Interest expense on the Note for the three months ended March 31, 2026, consists entirely of contractual interest accrued at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20260331__us-gaap--ShortTermDebtTypeAxis__custom--SecuredPromissoryNoteMember_zftRioNzc8m7" title="Interest rate percentage">10% per annum. The total interest accrued and expensed in connection with the Note amounted to $1,042 for the three months ended March 31, 2026.

2000000

250000

0.10

443984

250000

0.4369

1042

15022

80465

251042

170577

The following table represents the fair value at issuance (March 16, 2026) and as at March 31, 2026: SCHEDULE OF FAIR VALUE ISSUANCE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260316_zjZlqV7HdFJ1" style="border-bottom: Black 1pt solid; text-align: center">March 16, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331_zy2QQB7kKIfe" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_maCDzIye_zZvg5lMTTbZf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Convertible note payable, at fair value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">160,194</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">170,577</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DerivativeLiabilities_iI_maCDzIye_zCZn7rVA2Se7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrant liability, at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">89,806</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">95,487</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleDebt_iTI_mtCDzIye_zs0KrvWPob2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">250,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">266,064</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

160194

170577

89806

95487

250000

266064

The following table represents the roll-forward of the Note and Warrant liabilities from the date of issuance (March 16, 2026) through March 31, 2026: SCHEDULE OF NOTE AND WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260101__20260331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeNA7Om7dsg1" style="border-bottom: Black 1pt solid; text-align: center">Convertible Note (incl. conversion feature)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260101__20260331__us-gaap--ShortTermDebtTypeAxis__us-gaap--WarrantMember_zWCSmzsJU2ki" style="border-bottom: Black 1pt solid; text-align: center">Warrant</td><td style="padding-bottom: 1pt"> </td><td style="font-style: italic; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260101__20260331_zZtgYPGNecab" style="border-bottom: Black 1pt solid; font-style: italic; text-align: center">Total</td><td style="padding-bottom: 1pt; font-style: italic"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleDebt_iS_zjMcrzOtW9o9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Opening Fair Value, January 1, 2026</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--FairValueAtIssuance_z7wdCFfzrSQg" style="vertical-align: bottom; background-color: White"> <td style="width: 46%">Fair Value at Issuance (March 16, 2026)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">160,194</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">89,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtSecuritiesTradingUnrealizedGainLoss_iN_di_zuHpNVxPEXcb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in Fair Value (recognized in earnings)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,341</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,681</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,022</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedInterestOnPromissoryNote_z4SEIeVBxtsg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense accrual</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,042</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,042</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleDebt_iE_z7F5tjJZKZB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Ending Fair Value, March 31, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">170,577</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">95,487</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">266,064</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

160194 89806 250000

-9341

-5681

-15022

1042 1042

170577

95487

266064

The following table indicates the fair value compared to the unpaid principal balance: SCHEDULE OF UNPAID PRINCIPAL BALANCE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260316_z5Lau5TuMcCj" style="border-bottom: Black 1pt solid; text-align: center">March 16, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260331_zXeum7dhGbLj" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentFaceAmount_iI_zwuD688fhTGg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Unpaid principal and accrued interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">251,042</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_zXkTFkIDMWfi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">160,194</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">170,577</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentFairValue_iNTI_di_zvFT9GGJ8jqh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Fair value over/(under) unpaid principal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(89,806</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(80,465</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table>

250000

251042

160194

170577

89806

80465

18.5461

500000000

26959850

The significant quantitative inputs used under these valuation methods were as follows: SCHEDULE OF VALUATION OF CONVERTIBLE NOTE AND WARRANT Convertible Note (including embedded conversion feature): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260316__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zCpzwUwpj5Cd" style="border-bottom: Black 1pt solid; text-align: center">March 16, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zjHt3G8muyI" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Valuation assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zq4JbuGX7IOc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%">Stock Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.5461</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.5461</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zrKgz7Ppup07" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59.54</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62.63</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zFjl7xkq7Oz6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.72</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.72</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zyNk1MQEJq8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Debt discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18.75</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19.12</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zlQoJI1It5Tk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Expected term remaining</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.50 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.46 years</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__custom--MeasurementInputDiscountRateCalibratedMember_z3bfA2FiOWk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Note discount rate (calibrated)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43.69</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40.13</td><td style="text-align: left">%</td></tr> </table> Warrants: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260316__us-gaap--ShortTermDebtTypeAxis__us-gaap--WarrantMember_z1Hs3ZezFAsl" style="border-bottom: Black 1pt solid; text-align: center">March 16, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260331__us-gaap--ShortTermDebtTypeAxis__us-gaap--WarrantMember_zMPOZOI5CAoi" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Valuation assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zYS3hBUN5kyb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%">Stock Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.5461</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18.5461</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zb5n8e66X7Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63.10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62.41</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2b27Rml5Elf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.92</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zT7U1uiu4Jej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_ziFYwD8ZsQPl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Expected term remaining</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.96 years</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z8L6ImDVdyo1" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.96 years</td><td style="text-align: left"> </td></tr> </table>

18.5461

59.54

62.63

3.72

18.75

19.12

0.50

0.46

43.69

40.13

18.5461

63.10

62.41

3.80

3.92

4.96

0.10

1042

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">12.</td><td style="font: 10pt Times New Roman, Times, Serif">Shareholder’s Equity</td></tr></table> SHAREHOLDER’S EQUITY Common Shares: The Company is authorized to issue an unlimited number of no-par value common shares. During the three months ended March 31, 2026, the Company received proceeds of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zChWZhd9sWy5" title="Cash and non-cash consideration">30,000 pursuant to a private placement subscription. Direct and incremental costs of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zY06ZmKhEiA1" title="Incremental costs">10,075 were netted against the proceeds, resulting in a net amount of $19,925. As the corresponding 20,000 common shares were not formally issued until April 1, 2026, the proceeds were classified as “Shares to be issued” within shareholder’s equity as of March 31, 2026. During the comparative three months ended March 31, 2025, the Company issued 1,017,000 common shares for cash and non-cash consideration of $858,593. During the three months ended March 31, 2026, the Company recognized $58,834 of share-based compensation expense in connection with vested awards under the Company’s Equity Incentive Plan (“EIP”) (March 31, 2025: $21,876). See Note 14 – Share-based Compensation for additional details. Stock split: On February 5, 2026, the Company affected a 10-for-1 forward stock split of its issued and outstanding common shares. In accordance with ASC 260, Earnings Per Share (EPS), the weighted-average shares outstanding, earnings/(loss) per share, and the exercise prices of the outstanding options and warrants have been retroactively restated on a post-split basis as if the split had occurred at the beginning of the earliest period presented. Accordingly, the number of common shares outstanding as of March 31, 2026 was 26,939,850 shares (December 31, 2025: 26,939,850 shares). Subscription Receivable: As of March 31, 2026, the share subscription receivable balance was $71,740 (December 31, 2025: $72,961). This balance is presented as a deduction from shareholder’s equity. Subsequent to the period end, the aggregate obligation was settled in April 2026 through the transfer of GSL common shares to the Company.

30000

10075

19925

20000

1017000

858593

58834 21876

26939850

71740

72961

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">13.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revenue</td></tr></table> REVENUE The Company entered into a consulting services agreement with an unrelated customer to provide AI-powered regulatory-grade assessment, digital twin modeling and clinical trial support services in connection with the customer’s drug development program on September 25, 2025. The total contract value is $<span id="xdx_90A_ecustom--ContractAgreementAmount_iI_c20250925__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--RevenueAgreementMember_zUgZ6dQIaGk8" title="Contract value">750,000 with performance and payments structured across Phase 1 ($250,000) and Phase 2 ($500,000). Phase 1 fees were fully earned during the three months ended March 31, 2026, Pursuant to the agreement, this $250,000 obligation will be settled through the customer’s issuance of a variable number of its restricted private equity securities with an aggregate value of $250,000. Issuance is contingent upon specific equity financing or clinical trial milestones, as defined in the agreement. If shares are not issued by the contractual long-stop date, the obligation converts to a cash settlement. Phase 2 fees are structured across multiple milestone-based deliverables. Revenue for Phase 2 will be recognized over time using an output method upon milestone achievement and client acceptance. Phase 2 payments are payable in cash or, at the customer’s election, in equity. Because the monetary value of both phases is contractually fixed, the transaction price is not subject to equity price fluctuations under ASC 606, Revenue from Contracts with Customers. Earned but unissued amounts are recorded as contract assets at the contractually fixed value and are reclassified to equity investments upon formal share issuance. During the three months ended March 31, 2026, the Company recognized $250,000 of revenue under this arrangement. As of March 31, 2026, no shares have been issued and no cash has been received. Executed Contracts not Yet Commenced Although the following revenue agreements were executed either during or prior to the three months ended March 31, 2026, performance obligations have not yet commenced, and no revenue has been recognized: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On November 20, 2025, the Company entered into a <span id="xdx_90A_ecustom--AgreementTermOfContract_dtY_c20251120__20251120__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zXOrU186Zh8b" style="display: none" title="Agreement term of contract">3three-year software services agreement with a hospital group for a total contract value of $<span id="xdx_901_ecustom--ContractAgreementAmount_iI_c20251120__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SoftwareServicesAgreementMember_zN9baoEA3OA" title="Contract value">10,000,000 ($<span id="xdx_908_eus-gaap--FeeIncome_c20251120__20251120__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SoftwareServicesAgreementMember_z6LhrucXHJbc" title="Service agreement fee">5,000,000 in the first year across five milestones). Services commencement and revenue recognition are anticipated to begin later in 2026.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 11, 2026, the Company entered into an exclusive three-year regional software license agreement, consisting of a <span id="xdx_906_ecustom--RoyaltyPercentage_pid_dp_uPure_c20260311__20260311__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SoftwareServicesAgreementMember_z3t3aD4lULbd" title="Royalty percentage">4% usage royalty and a $<span id="xdx_90E_eus-gaap--FeeIncome_c20260311__20260311__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SoftwareServicesAgreementMember_zb6IWCVtS7fl" title="Service agreement fee">500 per genetic testing fee. Implementation has not yet commenced.</td></tr></table>

750000 250000 500000 250000 250000

250000

P3Y 10000000

5000000

0.04

500

<p id="xdx_800_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z4bVwiM6kOLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">14.</td><td style="font: 10pt Times New Roman, Times, Serif">Share-based Compensation</td></tr></table> SHARE-BASED COMPENSATION The components of share-based compensation are as follows: SCHEDULE OF SHARE-BASED COMPENSATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260331_zd7DI2EZ8T62" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250101__20250331_zXvLvdhhWrw4" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zxiby3jOdD37" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Share-based compensation expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">34,297</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zGV0MDvsPuDb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,439</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--CapitalizedToIntangibleAssetsUnderDevelopment_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zibSa8gVUIQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Capitalized to intangible assets under development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,876</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ShareBasedCompensationExpenses_zADJbPSlrylk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">58,834</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">21,876</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Of the total share-based compensation incurred during the three months ended March 31, 2026 and March 31, 2025, a portion was capitalized as part of the cost of the GNQ intangible asset under development in accordance with ASC 350-40, Intangibles – Goodwill and Other – Internal-Use Software, as it relates directly to employees engaged in the application development stage of the platform. The allocation between amounts expensed and capitalized is provided in the table above. As at March 31, 2026, there were 2,693,985 common shares issuable under the EIP (December 31, 2025: 2,693,985). A total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxIiVwlXnPAd" title="Options granted">31,800 options were granted during the three months ended March 31, 2026 (Mar 31, 2025: <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqcwdPafEfHi" title="Options net of forfeiture">198,333, net of forfeitures). The weighted average grant date fair value of the granted options amounted to $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331_z61fSisDKczd" title="Weighted average grant date fair value, granted">31,507. <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z11SyNmYySad" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.25in">EIP options are valued using the Black-Scholes method. The following are the weighted average valuation assumptions used for EIP awards granted during the periods presented: SCHEDULE OF DETERMINATION OF FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260331_zT7Er5YMIYT6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250331_zDEWyYsABGL9" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Valuation assumptions:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zbu3DObfhww8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zqLPbqDI1bn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">85.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">75.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.00 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.59 years</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zeME3INqd8r6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.22</td><td style="text-align: left">%</td></tr> </table> The risk-free rate is the Bank of Canada zero-yield bond rate matching the contractual life of each grant. The contractual term is used as the expected term in the absence of sufficient historical exercise data. Expected volatility is based on the historical volatility of a comparable peer group of publicly traded companies over a period matching the expected term. No dividend yield is applied.

The components of share-based compensation are as follows: SCHEDULE OF SHARE-BASED COMPENSATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260331_zd7DI2EZ8T62" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250101__20250331_zXvLvdhhWrw4" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zxiby3jOdD37" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Share-based compensation expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">34,297</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zGV0MDvsPuDb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,439</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--CapitalizedToIntangibleAssetsUnderDevelopment_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zibSa8gVUIQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Capitalized to intangible assets under development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,876</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ShareBasedCompensationExpenses_zADJbPSlrylk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">58,834</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">21,876</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

34297

3439

21098 21876 58834 21876

2693985

31800

198333

31507

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z11SyNmYySad" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.25in">EIP options are valued using the Black-Scholes method. The following are the weighted average valuation assumptions used for EIP awards granted during the periods presented: SCHEDULE OF DETERMINATION OF FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260331_zT7Er5YMIYT6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250331_zDEWyYsABGL9" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Valuation assumptions:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zbu3DObfhww8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zqLPbqDI1bn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">85.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">75.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.00 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.59 years</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zeME3INqd8r6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.22</td><td style="text-align: left">%</td></tr> </table>

0.8500

0.7500

P3Y

P9Y7M2D

0.0270

0.0322

As of March 31, 2026, there was $262,349 (December 31, 2025: $289,676) of unrecognized compensation cost related to unvested stock options granted under the EIP, which is expected to be recognized over a weighted average period of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_za46XjbUGPPh" title="Weighted average period expected term">1.79 years. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">15.</td><td style="font: 10pt Times New Roman, Times, Serif">Employee benefit plans – 401(k) Plan</td></tr></table> EMPLOYEE BENEFIT PLANS – 401(K) PLAN The Company incurred the following employee benefit plan expenses: SCHEDULE OF EMPLOYEE BENEFIT PLANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260331_zeE6E37DQ0g" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_zX8cdvdAufwf" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_ecustom--CapitalizedToIntangibleAssetsUnderDevelopment_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_zi4L2xea9uRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Capitalized to intangible assets under development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,833</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_z8szkLSZ6Ku1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,221</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_zfKuXz1JyVM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Compensation expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,885</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_zhQARVadmuB" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,939</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

262349

289676

P1Y9M14D

The Company incurred the following employee benefit plan expenses: SCHEDULE OF EMPLOYEE BENEFIT PLANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260331_zeE6E37DQ0g" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_zX8cdvdAufwf" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_408_ecustom--CapitalizedToIntangibleAssetsUnderDevelopment_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_zi4L2xea9uRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Capitalized to intangible assets under development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,833</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_z8szkLSZ6Ku1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,221</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_hus-gaap--PlanNameAxis__custom--EmployeeBenefitPlansMember_zfKuXz1JyVM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Compensation expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,885</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_zhQARVadmuB" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,939</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

3833

3221

1885

8939

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">16.</td><td style="font: 10pt Times New Roman, Times, Serif">Research and Development</td></tr></table> RESEARCH AND DEVELOPMENT The Company incurred the following research and development expenses: SCHEDULE OF RESEARCH AND DEVELOPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_zcRwHX1kRQV2" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_zi64BI4plNil" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_ecustom--ConsultingAndProfessionalFees_zz1NCJM04VRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Consulting and professional fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">27,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">39,831</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CostDirectLabor_zn4Len7eSZgg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Direct labor costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169,815</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EmployeeBenefitsPlanExpenses_z5a2kYvQTBs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Employee benefits plan expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,439</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_zmY9wibK7wn4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">200,254</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">39,831</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

The Company incurred the following research and development expenses: SCHEDULE OF RESEARCH AND DEVELOPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_zcRwHX1kRQV2" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_zi64BI4plNil" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_ecustom--ConsultingAndProfessionalFees_zz1NCJM04VRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Consulting and professional fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">27,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">39,831</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CostDirectLabor_zn4Len7eSZgg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Direct labor costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169,815</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EmployeeBenefitsPlanExpenses_z5a2kYvQTBs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Employee benefits plan expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,439</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_zmY9wibK7wn4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">200,254</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">39,831</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 27000 39831

169815

3439

200254

39831

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">17.</td><td style="font: 10pt Times New Roman, Times, Serif">Income Taxes</td></tr></table> INCOME TAXES The Company files income tax returns in Canada and the United States. The Company is in a net loss position for both accounting and tax purposes. No tax expense or benefit is booked as the realization of any tax loss carryforwards cannot be more likely than not to be realized, based on available evidence, including projected future taxable income. There were no uncertain tax positions as at the three months ended March 31, 2026 and the year ended December 31, 2025.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">18.</td><td style="font: 10pt Times New Roman, Times, Serif">Loss per Share</td></tr></table> LOSS PER SHARE The following table sets forth the computation of basic and diluted net loss per share: SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_zoToMABeXAz7" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_z0PtU0ACSeOb" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_zr6DWfg9LIai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net profit/(loss)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,531,458</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(404,924</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Weighted-average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">26,939,850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,351,250</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Basic and diluted net profit/(loss) per share</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.06</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.02</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table> Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. The Company was in a loss position for all periods presented, therefore basic net loss per share and diluted net loss per share are the same for all periods as the inclusion of all potential common securities outstanding would have been anti-dilutive.

The following table sets forth the computation of basic and diluted net loss per share: SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_zoToMABeXAz7" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_z0PtU0ACSeOb" style="border-bottom: Black 1pt solid; text-align: center">Three months ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_zr6DWfg9LIai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net profit/(loss)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,531,458</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(404,924</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Weighted-average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">26,939,850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,351,250</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Basic and diluted net profit/(loss) per share</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.06</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.02</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table>

-1531458

-404924

26939850

21351250

-0.06

-0.02

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">19.</td><td style="font: 10pt Times New Roman, Times, Serif">Commitments and Contingencies</td></tr></table> COMMITMENTS AND CONTINGENCIES Purchase of Equipment As previously disclosed, the Company had a commitment to purchase multi-omics testing equipment from a third-party supplier. On June 26, 2026, the Company executed this commitment by purchase for a total cost of $343,080, including freight and shipping costs. The equipment was delivered to the South Carolina laboratory and invoiced by the supplier but has not yet been placed into service. Indemnification The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company’s request in such capacity. The Company has purchased directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company’s exposure and enable it to recover a portion of any amounts it pays under its indemnification obligations. The Company had no liabilities recorded for these agreements as of March 31, 2026, as no amounts were probable. Employee Agreements The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including accelerated vesting of shares under the EIP.

343080

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">20.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Related-Party Transactions and Balances</td></tr></table> RELATED-PARTY TRANSACTIONS AND BALANCES Related-party relationships and transactions are identified and disclosed in accordance with ASC 850, Related Party Disclosures. Related parties include affiliates, principal owners (holders of 10% or more of the voting interest), management (including persons serving in management capacities as consultants and all members of the Board of Directors), immediate family members of management and entities controlled by or under common control with those parties. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">a)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Related parties</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">(i)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Board Member(s)</td></tr></table> During the three months ended March 31, 2026, the Company granted an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zNIIVmigFH36" title="Stock options granted">31,800 stock options (<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260331__srt--TitleOfIndividualAxis__srt--DirectorMember_zmsAlhLrHMOj" title="Stock options granted">10,600 per director) to three newly appointed members of the Board of Directors. The options have a nominal exercise price, a three-year term, and vested immediately upon grant. Consistent with the accounting treatment of all grants under the Company’s EIP, the Company estimated the grant-date fair value of these options using the BSM option-pricing model. Because the awards vested immediately, the Company recognized the entire $31,507 as share-based compensation expense during the three months ended March 31, 2026. The Company did not pay or award any compensation to members of its Board of Directors for services rendered in their capacity as directors for any prior period, including the three months ended March 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(ii)</td><td style="font: 10pt Times New Roman, Times, Serif">Green Sky Labs Inc. (“GSL”)</td></tr></table> During the three months ended March 31, 2026, $<span id="xdx_904_eus-gaap--AdministrativeFeesExpense_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zdpvhZXG34K5" title="Management and administrative services">15,000 was charged under the management support and administrative services agreement (March 31, 2025: $<span id="xdx_901_eus-gaap--AdministrativeFeesExpense_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zqvpZMksNMz8" title="Management and administrative services">15,000), resulting in a net amount owed by GSL to the Company as of March 31, 2026 of $1,597,672 (December 31, 2025: $1,612,672) under the revolving loan agreement. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">(iii)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">My Next Health Inc. (“MNH”)</td></tr></table> During the three months ended March 31, 2026, the Company advanced funds amounting to $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncMember__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanAgreementMember_z9iYuEss45oa" title="Advance from related party">1,307,849 to MNH and received repayments of previous advances totaling $<span id="xdx_90F_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncMember__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanAgreementMember_ztKeaUdUPZA3" title="Repayment of notes payable">2,920,749. As of March 31, 2026, the outstanding balance due from MNH to the Company was $88,663 (Dec 31, 2025: $1,701,563). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">(iv)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Bearco Investments Ltd.</td></tr></table> As of March 31, 2026, the outstanding loan remained at $<span id="xdx_90E_eus-gaap--UnsecuredDebt_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BearcoInvestmentsLtdMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z0MgtEqp54G9" title="Unsecured debt">20,000 (December 31, 2025: $<span id="xdx_907_eus-gaap--UnsecuredDebt_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BearcoInvestmentsLtdMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zqWD2dQOG50f" title="Unsecured debt">20,000). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">(v)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trenchant Technologies Capital Corp. (“Trenchant”)</td></tr></table> Effective February 5, 2026, Trenchant’s nominee, Tom English, was appointed to the Board of Directors of the Company. No amounts were paid or outstanding to Trenchant during the three months ended March 31, 2026 or the year ended December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">(vi)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Compensation of key management personnel</td></tr></table> The Company entered into consulting arrangements with certain members of executive management and affiliated entities. During the three months ended March 31, 2026, the Company incurred consulting fees of $253,000 with related parties (March 31, 2025: $253,000) related to these arrangements. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(vii)</td><td style="font: 10pt Times New Roman, Times, Serif">Compensation of immediate family members</td></tr></table> The Company employed Nimish Saxena, the son of the CTO of the Company, as Product Manager – Digital Twins. Compensation expense recognized in connection with this employment arrangement amounted to $46,311 (includes share-based compensation and other employee benefits) for the three months ended March 31, 2026 (March 31, 2025: $37,995). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b)</td><td style="font: 10pt Times New Roman, Times, Serif">Due from Related Parties</td></tr></table> Amounts due from related parties consisted of the following: SCHEDULE OF AMOUNTS DUE FROM RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260331_zoLy0jYFPOEl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231_zSvxk2j6oESl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--OtherReceivables_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zQnqjWbRbxfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Due from Green Sky Labs Inc.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,597,672</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,612,672</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherReceivables_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncCanadaMember_z98cEQv3BFD8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Due from My Next Health Inc. (Canada)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">887,131</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherReceivables_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncUSMember_zTEDMIZItQif" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Due from My Next Health Inc. (US)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">88,663</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">814,432</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherReceivables_iI_zJBdsdX1mNll" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,686,335</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,314,235</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Amounts due from related parties are governed by revolving loan agreements dated August 23, 2023 entered into with both GSL and MNH. Under these agreements, the net balance with each counterparty reflects cumulative advances made between the parties, reduced by expenses paid by GSL or MNH on behalf of the Company, and increased by expenses paid by the Company on behalf of GSL or MNH. During the three months ended March 31, 2026, there was a net reduction in the amounts due from MNH of $<span id="xdx_906_ecustom--NetReductionDueFromRelatedParty_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSLorMNHMember__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanAgreementMember_z1IvoaFaqzta" title="Net reduction due from related parties">1,612,900 (the net impact of additional advances made to related parties of $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSLorMNHMember__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanAgreementMember_zbuNPzekcSo" title="Advance from related party">1,307,849 offset by repayments made by related parties of $<span id="xdx_900_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSLorMNHMember__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanAgreementMember_zbwV2NI5JFyb" title="Repayment of notes payable">2,920,749). During the same period, there was a net reduction in the amounts due from GSL of $<span id="xdx_90C_eus-gaap--OtherReceivables_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--RevolvingLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_z64Hi7yirgbg">15,000. The outstanding balances are intended to be settled in full within twelve months and are therefore classified as current assets. The Company has assessed the recoverability of these balances and determined that no impairment is required as at March 31, 2026. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">c)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts Payable to Related Parties</td></tr></table> Amounts due to related parties in respect of accounts payable and accrued liabilities consisted of the following: SCHEDULE OF AMOUNTS DUE TO RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260331_zFxOIKdZIv9h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zlkQU74q1mG" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_ecustom--ConsultingFeesExpenseReimbursements_iI_maAPCANz85c_zr1SPlez3DU" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Consulting fees & expense reimbursements to CTO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16,342</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,022</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ExpenseReimbursement_iI_maAPCANz85c_zNU54vXEagi8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expense reimbursement to the CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,892</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndConsultingFeesPayable_iI_maAPCANz85c_znvfSb5kYl39" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payroll and expenses payable to Nimish Saxena</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,587</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FeePayable_iI_maAPCANz85c_z7vIrMYaY8Gl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accounting fees payable to related party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrentAndNoncurrent_iTI_mtAPCANz85c_z2KKp4UuA7k9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">23,131</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">98,001</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d)</td><td style="font: 10pt Times New Roman, Times, Serif">Short-term Loan</td></tr></table> Short-term loan consisted of the following: SCHEDULE OF SHORT-TERM LOAN <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260331_zMK1Z8WrsZ49" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zwrALxYWQfxh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--UnsecuredDebt_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BearcoInvestmentsLtdMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zGMsEeuXn4V1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Bearco Investments Ltd.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">20,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">20,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--UnsecuredDebt_iI_zVmlovnblKGl" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">e)</td><td style="font: 10pt Times New Roman, Times, Serif">Investment in a Related Party</td></tr></table> The Company holds an investment in Trenchant. The continuity of this investment is as follows: SCHEDULE OF INVESTMENT RELATED PARTY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--RelatedPartyTransactionsByRelatedPartyAxis_custom--TrenchantCommonSharesMember_zmfvMb83WEGj" style="border-bottom: Black 1pt solid; text-align: center">Trenchant Common Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--RelatedPartyTransactionsByRelatedPartyAxis_custom--TrenchantWarrantsMember_zswehIs7wpPl" style="border-bottom: Black 1pt solid; text-align: center">Trenchant Warrants</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_zPQX8E0M4mg9" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43C_c20250101__20251231_eus-gaap--LongTermInvestments_iS_zqcneCHOAay6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Opening Balance, January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">701,950</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">62,819</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">764,769</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GainLossOnInvestments_zj8viwFO73Y5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Loss on fair value of investment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(333,502</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(60,116</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(393,618</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_439_c20260101__20260331_eus-gaap--LongTermInvestments_iS_zMmTHbS2HhP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance, December 31, 2025</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">368,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,703</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">371,151</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GainLossOnInvestments_zw3RfFqfKNdc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Loss on fair value of investment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30,068</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,695</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,373</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_436_c20260101__20260331_eus-gaap--LongTermInvestments_iE_z1UhPn66zoEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Balance, March 31, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">398,516</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">398,524</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> The investment is remeasured to fair value at each reporting date, with changes in fair value recognized within the Statement of Operations. The Trenchant common shares are subject to a voluntary lock-up agreement whereby 50% were restricted from transfer until April 29, 2025, and the remaining 50% until April 29, 2026. No discount for lack of marketability was applied as the transfer restriction is a characteristic of the Company as holder and not the underlying shares themselves. Accordingly, the Level 1 quoted market price was used without adjustment. The <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrenchantWarrantsMember_z5PlCUzYJYt1" title="Warrant shares issued">2,600,000 warrants of Trenchant, exercisable at C$<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uCADPShares_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrenchantWarrantsMember_ze0aXdQhYmK3" title="Exercisable share">0.50 (equivalent to approximately US$<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrenchantWarrantsMember_zqOPUVYHIEb9" title="Exercisable share">0.36) per share expired on April 29, 2026. The Company has not exercised any of the warrants. The Trenchant common shares are classified within Level 1 of the fair value hierarchy based on the quoted market price of the Trenchant shares on the Canadian Securities Exchange (“CSE”) at each measurement date. The warrants are classified within Level 3 given the use of unobservable inputs in the BSM option-pricing model. During the three months ended March 31, 2026, the Company recognized a gain on fair value of investments of $27,373 (March 31, 2025: loss of $168,965), reflecting the change in Trenchant’s quoted share price over the respective periods.

31800

10600

31507

15000

1597672

1612672

1307849

2920749

88663

1701563

20000

253000

46311

37995

Amounts due from related parties consisted of the following: SCHEDULE OF AMOUNTS DUE FROM RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260331_zoLy0jYFPOEl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231_zSvxk2j6oESl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--OtherReceivables_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GreenSkyLabsIncMember_zQnqjWbRbxfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Due from Green Sky Labs Inc.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,597,672</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,612,672</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherReceivables_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncCanadaMember_z98cEQv3BFD8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Due from My Next Health Inc. (Canada)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">887,131</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OtherReceivables_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MyNextHealthIncUSMember_zTEDMIZItQif" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Due from My Next Health Inc. (US)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">88,663</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">814,432</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherReceivables_iI_zJBdsdX1mNll" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,686,335</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,314,235</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1597672

1612672

887131

88663

814432

1686335

3314235

1612900

1307849

2920749

15000

Amounts due to related parties in respect of accounts payable and accrued liabilities consisted of the following: SCHEDULE OF AMOUNTS DUE TO RELATED PARTIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260331_zFxOIKdZIv9h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zlkQU74q1mG" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_ecustom--ConsultingFeesExpenseReimbursements_iI_maAPCANz85c_zr1SPlez3DU" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Consulting fees & expense reimbursements to CTO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16,342</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88,022</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ExpenseReimbursement_iI_maAPCANz85c_zNU54vXEagi8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expense reimbursement to the CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,892</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndConsultingFeesPayable_iI_maAPCANz85c_znvfSb5kYl39" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payroll and expenses payable to Nimish Saxena</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,587</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FeePayable_iI_maAPCANz85c_z7vIrMYaY8Gl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accounting fees payable to related party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrentAndNoncurrent_iTI_mtAPCANz85c_z2KKp4UuA7k9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">23,131</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">98,001</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 16342 88022 6789 6892 1587 1500

23131

98001

Short-term loan consisted of the following: SCHEDULE OF SHORT-TERM LOAN <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260331_zMK1Z8WrsZ49" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zwrALxYWQfxh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--UnsecuredDebt_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BearcoInvestmentsLtdMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zGMsEeuXn4V1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Bearco Investments Ltd.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">20,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">20,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--UnsecuredDebt_iI_zVmlovnblKGl" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

20000

The Company holds an investment in Trenchant. The continuity of this investment is as follows: SCHEDULE OF INVESTMENT RELATED PARTY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--RelatedPartyTransactionsByRelatedPartyAxis_custom--TrenchantCommonSharesMember_zmfvMb83WEGj" style="border-bottom: Black 1pt solid; text-align: center">Trenchant Common Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--RelatedPartyTransactionsByRelatedPartyAxis_custom--TrenchantWarrantsMember_zswehIs7wpPl" style="border-bottom: Black 1pt solid; text-align: center">Trenchant Warrants</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_zPQX8E0M4mg9" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43C_c20250101__20251231_eus-gaap--LongTermInvestments_iS_zqcneCHOAay6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Opening Balance, January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">701,950</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">62,819</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">764,769</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GainLossOnInvestments_zj8viwFO73Y5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Loss on fair value of investment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(333,502</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(60,116</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(393,618</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_439_c20260101__20260331_eus-gaap--LongTermInvestments_iS_zMmTHbS2HhP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance, December 31, 2025</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">368,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,703</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">371,151</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GainLossOnInvestments_zw3RfFqfKNdc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Loss on fair value of investment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30,068</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,695</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,373</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_436_c20260101__20260331_eus-gaap--LongTermInvestments_iE_z1UhPn66zoEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Balance, March 31, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">398,516</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">398,524</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

701950

62819

764769

-333502

-60116

-393618

368448

2703

371151

30068

-2695

27373

398516

398524

2600000

0.50

0.36

27373

168965

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">21.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Concentration of Credit Risk</td></tr></table> CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, subscription receivable, other receivables and revolving loan receivables from related parties. The subscription receivable from two equity investors was settled subsequent to the three months ended March 31, 2026. The outstanding revolving loan receivables are from Company’s parent and ultimate parent companies and are expected to be settled in 2026.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">22.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Subsequent Events</td></tr></table> SUBSEQUENT EVENTS Management has evaluated events subsequent to the three months ended March 31, 2026 and up to July 6, 2026, for transactions and other events that may require adjustment of and/or disclosure to the consolidated financial statements. Bridge financing and secured convertible promissory note Concurrently with the execution of the BCA, the Company entered into a side letter agreement with IBAC pursuant to which the Company is authorized to complete a bridge financing of up to $<span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20260316__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--BridgeFinancingMember_zy30FM99r1Hb" title="Secured convertible promissory note amount">2,000,000 through the issuance of secured convertible promissory notes and accompanying common share purchase warrants. In addition to the $<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--SecuredPromissoryNoteMember_zurOAEsWy8Q9" title="Convertible notes issued amount">250,000 convertible promissory note issued during the three months ended March 31, 2026, the Company issued an additional $<span id="xdx_90F_eus-gaap--SecuredDebt_iI_c20260331__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--SecuredPromissoryNoteMember_z3O2MO3QZJcj" title="Convertible notes issued amount">100,000 in promissory notes subsequent to quarter-end. Refer to Note 11 – Convertible Promissory Note for details on key terms. South Carolina Laboratory Lease On May 5, 2026, the Company entered into a sublease agreement with Clemson University, South Carolina for approximately 1,671 square feet of laboratory space located in Greenville, SC. The sublease has an initial term of <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znnKugLKLCHc" title="Sublease lease term">one year commencing June 1, 2026, with up to three consecutive one-year<span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20260601__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoq9RNVipei8" style="display: none" title="Initial term">1 renewal options. Either party may terminate upon 90-days written notice. Base rent is $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20260505__20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1Gqf5kATECf" title="Rent">40,104 per year ($<span id="xdx_905_eus-gaap--PaymentsForRent_c20260505__20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zTUV3kVnGSdg" title="Rent">3,342 per month), plus a monthly equipment access fee of $<span id="xdx_900_ecustom--EquipmentAccessFee_c20260505__20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsMUzJc2cuIh" title="Equipment access fee">975, resulting in total committed payments of approximately $<span id="xdx_904_ecustom--CommittedPayments_c20260505__20260505__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaWOa6oC2go8" title="Total committed payments">51,804 over the initial term. Since the initial lease term is 12 months or less, the Company will utilize the short-term lease practical expedient under ASC 842, Leases and will not recognize a right-of-use asset or lease liability in connection with this arrangement. Management agreements Effective April 1, 2026, the Company’s Chief Operating Officer resigned from their position. Subsequent to year end, the Company entered into management agreements with a new Chief Financial Officer/Chief Revenue Officer and new Chief Medical Officer. Each agreement provides for customary compensation arrangements, including base compensation and performance-based initiatives. Revenue agreement On April 22, 2026, the Company also entered into a consulting agreement to provide its Drug Assessment Platform services in connection with the customer’s lead drug development program. The agreement has a two <span id="xdx_906_ecustom--AgreementTermOfContract_dtY_c20260422__20260422__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYzXtr3lHKkd" style="display: none" title="Agreement term of contract">2-year term and a total contract value of $<span id="xdx_90A_ecustom--ContractAgreementAmount_iI_c20260422__us-gaap--ClassOfWarrantOrRightAxis__custom--ShareCapitalAndWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPDeV00fZHgh">3,300,000 payable entirely in the customer’s equity. The Company’s previous Chief Operating Officer (who resigned April 1, 2026), has material involvement in, or control over, the counterparty. Partial revenue from this agreement will be recognized during the three months ending June 30, 2026. Equity Instrument Issuances Subsequent to the three months ended March 31, 2026, the Company issued a total of <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260401__20260720__us-gaap--StatementEquityComponentsAxis__custom--EquityInstrumentsIssuancesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z16lynd7H2U1" title="Number of Common shares">136,000 common shares. This total included <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260401__20260720__us-gaap--StatementEquityComponentsAxis__custom--EquityInstrumentsIssuancesMember_zpHzFVb2SE79" title="Common shares">20,000 shares formally issued to fulfill share issuance obligations previously recorded within “Shares to be issued” as of March 31, 2026. The Company also issued <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260401__20260720__us-gaap--StatementEquityComponentsAxis__custom--ShareSubscriptionReceivableMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSLorMNHMember_zwMIoc2JTgec" title="Common shares">116,000 shares to two investors (one of whom is a related party by virtue of an executive role at MNH) in a non-cash transaction settled through the receipt of shares in the related party, GSL. Additionally, the Company granted a total of 660,000 options under its EIP to certain new officers, employees, and consultants including newly appointed management team members. All granted options are subject to standard vesting schedules in accordance with the terms of the EIP.

2000000

250000

100000

1671

P1Y

40104

3342

975 51804 P2Y 3300000

136000

20000

116000

660000

Reflects retrospectively the 10-for-1 forward stock split that became effective on February 05, 2026 Reflects retrospectively the 10-for-1 forward stock split that became effective on February 05, 2026 Reflects retrospectively the 10-for-1 forward stock split that became effective on February 05, 2026 Reflects retrospectively the 10-for-1 forward stock split that became effective on February 05, 2026.